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Abstract 
An investigation into the combined tocolytic effect of 
magnesium and other tocolytics. 
Blessing Osaghae 
Preterm births are a leading cause of perinatal morbidity and mortality, and its 
occurrence has remained unchanged. To improve perinatal mortality, several 
tocolytics were developed; however, this has not been accompanied by an 
improvement in infant outcome (Keirse, 2003a). They delay labour long enough to 
administer corticosteroids. 
According to the NICE guidelines (NICE, 2016), women who are at risk of preterm 
birth before 30 weeks of pregnancy are to be administered magnesium sulphate 
(MgSO4) to help reduce the risk of cerebral palsy. So, although MgSO4 is not 
currently used for the treatment of preterm labour in the UK, it is being 
administered clinically in combination with a tocolytic which could either be 
indomethacin, nifedipine, or atosiban. This means that in certain preterm cases 
(<30 weeks), a dual tocolytic therapy would be given 
The aims of this thesis were mainly to: (1) investigate the effect of magnesium 
sulphate at different gestations of pregnancy and how hormonal changes may 
affect its efficacy; (2) to investigate the dual tocolytic effect of magnesium sulphate  
(MgSO4) and other tocolytics (atosiban, indomethacin and nifedipine) (3) to 
determine the expression of L-type calcium channels especially the α1c subunit (Cav 
1.2) across different gestational states of mouse, and in doing so, (4) establish a 
panel of stable housekeeping genes that could be used across gestational states of 
mouse myometrium. 
Magnesium sulphate concentration-dependently decreased spontaneous and 
oxytocin-induced contractions. In spontaneous contractions, MgSO4 showed a more 
potent effect at term and the least effect in non-pregnant tissues. In the presence 
of oxytocin however, there was no difference in the potency of MgSO4 across all 
gestations studied. Having established the effect of MgSO4 on my samples, I then 
investigated its combined effect with indomethacin, atosiban and nifedipine. In the 
21 
 
presence of oxytocin, MgSO4 +atosiban produced a synergistic tocolytic effect on 
contractions, MgSO4 plus indomethacin produced an antagonistic effect while there 
was no significant difference in the effect of MgSO4 plus nifedipine compared to 
MgSO4. Although MgSO4 plus atosiban produced the greatest tocolytic effect 
compared to other combinations, I found that extracellular acidification reversed its 
effect, increasing force and frequency of contractions. Since magnesium acts at L-
type calcium channels, I investigated and quantified the expression of L-type 
calcium channel (Cav 1.2) and found that expression increased towards term with 
further increase postpartum. 
From this work I have shown that magnesium concentration-dependently reduces 
spontaneous contractions but its effect is reduced in the presence of oxytocin which 
may explain why magnesium is not effective clinically.  The synergistic effect seen 
with MgSO4 plus atosiban suggests that oxytocin receptor antagonists may be the 
most efficient tocolytics in cases where magnesium is administered. The increase in 
Cav 1.2 expression towards term indicates its role in parturition.  
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Chapter 1 
General Introduction 
My thesis investigates the effect of magnesium in combination with other tocolytics 
on in vitro uterine contractions. In this introductory chapter, I will describe the 
anatomy of the uterus (human and mouse). I will then describe the structure of the 
myometrium, its function and mechanism.  The mechanism of contraction would 
also be covered in this thesis as well as the regulation of intracellular calcium in 
uterine contractions and the role of the sarcoplasmic reticulum. Furthermore, the 
process by which hormones modulate force of contraction will be explained as well 
as the mechanism of action of oxytocin and prostaglandins.  
In this thesis, I will describe the prevalence and challenges of preterm birth and 
labour.  I will then review what is known about the tocolytics used in this thesis and 
their mechanism of action. I will also review the concept of combined tocolytics, the 
benefit and challenges. In general, this review mainly covers literature on human 
myometrium and mouse (my experimental model) where possible. 
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1.1 Uterus 
1.1.1 The Human uterus 
The human uterus is a hollow, pear-shaped muscular organ and sits inverted within 
the pelvic region. It is situated between the urinary bladder and the rectum. It 
measures between 6 to 8 cm long, 5 cm broad and the thickness is about 2 to 3 cm. 
A typical non-pregnant uterus weighs about 30 - 40 grams but increases greatly in 
pregnancy (Gray, 2000). 
Anatomically, the human uterus comprises mainly of four regions: the fundus, 
uterine the body, the isthmus and the cervix (Figure 1.1). The fundus is the 
rounded, broad upper area in which the fallopian tubes are connected to the 
uterus. The body, otherwise referred to as “the corpus” is the main part of the 
uterus, which starts below the level of the fallopian tubes and continues 
downwards until the uterine walls. The cavity begins to narrow; the isthmus is the 
lower, narrow neck region; and the cervix, which is the lowest section of the uterus, 
extends from the isthmus until it opens into the vagina.  
The walls of the uterus compose of three tissue layers: the perimetrium, the 
myometrium and the endometrium. The perimetrium is the outer layer, like an 
external skin of the uterus that protects the uterus from friction. The myometrium 
forms the middle layer off the uterus, which allows the uterus to expand and 
contract during pregnancy and labour. The endometrium is the non-excitable layer 
that borders around the hollow lumen of the uterus.  
The uterus is supplied with blood by the two uterine arteries, which are branches of 
the internal iliac arteries, and by ovarian arteries, which connect with the ends of 
the uterine arteries and send branches to supply the uterus. The uniqueness of the 
uterus lies in the sequential changes necessary for completion of pregnancy (Young, 
2007). 
 
  
25 
 
  
Vagina 
Perimetrium 
Myometrium 
Endometrium 
 Fundus 
Cervix 
Ovary 
Fallopian tube 
Uterus 
Figure 1. 1: The Anatomy of the Human Uterus  
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1.1.2 The Mouse uterus 
 The mouse, like other rodents, has a duplex uterus, consisting of two 
branches, known as horns enabling multiple offspring to be developed on both 
horns. The mouse uterus is a duplex unit, consisting of two horns and come 
together above the cervix. The cervix composes of the caudal region which is 
narrow and projects into the cranial part of the vagina (Figure 1.2). It contains a 
single undivided lumen or canal. 
Over the years, the mouse has been an excellent model for investigating preterm 
birth and the general physiology of parturition. Much of our understanding of 
uterine contraction originates from animal studies, including mouse, rat and 
baboon (Wray et al., 2001). The study of animal myometrial tissue during pregnancy 
has its obvious advantages compared with the study of human myometrial tissue 
which can usually only be obtained during caesarean section or hysterectomy. The 
vast majority of work on human myometrium come from elective non-labouring 
women, as it is very difficult to obtain labouring samples due to the context in 
which the caesarean section arise. Animal myometrium can be acquired at different 
gestations from pregnant animals, and changes in uterine activity directly measured 
in vivo, so that the switch from quiescence to pre-labour and labour stages can be 
elucidated (Tribe, 2001).  
One advantage in using the mouse is that the short gestation period is convenient 
for experimentation. Using mouse also allows for generation of knockout models 
which are beneficial in investigating genes that influence parturition (Ratajczak et 
al., 2010). The EC coupling and contraction mechanism of mouse myometrium is 
similar to the human (Matthew et al., 2004a). Both mouse and human myometrial 
smooth muscles require L-type calcium entry; express many of the same ion 
channels and transporters that govern excitability and ionic homeostasis (Matthew 
et al., 2004a). In addition, major components of labour and delivery are maintained 
in both mice and humans.  For example, the expression of certain contraction-
associated proteins like prostaglandin, oxytocin, and connexin-43 are all elevated in 
both human and mice (Ratajczak and Muglia, 2008, Cook et al., 2000).  
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There are however fundamental differences between mouse and human 
reproductive anatomy and physiology. While the mouse has a bicornuate uterus, 
the human uterus has a pear shaped uterus. The mouse also has a larger litter size 
than humans. In mouse pregnancy, there is a drastic decline in maternal 
progesterone at the end of pregnancy (Hardy et al., 2006), however this decline is 
not seen at the onset of human labour (Mendelson, 2009). In humans rather, both 
progesterone levels and progesterone receptor levels remain elevated throughout 
pregnancy and into labour (Hardy et al., 2006, Challis et al., 2000).  Despite these 
differences in uterine shape, number of embryos, and site of generation of 
progesterone in late gestation (Ratajczak et al., 2010), nonetheless, the genetic 
traceability and basic similarities in EC coupling, makes the mouse an attractive 
experimental model (Ratajczak and Muglia, 2008) and there remains some similarity 
in the structural morphology. The uterine wall of the mouse, as with human, 
consists of the endometrium (the interior layer that lines the body of the uterus), 
the myometrium (smooth muscle layer) and the perimetrium (the outermost serosa 
layer).  
Unlike humans who menstruate, the uterine lining of the mouse uterus is not shed 
and passed out of the body. Instead, the endometrial layer is transformed for the 
next cycle. These periodic changes in the endometrium, as well as changes that 
occur in the ovaries and vagina, are part of the oestrus cycle of the mouse. In the 
mouse, the oestrous cycle is divided into 4 stages (proestrus, oestrus, metestrus, 
and diestrus) and repeats every 4 to 5 days unless interrupted by pregnancy, 
pseudo-pregnancy, or anoestrus (Byers et al., 2012). The main hormones that 
regulate the oestrus cycle are: gonadotropin releasing hormone, which is secreted 
by the hypothalamus and stimulates the release of gonadotropins by the pituitary 
gland; the gonadotropins luteinising and follicle stimulating hormones secreted by 
the pituitary gland; oestrogen (E2), progesterone which is synthesised in the 
ovaries; and prolactin, which is secreted by the pituitary gland following mating 
(Freeman, 2006). During proestrus, E2-secreting follicles grow under the influence 
of follicle stimulating hormones, increasing the secretion of E2 (Fortune, 1994; 
(Fortune, 1994, Maeda et al., 2000). This results in an increase in E2 levels, and 
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stimulates the release of luteinising hormones. The release of the luteinising 
hormone in turn results in stimulating ovulation during the oestrus stage.  During 
the oestrus stage, rodents like rats and mice are sexually receptive and mating is 
possible. Within several hours, ovulation occurs and the follicles are transformed 
into corpora lutea. During metestrus, the corpora lutea grows post-ovulation, 
secreting Progesterone (P4). In diestrus stage, the corpora luteal continue to 
secrete high quantities of P4. It is during this stage of the oestrus cycle that FSH 
levels begin to increase in the absence of pregnancy, and stimulate the growth of a 
new set of follicles, which will occur in the proestrus stage of the following cycle 
(Westwood, 2008, Freeman, 2006).  
Blood is supplied to the uterus through the uterine artery which branches out 
through the myometrium to give off arcuate arteries, then radial arteries and 
further spiral arteries. The spiral arteries then supply blood to the endometrium, 
placenta and decidua during pregnancy.  In humans, the size of the uterine artery 
doubles during pregnancy (Palmer et al., 1992) . Similar findings have been shown in 
animal studies including rodents (K Griendling et al., 1985, Keyes et al., 1997). 
As a result of the position and network of the arteries, contraction will cause a 
compression of the uterine vessels resulting in reduced blood flow. This event leads 
to hypoxia and pH changes. 
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(a) 
Figure 1. 2: The Anatomy of the mouse uterus 
(a) An illustration of the mouse duplex uterus, showing each horn with its 
respective ovary, uterine tube, and cervix. (b) Schematic of the uterine horns 
showing the lumen and the myometrium sandwiched between the endometrium 
and serosa. 
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1.2 Mouse pregnancy and parturition 
Pregnancy is the process of carrying one or more developing embryo or 
spermatozoa forming a zygote and ends once the foetus and the placenta are 
expelled from the uterus (Mahendroo, 2012). The length of gestation, physiological 
and molecular events leading to foetal development, maturation and subsequently 
labour vary between species. Mouse pregnancy is considered term at approximately 
day 19. Pregnancy in humans is maintained by P4 synthesised in the corpus luteum 
during the first seven weeks of pregnancy, a role which is taken over by the 
placenta from week 12 to term (Mesiano, 2009). In rodents, pregnancy is 
maintained by the corpora lutea, such that the removal of the ovaries results in 
labour and delivery of the pups (Maeda et al., 2000). Parturition is a complex 
physiological process whose fundamental determinants have remained 
elusive. Parturition is initiated in most non-primate mammals, including mice, 
through a decrease in circulating progesterone caused by elevated prostaglandins. 
The process of parturition is divided into four phases. Phase 0 is the quiescent 
phase in which the uterus is kept in a state of quiescence due to the repression of 
uterotonic signals as well as the unresponsiveness of the uterus to uterotonic 
stimulation (Girotti and Zingg, 2003). This phase constitute the longest phase of 
pregnancy. This is followed by phase 1 also known as the activation phase which is 
characterised by an increase in capacity to respond efficiently to uterotonic signals. 
This phase involves possible changes in oestrogen levels. Phase 2 is the stimulation 
phase and is characterised by increase in the activity of uterotonins: oxytocin and 
prostaglandins, and the uterotonic signals result in uterine contractions. Phase 3 is 
the involution phase of parturition and follows delivery of foetus and placenta as 
well as return of the uterus back to normal dimensions of non-pregnant state. 
Parturition in mouse is preceded by a sharp decline in the levels of circulating 
progesterone, a phenomenon that is not observed in human parturition. Labour in 
humans occurs in the presence of high, and sometimes increasing, levels of 
progesterone (Zakar and Hertelendy, 2007). The role of Prostaglandins F2α (PGF2α) 
in the initiation of labour in mice was confirmed in studies of genetically altered 
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mice. A study showed that labour could not be initiated in FP knock-out mice, FP-/-, 
as luteolysis and progesterone withdrawal did not occur (Sugimoto et al. 1997). In 
addition to the maintenance of high circulating levels of progesterone in FP-/- mice, 
OTR expression was not upregulated in uterine tissues as is consistent with the 
onset of labour. In mice lacking polylactide (PLA2), and mice lacking the constitutive 
COX-1 enzyme, progesterone levels remained elevated while labour was delayed, 
suggesting that PLA2, COX-1, PGF2α, and FP are required for luteolysis and the 
systemic withdrawal of  progesterone in mice at term (Ratajczak and Muglia, 2008, 
Sugimoto et al., 2015).   
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1.3 The Myometrium 
1.3.1 The Structure of the Myometrium 
 The uterus of humans and mice is a myogenic organ (Wray, 1993), 
spontaneously contracting in vivo and in vitro without neural or hormonal stimuli. 
These contractions are produced by the myometrium which consists 
overwhelmingly of uterine smooth muscle cells. Uterine smooth muscle has a 
phasic contractility pattern, maintaining its resting tone with discrete, intermittent 
contractions, of varying frequency, amplitude and duration, depending upon 
gestational and hormonal conditions (Aguilar and Mitchell, 2010). 
In human myometrium, four distinct layers have been identified: the fasciculus layer 
(consisting of myocyte and connective tissue), the cylindrical bundles (consisting of 
densely packed myocytes), sheet-like bundle (consisting of densely packed sheet of 
myocytes), fibre bundle (consisting of loosely packed and few myocytes), and 
communicating bridge (consisting of large bridges adjacent to fascicule) (Young and 
Hession, 1999). In mouse myometrium however, there are only two distinct layers: 
the outer longitudinal and inner circular smooth muscle layers. 
1.3.2 Myometrial contractile machinery 
Myometrial cells are long and spindle-shaped, which is typical of most visceral 
smooth muscle. These cells vary in length (300 µm to 600 µm) and diameter (5 µm 
to 10 µm). These cells are densely filled with muscle fibres (myofilaments) which 
occupy 80-90% of the total cell volume, with the remaining 10-20% taken up by the 
nucleus, sarcoplasmic reticulum and mitochondria (Aguilar and Mitchell, 2010).  
The myometrium has thin and thick filaments with the main components of these 
filaments being actin and myosin respectively. In the uterine smooth muscle, there 
is approximately 6-fold more actin than myosin (Word et al., 1993). 
Actin filaments are circular, soluble globular protein measuring 6-8 nm in diameter. 
There are six isoforms of actin which are expressed from different genes (Aguilar 
and Mitchell, 2010), with the main actin isoforms (α, β and γ type) expressed in 
myometrial cells (Taggart and Morgan, 2007). The main roles of the different actin 
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isoforms are yet to be established, however, it is suggested that α- and β-actin are 
invariant with respect to total protein during pregnancy whereas γ-actin is 
suggested to exhibit an increased expression and altered localization towards term 
(Taggart and Morgan, 2007). Smooth muscle actin has been suggested to exist as 
part of both a contractile domain directly involved in force-generating events and a 
cytoskeletal domain important for structural integrity. 
Myosin filaments, which measure 15-18 nm in diameter are the prototype 
molecular motor (Taggart and Morgan, 2007). This protein converts chemical 
energy in the form of ATP to mechanical energy, thus generating force and 
movement. The size of myosin in different tissues varies, but in smooth muscle, 
myosin is 470kDa in size, with two globular head groups joined by 150nm long tail. 
Associated with each head are 20 and 17kDa light chains. Contraction and 
relaxation are regulated by the phosphorylation of serine 19 on the 20kDa chains 
(Word et al., 1993). The actin and myosin filaments run in parallel and in the 
longitudinal dimension of the cell. Smooth muscles also contain intermediate 
filaments, so called because of their diameter (10 nm). These filaments are 
composed predominantly of desmin (Leoni et al., 1990). 
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1.4 Gap junctions 
In various tissues, it is well established that gap junctions drive the cell-to-cell 
communication. The gap junction proteins are regulated primarily through 
endocrine mechanisms and the protein density is up-regulated by oestrogen and 
prostaglandins, and down-regulated by progesterone. There is also evidence that an 
increase in Ca2+ and a decrease in pH can reduce the permeability of gap junctions 
(Spray and Bennett, 1985, Skerrett and Williams, 2017).  In the myometrium, gap 
junctions play a leading role in the transition from a quiescent to an excitable state.  
In the final stages of gestation, the gap junction content in the myometrium has 
been shown to increase (Garfield et al., 1977) and the changes or increase in gap 
junction content may be relative to the changes in hormonal levels (Garfield et al., 
1979). 
In non-pregnant myometrium and early pregnancy, only few gap junctions have 
been shown between the cells (Miller et al., 1989). There is a drastic increase in the 
number of gap junctions in the days preceding labour. These values reach a peak at 
term and delivery (Miller et al., 1989). During normal delivery, an individual cell will 
have around 1000 gap junctions which increase in diameter to around 250 nm 
(Garfield et al., 1977). This is then followed by a dramatic down-regulation of gap 
junctions within 24 hours of delivery. 
The channels enable electrical signals to be transmitted throughout the 
myometrium and so allow the uterus to synchronise contractions in labour. This 
synchrony of contractions occurs through transmission of electrical activity via 
connected myofibrils to muscle fibres. The activated myocytes produce 
prostaglandin, and cause depolarisation of surrounding myocytes. This activity 
continues as more myocytes are activated leading to contraction (Smith et al., 
2007). The permeability of the junctions is up-regulated by oxytocin, and 
downregulated by relaxin. While an increase in the gap junction density increases 
tissue conductance, myogenic mechanisms are required to initiate activity within 
the cell. 
35 
 
The regulation of gap junction coupling is thought to determine uterine electrical 
activity in two ways. First, preterm, uterine quiescence is enforced by limiting the 
flow of excitation from cell to cell. Second, during labour, an increased amount of 
coupling is needed for robust contractile activity (Miyoshi et al., 1996). There is no 
question that more gap junctions will enhance cell-to-cell communication; however, 
there is no relevance if the new gap junctions do not open or if their contribution to 
improved coupling is not significant (Miyoshi et al., 1996). Increased propagation 
might be demonstrated as an increase in either the velocity of propagation or the 
distance over which propagation occurs. Miller et al. (1989) studied the propagation 
of spontaneous activity in muscle strips in vitro and found both propagation 
velocities and distances at term to be about 2 or 3 times the preterm values. Their 
findings show a net increase in propagation at term, the expected effect of 
increased junctional conductance (Miyoshi et al., 1996). 
 
1.5 Myometrium cell excitability 
The ability of the uterus to contract is made possible by the underlying electrical 
activity of the myometrial cells (Wolfs and van Leeuwen, 1979).  
It is established that excitation of the myometrial cells relies on the movement of 
K+, Na+, Cl- and Ca2+ ions, through their respective ionic channels (Fatt and Ginsborg, 
1958). Although these ions determine the resting membrane potential of the cell 
resulting in the generation of action potential, the resting membrane potential is 
predominantly set by K+. An influx of Ca2+ is driven by spontaneous changes in 
membrane potential (Wray, 1993), depolarising the cell and allowing smooth 
muscle contraction whereas an efflux of potassium leads to repolarisation that 
causes cell relaxation. These phenomena indicate that the excitability of the uterus 
is modulated through ionic transport, and relies on the gating properties of ion 
channels. 
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1.5.1 Electrical activity and Membrane potential 
The uterus is a myogenic organ and an excitable tissue, spontaneously contracting 
without the need for an external stimulus. It fires an action potential and has a 
resting membrane potential (Wray et al., 2015). The initiation as well as 
coordination of its activity is characterised by cycles of depolarisation and 
repolarisation that occur within the plasma membrane. These changes constitute 
action potentials.  
Resting membrane potential is where minimal or no change in membrane potential 
occurs. The resting membrane potential in the uterus has been measured to be 
between - 35mV and - 80mV. The value varies depending on the gestational state 
and muscle layer (Parkington et al., 1999).   This value may also be different 
between species. In human, the resting membrane potential at term is reported to 
be approximately -55mV (Parkington et al., 1999). This becomes more negative 
towards mid-pregnancy (- 60mV) and increases near term and parturition to - 45 
mV (Kuriyama and Suzuki, 1976, Parkington et al., 1999) and these values are 
similar to that in pregnant rat (Kuriyama and Suzuki, 1976). 
The excitability of the myometrium is controlled by the movements of Na+, K+, Cl- 
and Ca2+ ions between the intracellular and extracellular spaces (Aguilar and 
Mitchell, 2010). The myometrial plasma membrane is known to be more permeable 
to the K+ ions. The ionic gradient is maintained such that the K+ ion content within 
the cell is high, and Ca2+ level is low (Kao et al., 1989). While the K+ is concentrated 
within the cytoplasm, Na+, Cl- and Ca2+ are found to be concentrated outside the 
uterine myocytes (Sanborn, 1995). 
Upon depolarisation of the plasma membrane, there is an influx of Ca2+ which 
occurs as a result of voltage gated calcium channel (VGCC) activation. Repolarisation 
is caused by an outward flow of potassium ions (Figure 1.3). Depolarisation of the 
surface membrane is associated with pacemaker activity and the presence of 
pacemaker cells in the myometrium remains to be elucidated (Shmygol et al., 2007). 
Interstitial cells of Cajal (ICC) have been located in other smooth muscles such as 
urinary bladder and gastrointestinal smooth muscle. These ICC-like cells also known 
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as telocytes have also been found in myometrial smooth muscle (Duquette et al., 
2005). Uterine telocytes are also assumed to play a pacemaker role in the 
myometrium (Othman et al., 2016); however, there remains a debate whether 
these cells perform this function. (Roatesi et al., 2015) suggests that based on 
available data, the pacemaking role of ICC is not required in the uterus (Campeanu 
et al., 2014) but is needed in organs like gut (Carmona et al., 2011), vasculature 
(Cantarero et al., 2011) and urinary tract (Gevaert et al., 2012) that require 
permanent peristaltic wave action to remove their content. In fact, the lack of 
regular slow waves of depolarisation in uterine telocytes has already been shown 
(Duquette et al., 2005, Cretoiu et al., 2013), supporting this point. In the pregnant 
uterus, the site and behaviour of pacemakers has been long researched (Rabotti 
and Mischi, 2015, Lammers, 2012) . It has previously been suggested that uterine 
contractions originate from the fundus (Buhimschi, 2009), however in the rat, 
pacemaker activity is suggested to occur more frequently at the ovarian end of the 
horn (Crane and Martin, 1991). Recent imaging studies have confirmed that in 
guinea pig and rat, the pacemaker area originates at the mesometrial border or 
near the ovarian end (Lammers et al., 2015). 
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Figure 1. 3: Schematic representation showing membrane potential, 
calcium flux and muscle contraction 
Due to ion flux across the membrane, the membrane potential gradually 
rises and falls but these fluctuations do not cross the threshold level. Once 
calcium channels open, calcium enters into the cell and depolarisation 
occurs, causing generation of action potential. When potassium channels 
open, potassium leaves the cell, causing repolarisation, the calcium channel 
closes and the action potential is terminated.  
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1.5.2 Voltage-gated calcium channels 
The voltage-gated calcium channels (VGCC) are activated by changes in membrane 
potential. They are divided into three main types: Cav 1 (L-type), Cav 2 (P-type, N-
type and R-type) and Cav 3 (T-type calcium channels) (Lipscombe et al., 2004), of 
which the L-type and T-type have been identified and expressed in the myometrium 
(Lee et al., 2009, Young et al., 1993). A full list of the subunits and their function is 
shown in Table 1.1. Both channels have been reported in human (Blanks et al., 
2007, Parkington and Coleman, 2001), and animal (Collins et al., 2000, Ohkubo et 
al., 2005) myometrium.  
The T-type calcium channels comprise of three main subunits: Cav 3.1, Cav 3.2, and 
Cav 3.3. They are thought to play a role in the generation and modulation of 
frequency, by producing low voltage activated currents in spontaneous uterine 
contractions (Lee et al., 2009). Although the T-type calcium channels have been 
identified in the myometrium, the L-type channels are regarded the major channel 
for calcium entry and excitation-contraction coupling (Lipscombe et al., 2004). 
The L-type calcium channel is a hetero-oligomeric complex of protein consisting of 
different subunits: α1, β, γ and α2/δ (Collins et al., 2000) (Figure 1.4). The α1 
subunit contains the channel pore and has the characteristic functional and 
pharmacological properties of calcium-channel ion permeability; voltage sensing 
and agonist binding, whereas the others are auxiliary subunits that modulate 
channel activity (Keef et al., 2001). These channels produce high-voltage, long 
lasting currents and account for the calcium current in the myometrium (Shmygol et 
al., 2007). They comprise of four main α subunits: Cav 1.1, Cav 1.2, Cav 1.3 and Cav 
1.4. 
Nifedipine, the L-type calcium channel blocker inhibits spontaneous uterine 
contractions, indicating that L-type calcium channel is the main source of calcium 
entry (Wray et al., 2003). In addition, removal of calcium from a solution bathing 
the uterus results in the contractions ceasing. Direct or indirect agonist stimulation 
could result in L-type calcium channel opening without depolarizing the membrane 
through guanosin-5’-triphosphate binding proteins (Wray, 1993). 
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Figure 1. 4: Subunit structure of L-type voltage gated calcium channel 
The α1-subunit forms the ion-conducting pore and is comprised of four 
repeats (I, II, III and IV) with each repeat containing six membrane-
spanning domain. Adapted from Dolphin 2018. 
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Type Subunits Specific blocker Functions 
L-type Cav 1.1 Dihydropyridine 
(DHP) 
Excitation-contraction coupling in skeletal 
muscle  
L-type Cav 1.2 DHPs Excitation-contraction coupling in cardiac 
and smooth muscle 
L-type Cav 1.3 DHPs Hearing, sinoatrial node function 
N-type Cav 1.4 DHPs Synaptic transmission in CNS, motor 
nerves 
P/Q-
type 
Cav 2.1 ω-CTx-GVIA Neurotransmitter release, 
Dendritic Ca2+ transients 
R-type Cav 2.2 ω-Agatoxin Synaptic transmission in Peripheral 
nervous system (and  Central nervous 
system  especially in early development) 
T-type Cav 2.3 SNX-482 Neurotransmitter release, Dendritic 
Ca2+ transients 
T-type Cav 3.1 None Neuronal excitability, pacemaker activity 
and repetitive firing 
T-type Cav 3.2  Pacemaker activity and repetitive firing 
T-type Cav  3.3  Pacemaking and neuronal excitability 
 
Table 1. 1: Calcium channel types, subunits and physiological functions  
(Dolphin, 2018) 
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1.5.3 Potassium channels 
During pregnancy, the uterine smooth muscle changes remarkably. Although the 
uterus is a myogenic organ, spontaneously contractility, nevertheless, it must 
remain quiescent during the changes that occur during stretch resulting from 
pregnancy and suddenly develop powerful and organized contraction needed for 
labour (Smith et al., 2007). This transition in the uterus from quiescent state during 
pregnancy to labour at the end of gestation is thought to be propelled by changes in 
electrical currents within the myometrial cells (Smith et al., 2007), and potassium 
channels form a part of the mechanism that allows for these changes in the uterus. 
In the myometrium, several types of K+ channels have been identified including: 
calcium-activated potassium (KCa) channel (Perez et al., 1993), the ATP-sensitive 
K+ (KATP) channel (Modzelewska et al., 1998), and voltage-gated K+ (Kv) channels 
(Knock et al., 1999). The variety of K+ channels present in the myometrium indicates 
the complexity of the mechanisms involved in the regulation of the muscle tone 
(Brainard et al., 2007). 
- Calcium activated K+ channels 
In smooth muscles, there are three subclasses of KCa channels that are activated 
with increase in intracellular Ca2+ levels (Blatz and Magleby, 1987, Vergara et al., 
1998). They include the large or big conductance calcium-activated K+ (BKCa), which 
is the most abundant and well-studied in smooth muscle, including the 
myometrium; the intermediate calcium-activated K+ (IKCa); and small conductance 
calcium-activated K+ (SKCa) channels.  
The BKCa channel is shown to be the predominant K+ channel type in non-pregnant 
(Pérez et al., 1993), pregnant human myometrium (Anwer et al., 1993, Khan et al., 
1997) and non-pregnant rat (Song et al., 1999). In normal pregnancy, increased 
intracellular Ca2+ levels activate the BKCa channel (Khan et al., 1993, Anwer et al., 
1993), which could decrease membrane excitability and maintain quiescence 
throughout pregnancy. Using K+ channel blockers: tetraethyl ammonium chloride, 
barium and 4-aminopyridine, BKCa channels are inhibited, resulting in increased 
force and frequency of contractions in human myometrium (Anwer et al., 1993, 
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Khan et al., 1998), partly suggesting that a few of BKCa channels are active at rest 
and may play important role in tissue function. In rat myometrium however, 
inhibition of BKCa channels has resulted in little or no effect in non-pregnant and 
pregnant contractions. The mechanisms underlying ion channel function in labour 
have not been fully understood. Studies in pregnant uterus have shown that BKCa 
channels appear to lose their Ca2+ and voltage dependence with the onset of labour 
(Khan et al., 1997, Khan et al., 1993); overall, the expression of BKCa channels is 
reduced with the onset of labour (Noble et al., 2009). 
Physiologically, the IKCa channels play an important role in salt and fluid transport. 
They also maintain a negative resting membrane potential to help accumulate 
electrical gradients for ion transport (Jensen et al., 2001, Begenisich et al., 2004). 
IKCa channels have a similar structure consisting of a central pore, a calcium sensing 
region and 6 transmembrane spanning regions (Tharp and Bowles, 2009) and unlike 
the BKCa channels, they lack a voltage sensing region, therefore unaffected by 
membrane voltage.  
The SKCa channels have been shown to be expressed in myometrium (Noble et al., 
2010). They have a similar structure to voltage gated potassium channels (Maylie et 
al., 2004), contribute to outward current and regulate membrane potential. The 
SKCa channels are encoded by four genes: SK1, SK2, SK3 and SK4. They don’t 
contain a calcium binding motif to allow direct interaction with calcium, however 
the proximal c terminal domain interacts with calmodulin (Maylie et al., 2004).  SK1-
3 give rise to SK channels that are sensitive to the venom apamin, activated by 
calcium but act independent of membrane voltage while the SK4 is apamin 
insensitive and has greater unit conductance (Maylie et al., 2004). The SK channels 
play a role in the myometrium as regulators of contractions during gestation and 
labour (Brainard et al., 2007).  
Studies have shown that the expression of SK2 can affect the synchronisation of 
uterine contractions by inhibiting calcium entry though L-type Calcium channels 
(Brown et al., 2007). In the mouse uterus, SK3 channels expression has been 
demonstrated to depress phasic contractions by inhibiting calcium influx. In 
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transgenic mice, overexpression of SK3 has been shown to delay parturition 
resulting from inefficient uterine contractions (Bond et al., 2000). Other studies in 
humans have shown that SK3 channels are downregulated in pregnancy, signifying a 
role in maintaining uterine quiescence (Rahbek et al., 2013, Mazzone et al., 2002). 
- ATP-sensitive potassium (KATP) channels 
The KATP channels were first described in cardiac myocytes following their closure in 
response to high intracellular ATP levels (Noma, 1983). They play a major role in 
coupling cellular metabolism to membrane excitability. The KATP channels belong to 
the class of K+ channel known as  inward rectifiers, formed from two membrane-
spanning regions (M1 and M2) flanking the pore (H5) and therefore distinct from 
voltage-gated K+ channels (Khan et al., 2001).  
In human myometrium, the mRNA expression of Kir 6.1, Kir 6.2, SUR1 and SUR2B 
(isoforms of KATP) have been detected and Kir6.1/SUR2B appear to be the 
predominant (Curley et al., 2002).The KATP exist in the rat myometrium and is 
composed of Kir 6.1 and SUR2B subunits (Xu et al., 2011). In the mouse 
myometrium, KATP seem to play an essential role via activation of Kir 6.2 and SUR2B 
(Hong et al., 2016).   
The functional role of KATP channels have been assessed through use of channel 
agonists and antagonists. In human myometrium, KATP channel openers can inhibit 
spontaneous and oxytocin-stimulated contractions (Morrison et al., 1993). One KATP 
opener, diazoxide showed less inhibitory effect in term labouring tissue compared 
to non-labouring suggesting less of a role for KATP channels in labour and overlaps 
with the reduction in potassium channels expression, allowing for the onset of 
powerful contractions. On the other hand, a KATP channel blocker glibenclamide 
induces spontaneous uterine contractions (Bailie et al., 2002).  There is evidence of 
varied results of KATP channel effect between pregnant and non-pregnant 
myometrium indicating difference in expression during gestation (Longo et al., 
2003, Bailie et al., 2002). An increase in outward potassium current causes 
hyperpolarisation of the surface membrane and decreases excitability of the 
smooth muscle cells (Heaton et al., 1993). 
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- Voltage gated potassium (K+) channels 
Voltage-gated K+ (Kv) channels are widely expressed in the myometrium, and play a 
role in maintaining resting membrane potential (Brainard et al., 2007). They are also 
involved in maintaining quiescence and initiation of uterine contractions (Knock et 
al., 1999). In response to depolarisation, K+ efflux occurs via these channels, which 
induces repolarisation of the membrane (Figure 1.3). 
There are four main subtypes of Kv channels: Kv1 (Shaker), Kv2 (Shab), Kv3 (Shaw) 
and Kv4 (Shal), and the Kv4 subtype plays the most important role in myometrium 
during pregnancy (Knock et al., 1999) and are the most subtype identified in human 
myometrium (Brainard et al., 2007) . The expression of KV4.1 and 4.3 has been 
shown to decrease throughout gestation while the Kv4.2 appears to increase before 
parturition (Suzuki and Takimoto, 2005). The decrease of Kv4.1 and 4.3 throughout 
gestation possibly suggests the involvement of hormones in regulating the channels 
in pregnancy. Another study in ovariectomised rats revealed that oestrogen down-
regulated membrane localisation, protein and current expression of Kv4.3 channels 
(Song et al., 2001). Although Kv channels are thought to  play a major role in 
reversing membrane depolarisation, during an action potential (), it is shown that Kv 
channels can also regulate resting membrane potential in smooth muscles like 
airway (Fleischmann et al., 1993) and arteries  (Ishikawa et al., 1997, Gurney et al., 
2003) 
 In mouse myometrium, the expression of Kv channel subtypes have been 
previously examined (Smith et al., 2007, Shi et al., 2016). Smith et al., who 
examined Kv expression across gestational states of mice, demonstrated differences 
in the expression levels of some Kv subunits. They showed a higher Kv1 expression 
in pregnant myometrium than non-pregnant. They also showed a higher Kv4.3 
expression in pregnant compared to non-pregnant tissues; however there was a 
profound reduction close to term. Similar reduction in Kv4.3 expression was 
observed in rat uterus (Song et al., 2001). Their findings suggest that besides 
regulating uterine contractions, Kv channels may have a role in functional changes 
that occur in pregnant myometrium.  
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-  Other K channels 
Although not as well studied, there is evidence for two-pore domain acid sensing K+ 
(TASK) channels in the myometrium. It is shown that the activation of TASK-2 
channels might play a major role in uterine relaxation (Kyeong et al., 2016). TASK-2 
channels are sensitive to changes in extracellular pH (Duprat et al., 1997) and can 
be inhibited by several pharmacological inhibitors (O'Connell et al., 2002). In the 
presence of stretch-activated channels, TASK-2 inhibitors resulted in strong 
longitudinal mouse myometrium (Kyeong et al., 2016). Similar result was obtained 
in uterine circular mouse myometrium when using TASK-2 channel inhibitors (Hong 
et al., 2013).  In comparison to non-pregnant myometrium, pregnant myometrium 
showed increased expression of TASK-2 channels (Kyeong et al., 2016) and this 
increased expression of TASK-2 channels might explain how the uterus 
accommodates the growing foetus during pregnancy. It is suggested that targeting 
these channels might be a means to preventing preterm labours. 
1.5.4 Sodium (Na+) channels 
As well as Ca2+ and K+, Na+ is also considered an important ion in regulating 
myometrial cell excitability (Anderson et al., 1971). Although not fully characterised, 
two voltage-gated Na+ channels: Nav2.1, Nav2.3 have been reported to be expressed 
in human and mouse myometrium (George et al., 1992, Phillippe, 1998). Sodium 
channels generate fast inward current resulting in membrane depolarization. In 
ovariectomised and oestrogen-treated rats, Anderson et al showed that Na+ and 
Ca2+ are essential to produce action potentials in myometrial tissue (Anderson et al., 
1971). In human pregnant myometrium, similar result was obtained (Inoue et al 
1990). In pregnant rats, Kao and McCullough showed that Na+ is the main carrier of 
the early inward current in day 18-21 myometrium (Kao and McCullough, 1975). A 
more recent study in non-pregnant rat suggest that the activation of Na+ channels 
cause opening of L-type calcium channels, resulting in Ca2+ influx and initiation of 
contraction (Seda et al., 2007). 
Some animal studies have shown an increase in Na+ current during pregnancy. Using 
electrophysiological experiment, (Inoue and Sperelakis, 1991) concluded that 
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Na+ current density increases towards term partly due to an increased number of 
cells expressing Na+ channels. They also detected the fast inactivating and 
tetodoxin-sensitive Na+ channels. Similar findings were observed in another study  
(Ohya and Sperelakis, 1989). These studies also suggest that, Na+ channels may 
augment uterine excitability through an elevation of intracellular Ca2+ due to 
activation of Na+/Ca2+ exchanger in response to an increase in transmembrane 
transport of Na+ (Ohya and Sperelakis, 1989, Inoue and Sperelakis, 1991). 
Another study showed in non-pregnant myocytes stimulated with oestrogen 
revealed the presence of Na+ channels and faster kinetics as gestation progressed 
but were nearly undetectable postpartum (Yoshino et al., 1997). The authors 
concluded that an increased Na+ current density and inhibition of K+ channels 
expression resulted in a more excitable myometrium starting mid-gestation and 
promotes coordinated uterine contractions during labour.  A more recent study 
(Reinl et al., 2018) which investigated the mRNA and protein expression of Na+ leak 
channel in mouse revealed that the expression levels decrease in mid-pregnancy, 
increases during labour and remains high in early postpartum period. This increase 
of protein expression observed during labour and in postpartum is similar to what is 
seen with contraction-associated proteins (Miller et al., 1989). The finding by Reinl 
et al., 2018 supports the findings that Na+ leak channel play an important role in 
uterine excitability.  
1.5.5 Chloride channels 
Chloride (Clˉ) channels, which are responsible for the movement of Clˉ ions across 
the cell membrane, are integral membrane proteins and the contribution of these 
channels to the regulation of myometrial tone has been acknowledged. In smooth 
muscles, the concentrations of intracellular Cl- have been measured using different 
techniques and range from 30-50 mM (Kitamura and Yamazaki 2001). The presence 
of Clˉ channels have been confirmed in the following smooth muscles: vascular 
(Pacaud et al., 1991), portal vein (Hogg et al., 1994), mesenteric artery (Klockner, 
1993), and myometrial (Adaikan and Adebiyi, 2005).  
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Two types of Cl− channels have been identified in the smooth muscle: calcium-
activated Cl (ClCa) and volume-regulated chloride (ClVr) channels (Shi et al., 2007), 
which could be activated by any of/ or a combination of changes in Ca2+]i, cAMP, 
pH, extracellular ligands, cell swelling. There is limited evidence to the regulation of 
ClVr in the myometrium, however, it is established that, pregnancy is associated with 
an increase in cell volume (hypertrophy) and ClVr may bring about this swelling.  
The ClCa channels play a role in controlling excitability in rat myocytes (Jones et al., 
2004). They have also been suggested to cause membrane depolarisation via the 
opening of L-type calcium channels (Jones et al., 2004) and lead to calcium influx 
and initiate contraction. Furthermore, inactivating ClCa channels would result in 
repolarisation and subsequently inhibit calcium entry and contraction. A specific 
ClCa channel blocker, niflumic acid has been shown to reduce both spontaneous and 
oxytocin-induced contraction in pregnant rat myometrium (Adaikan and Adebiyi, 
2005). These channels play a significant role in the generation of contractile tone 
and spontaneous contractions in many smooth muscle organs including the 
myometrium (Yarar et al., 2001) and recent studies have implicated their 
importance as the underlying pacemaker conductance in the rat uterus (Jones et al., 
2004). 
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1.6 Regulation of intracellular calcium in uterine contractility 
1.6.1 Role of calcium in uterine contractions 
Uterine contractions are initiated by an increase in [Ca2+]i either through entry of 
extracellular Ca2+ into the cell or via the release of [Ca2+]i from the SR (Shmygol et 
al., 2007, Babich et al., 2004). Consequently, the increase in [Ca2+]i activates a Ca2+ 
binding cytosolic protein, calmodulin (CaM) (Figure 1.5), which can bind four 
Ca2+ ions  (Johnson et al., 1996). Formation of the Ca-CaM complex activates a key 
enzyme, myosin light chain kinase (MLCK) by binding to it. This results in a marked 
increase in the phosphorylation of myosin regulatory light chains (MLC-20), and 
subsequent cross-bridge cycling (Shojo and Kaneko, 2001). Studies show that 
phosphorylation of MLC-20 by MLCK is a major factor of smooth muscle contraction 
(Longbottom et al., 2000). Myosin light chain kinase is highly specific and 
phosphorylates the serine 19 on MLC-20.  This initiates actin-myosin ATPase on 
myosin heavy chains generating mechanical energy for contraction (Kamm et al., 
1989). 
  
50 
 
   
Figure 1. 5: Schematic presentation of calcium entry and initiation of 
contraction in uterine smooth muscle. 
Agonist binds G-protein coupled receptor thereby activating G-protein and 
opening of receptor-operated and plasma membrane Ca2+ channels. In 
parallel, a cascade of events is turned on. The G-protein Gq stimulates PLC to 
cleave PIP2 into DAG and IP3. This induces Ca2+ release from internal stores 
resulting in a rise in [Ca2+]i. This calcium then binds to calmodulin (CaM) 
forming a complex which then activates myosin light chain kinase (MLCK). 
Once activated MLCK then phosphorylates the myosin light chain (MLC) which 
then binds to actin causing contraction. Dephosphorylation of MLC-20 by 
Myosin Light Chain Phosphatase (MLCP) removes the phosphate group from 
MLC and leads to relaxation.  
Calcium is removed from the cell via the use of the sodium calcium (Na+/Ca2+) 
exchanger or the plasma membrane calcium ATPase transporter protein 
(PMCA) or the Sarcoplasmic reticulum calcium ATPase transporter protein 
(SERCA) or a combination of these. The phosphate group is then removed from 
myosin by myosin light chain phosphatase (MLCP), leading to relaxation 
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1.6.2 Mechanism of calcium influx 
Initiation of smooth muscle contractions results from a rise in intracellular calcium 
concentrations from 10-7 M to 10-6 M (Horowitz et al., 1996). Spontaneous 
contraction of the myometrium relies on the calcium influx from extracellular space 
(Kawarabayashi et al., 1989). The release of Ca2+ from intracellular stores, along 
with Ca2+ influx from the extracellular space contributes to the activation of the 
pathway that lead to actin – myosin cross bridge cycling and production of force in 
the presence of ATP (Aguilar and Mitchell, 2010). As well as via the L-type Ca 
channels (Taggart and Morgan, 2007), with agonist stimulation, calcium can also 
enter via the store-operated calcium channels (SOCCs), and via receptor-operated 
calcium channels (ROCCs).  
Receptor-operated calcium channels (ROCCs) are a class of membrane bound 
channels that have a binding site for agonists such as neurotransmitter or 
hormones. The channels open when ligands bind to specific-associated receptors. 
Receptor operated currents have been reported in different types of smooth 
muscles (Smith et al., 2005, Thorneloe and Nelson, 2005).  
There are two types of ROCCs that can be activated by a specific agonist. One that 
can be activated by ATP (Kuriyama et al., 1998) and the other, which opens because 
of G-protein coupled receptors (Inoue et al., 1987). Activation of ROCCs may cause 
fluctuations in membrane potential leading to activation or inhibition of VGCCs 
(Wray, 1993).  
Calcium influx is also possible via the store operated calcium channel (SOCCs). As a 
result of calcium depletion in the SR, calcium can enter the cell via specific store 
channels found in the cell membrane (Putney Jr.* and Pedrosa Ribeiro, 2000). 
SOCC’s are activated by a reduction in the SR calcium content, which results in 
calcium entry known as store operated calcium entry (SOCE). This rise in calcium 
availability may contribute to contractility in the myometrium (Tribe et al., 2000).  
The role for SOCC in the myometrium is currently unclear, nevertheless, the 
underlying mechanism for SOCE are thought to have a relationship with transient 
receptor potential superfamily (TRP), which has been shown to be expressed in 
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human myometrium (Ku et al., 2006). The TRP family has been shown to be 
upregulated in term as well as labour suggesting a role in labour (Dalrymple et al., 
2004). 
1.6.3 Calcium efflux 
Relaxation or termination of myometrial contractions occur when there is a 
decrease in intracellular Ca2+ levels within the cell. This removal occurs via the SR or 
plasma membrane, and is achieved via two mechanisms: the plasma membrane 
Ca2+ ATPase (PMCA) and the Na+ /Ca2+ exchanger (Figure 1.5).  
The PMCA works to maintain resting Ca2+ levels and is described as a high affinity 
system tuned to keeping Ca2+ low (Matthew et al., 2004a) are activated by 
calmodulin binding, which removes auto-inhibition and increases its affinity for Ca2+ 
(Marin et al., 1999). The Na+ /Ca2+ exchanger extrudes one Ca2+ for three Na+ ions, 
which results in direct effect on excitability. It utilises the energy stored in the Na+ 
gradient provided by Na/K-ATPase to allow the efflux of calcium (Floyd et al., 2017). 
The movement of calcium can be reversed if the gradient is also reversed, but this is 
unlikely during normal physiological conditions. Within uterine tissues and cells, the 
Na+ /Ca2+ exchanger exudes 30% while PMCA exudes 70% of the calcium that enters 
the cell (Shmigol et al., 1998, Shmigol et al., 1999).  
Biochemically, relaxation of the myometrium follows a reversal of the Ca2+–CaM 
MLCK pathway. Dephosphorylation of MLCs occurs by myosin light chain 
phosphatase (MLCP), which can also be activated by small G-protein coupled 
protein kinase cascade (Kimura et al., 1996). This causes a dissociation of Ca2+ from 
CaM and inactivation of MLCK (Wray et al., 2003, Wray et al., 2001).  
1.6.4  Regulation of [Ca2+]i by the sarcoplasmic reticulum (SR) 
The uterus consists of an extensive SR, the internal store, which increases in 
pregnancy. The sarcoplasmic reticulum’s Ca2+ -ATPase (SERCA) is a pump found on 
the membrane of SR. It transports Ca2+ from the cytoplasm to the lumen of the SR 
against the calcium concentration gradient. Active transport using the energy from 
ATP hydrolysis is required. Calcium release from the SR occurs via two pathways: 
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Agonist or inositol triphosphate   (IP3) induced Ca2+ release (IICR) and Ca2+-induced 
Ca2+ release (CICR) via Ca2+ release channels (ryanodine receptors) on the SR gated 
by Ca2+ (Pehlivanoğlu et al., 2013). 
The myometrium is stimulated by a variety of agonists whose receptors are coupled 
to G-protein. This leads to the activation of phospholipase C (PLC) and generation of 
the messengers IP3 and DAG. IP3 causes release of calcium by binding to the IP3R on 
the SR (Bultynck et al., 2003), activating the release of calcium from the SR into the 
cytoplasm thereby increasing the [Ca2+]i. Ryanodine receptors (RyRs) sensitive to 
ryanodine, are activated by an increase in the local [Ca2+] and inhibited by 
phosphorylation by PKC (Bonev et al., 1997). It is mainly gated by calcium (Ca2+), as 
cytoplasmic calcium activates RyR channels; a process known as calcium-induced 
calcium release (CICR). RyR receptors do not play a major role on uterine function 
(Noble et al., 2009), as they are non-functional. 
1.6.4 Modulation of force 
The transformation of uterine activity from its state of quiescence to being active is 
regulated by a complex network of interactions (Kota et al., 2013). This interaction 
could be hormonal resulting in changes in force, frequency and duration of 
contractions. Oxytocin, prostaglandin, vasopressin and oestrogen can stimulate 
while progesterone, Nitric oxide (NO) and H2S and relaxin result in relaxation of 
uterine contractions.  
Before the onset of labour, there are two changes that must occur: (1) the uterus 
must be converted from quiescence to active with coordinated contractions, and 
(2), the cervix must dilate, thereby allowing the passage of the foetus from the 
uterus (Kota et al., 2013). These changes (Figure 1.4) are accompanied by shift from 
progesterone to oestrogen dominance, regulation of myometrial oxytocin receptor, 
leading to increased sensitivity to oxytocin, increased prostaglandin synthesis, 
increased gap junction formation, decreased nitric oxide (NO) activity and increased 
influx of calcium into myometrial cells (Kota et al., 2013, Garfield et al., 1998).  
At the level of plasma membrane, a number of G-protein coupled receptor can 
modulate the force of uterine activity. Upon G-protein coupling, activation of 
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different receptors would lead to stimulation of calcium entry thus initiating 
contraction. For instance, oxytocin and prostaglandin receptors are known to 
couple to the G-protein family. These two receptors are discussed further within the 
hormones section. 
1.6.5 Effect of pH change on myometrial contraction 
Changes in intracellular pH (pHi) within the uterus have been shown to cause large 
changes in producing force (Parratt et al., 1995, Taggart and Wray, 1995). Due to 
lactate production and ATP hydrolysis, the change in pHi with contractile activity 
may be anticipated (Taggart and Wray, 1995). Moreover, phasic contractions have 
been shown to be associated with acidification (Naderali et al., 1997).  The first 
measurement of pHi in the uterus was conducted in rats using 31P NMR 
spectroscopy (Dawson and Wray, 1985). They recorded pHi to be approximately 7.1 
for non-pregnant and pregnant rat. Similar measurement (pHi 7.1-7.2) was found in 
human myometrium (Parratt et al., 1994). 
The addition of an acid or base to contracting myometrium results in a change in 
contractility (Pierce et al., 2003). This addition results in a change in extracellular pH 
(pHo) and studies have shown that a change in the pHo may result in alteration of 
pHi thereby affect cell function (Wray, 1993, Austin and Wray, 1995). In human and 
rat myometrium, pHi has been shown to decrease while alkalinisation increase 
spontaneous contraction (Phoenix and Wray, 1993). 
An increase in frequency of contractions has been observed with intracellular 
alkalinisation (Heaton et al., 1992) while intracellular acidification has been shown 
to inhibit uterine contractions (Taggart and Wray, 1993). Although there is evidence 
showing the effect of pH on calcium and force production in human and rat 
myometrium, not much is known about the effect of pH alteration in mouse 
myometrium. 
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1.7 Hormones in pregnancy  
A complex cascade of autocrine and paracrine events involving mother, foetus, and 
the placenta controls pregnancy and labour. Two main changes prerequisite for 
labour are (i) change from the quiescent state to an actively and rhythmically 
contracting state and (ii) change of the cervix from a rigid structure to a soft one, 
known as cervical ripening (Castracane, 2000, Snegovskikh et al., 2006, Weiss, 
2000). In order to achieve a full gestational length, a fine balance of these two 
events is required. Interactive mechanisms such as increased oxytocin sensitivity, 
gap junction formation, increase in the prostaglandins, progesterone withdrawal, 
dominance of oestrogen over progesterone in the uterus, and relaxin action can 
shift this balance towards contractility (Rivera et al., 1990, Holt et al., 2011, Vidaeff 
et al., 2008). The roles of different hormones in pregnancy and labour are discussed 
below. 
1.7.1 Oxytocin 
It is a small nona-peptide hormone secreted by the posterior pituitary gland and 
synthesised by the hypothalamus. Oxytocin binds to a G-protein coupled receptor 
expressed in myometrium (Kimura et al., 1992). Activation of the oxytocin receptor 
stimulates G-proteins of the Gαq family. This results in the activation of 
phospholipase-C β (PLCβ). The PLC-catalysed hydrolysis of phosphatidylinositol 
biphosphate (PIP2) leads to the formation of two messengers:  inositol triphosphate 
(IP3) and diacylglycerol (DAG). IP3 binds to its specific receptor on the SR, thereby 
stimulating Ca2+ release, therefore leading to further Ca2+ influx. The DAG stimulates 
protein kinase C (PKC), but its role in myometrial contractility is unclear 
(Arrowsmith and Wray, 2014). 
The effects of oxytocin are mediated by the expression of oxytocin receptors (OTR). 
The OTR belong to the heterotrimeric G-protein coupled receptor family. Oxytocin 
receptors are abundant in pregnant uterine smooth muscles (Sanborn, 1995, Y Ku et 
al., 1995), with its concentration increasing towards the end of gestation (Fuchs et 
al., 1984), indicating oxytocin has increased potency as pregnancy progresses. This 
marked increase of OTRs toward term is the most consistent finding in parturition 
56 
 
literature (Arthur et al., 2007). Oxytocin stimulates uterine contractions via two 
pathways. Directly, oxytocin stimulates myometrial contractions via the PLC, 
resulting in the release of Ca2+ from intracellular stores (Rivera et al., 1990). 
Indirectly, oxytocin acts by stimulating the release of prostaglandin E2 (PGE2) and 
F2α. Prostaglandin in turn stimulates contractions. Both OTR and PKC activate the 
mitogen-activated protein kinase (MAPK) pathway which leads to prostaglandin 
production and therefore enhanced contractile activity (Molnar et al., 1999, 
Strakova et al., 1998). 
1.7.2 Prostaglandins 
Prostaglandins (PG) are bioactive lipids, synthesised within the amnion and chorion 
membranes as well as the decidua. They are derived from arachidonic acid (AA) that 
is converted to prostaglandin by the prostaglandin synthase enzyme. In the 
myometrium, there are two main stimulating PGs: PGF2α and PGE which are 
reported to increase in a time-dependent manner during the later stage of 
gestation. Active spontaneous labour is associated with an increase in PGE2 and 
PGF2α leading to biochemical pathway similar to acute inflammatory response 
(Brown et al., 1998). 
There are four PGE2 receptors subtypes: EP1, EP2, EP3 and EP4 which are all 
expressed in the myometrium during pregnancy (Astle et al., 2005). When PGE2 
binds to either EP1 or EP3 receptors, it results in contraction and potentiating 
inflammation while the binding of PGE2 to receptors EP2 and/ or EP4 would result in 
relaxation and suppressing inflammation (Brown et al., 1998). This suggests the role 
of PGE2 in maintaining quiescence.  
Although prostaglandin’s role in the regulation of parturition is well known, the 
underlying mechanism of action of prostaglandins bringing about these uterine 
responses is still poorly understood (Hertelendy and Zakar, 2004). 
- Interaction between prostaglandin and oxytocin in myometrium  
The first study supporting the interaction between PG and oxytocin in the 
myometrium was by Vane and Williams (Vane and Williams, 1973). They observed 
that PG inhibitors, indomethacin and meclofenamate reduced oxytocin-induced 
57 
 
contractions in isolated rat uterine strips. Other studies have shown that blocking 
PG biosynthesis, inhibited uterine stimulation in response to oxytocin (Garrioch, 
1978, Chan, 1983). (Wilson et al., 1988) reported that oxytocin’s ability to release 
arachidonic acids from decidua cells from women in labour is significantly greater 
than in non-labouring or non-pregnant women. This suggests that oxytocin 
activates phospholipases, enhancing PG biosynthesis thereby leading to dual 
stimulatory effect from PG and oxytocin. 
1.7.3 Progesterone 
Progesterone is a C-21 steroid hormone that plays a crucial role in pregnancy. 
Circulating progesterone in the system maintains uterine quiescence throughout 
gestation (Mesiano, 2007). In human, the corpus luteum is the main source of 
progesterone at the beginning of pregnancy (Garfield and Yallampalli, 1994), 
however this is changed to after a few weeks of pregnancy as the placenta takes 
over the production of progesterone to become the main source of progesterone in 
pregnancy and labour (Chwalisz and Garfield, 1994, Brown et al., 2004). 
Progesterone downregulates prostaglandin production, oxytocin receptor 
expression and inhibits calcium channel formation, in support of uterine quiescence 
(Fuchs et al., 1984, Garfield et al., 1998). 
With the onset of labour, there is a drop in circulating progesterone in mice 
(Sugimoto et al., 1997), but not in human (Challis et al., 2000) labour. In species like 
mice which depend on corpus luteum as the main source of progesterone, there is a 
withdrawal of progesterone before parturition and it is due to the death of corpus 
which is mediated by prostaglandin F2α. In mice, ovariectomy produced induction 
of preterm labour, whereas administration of progesterone delayed parturition 
(Skarnes and Harper, 1972). Genetically altered mice have been used to study 
mechanisms for declining serum progesterone levels in mice. However, FP receptor 
knockout mice did not deliver their pups at term as a result of functioning corpus 
luteum and, hence, absence of progesterone withdrawal (Sugimoto et al., 1997).  In 
human, the corpus luteum is also the main source of progesterone up to the 7th 
week of pregnancy. The role of progesterone in early human pregnancy is similar to 
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that of laboratory rodents, however, after the “luteo-placental shift,” when the 
developing placenta becomes the principal site of progesterone synthesis, the 
regulatory pathways diverge (Ratajczak and Muglia, 2008). 
1.7.4 Oestrogen 
Oestrogen plays an important role in uterine changes of early gestation. In mice, 
during the first 2 days of gestation, phase I oestrogen secretion occurs. During this 
stage, pre-ovulatory oestrogen stimulates proliferation of the luminal and glandular 
epithelial cells (Robertshaw et al., 2016). At day 3 of gestation, corpora luteal are 
formed, and progesterone secretion stimulates stromal cell proliferation. This 
becomes further potentiated by preimplantation oestrogen (phase II oestrogen 
secretion) on day 4, the day of implantation (Huet-Hudson et al., 1989). This phase 
of oestrogen secretion before implantation ceases epithelial cell proliferation and 
allows for differentiation to occur (Tan et al., 1999). During the remodelling of the 
uterine epithelium, the epithelial cells lose polarity through downregulation of the 
cell-to-cell adhesion molecule E-cadherin (Daikoku et al., 2011, Li et al., 2015). 
Increased endometrial capillary permeability at the location of the blastocyst is also 
exhibited, contributing to implantation (Matsumoto et al., 2002). 
1.7.4 Relaxin 
Relaxin is a potent vasodilator, relevant in regulating haemodynamics in pregnant 
and non-pregnant states (Conrad et al., 2004). Relaxin may play roles within the 
uterus that are important for implantation, placentation and pregnancy 
maintenance (Napso et al., 2018). In mice and other rodents, the concentration of 
circulating relaxin peaks towards term (Marshall et al., 2018).  In pregnant mice, 
relaxin is suggested to play a role in renal function during pregnancy as its 
deficiency leads to proteinuria (O'Sullivan et al., 2017).  Studies also show stiffer 
uterine vessels during pregnancy with relaxin-deficient mice (Gooi et al., 2013). It is 
further suggested that relaxin may be promoting blood flow to the pregnant uterus 
(Marshall et al., 2018). 
In early mouse pregnancy, relaxin modulates the uterine expression of genes 
involved in steroid hormone action and remodelling (Marshall et al., 2016). Studies 
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in mice with deficiency in relaxin signalling showed that obstructed deliveries occur 
at a higher rate and this was due to poor cervix maturation (Krajnc-Franken et al., 
2004, Kaftanovskaya et al., 2015). In summary, relaxin plays a key role in the initial 
changes at the start of pregnancy, as well as preparing the mother for lactation 
(Napso et al., 2018). 
1.7.5 NO and H2S 
H2S, the third endogenous gaseous transmitter is a biological gas endogenously 
produced from L-cysteine in a reaction catalysed by two enzymes: cystathionine β-
synthase (CBS) and/or cystathionine γ-lyase (CSE) (Hosoki et al., 1997, Li et al., 2011) 
and both CBS and CSE have been identified in the placenta and myometrium 
(Holwerda et al., 2012, Hu et al., 2016). H2S is involved in many physiological and 
pathophysiological processes including vasodilation (Skovgaard et al., 2011) 
angiogenesis (Papapetropoulos et al., 2009), and inflammation (Wallace et al., 
2012). In several tissues, the effects of H2S on smooth muscle contractile activity 
have been examined and it is generally associated with a reduction in contractile 
activity. 
In both rat and human myometrium, it has been shown that H2S is produced, with 
expression of CSE and CBS and that hypoxia increases H2S production (Patel et al., 
2009, You et al., 2011). You et al also showed that endogenous H2S produced by CSE 
and CBS suppresses the spontaneous contractility of pregnant human myometrial 
strips and that the expression of both enzymes as well H2S production decreased 
with the onset of labour (You et al., 2011). Their finding suggests that endogenous 
H2S is involved in the initiation and progress of labour in women. A more recent 
study by the same group showed that endogenous H2S produced locally play a 
critical role in the maintenance of uterine quiescence, and this effect is associated 
with suppression of inflammation in uterus (You et al., 2017). 
Nitric oxide (NO) is a reactive gas with a very short physiological half-life. It is 
synthesised from L-arginine by the enzyme nitric oxide synthase (NOS) (Ledingham 
et al., 2000).  Studies have demonstrated the ability of NO donors to decrease 
spontaneous and induced myometrial contraction in a cyclic guanosine 
60 
 
monophosphate (cGMP)-dependent and a cGMP-independent manner (Kuenzli et 
al., 1996, Yallampalli and Garfield, 1993). NO regulates smooth muscle cell 
contractility and spontaneous contraction during the oestrous cycle (Izumi and 
Garfield, 1995). The activity of NOS in maternal tissues increases early in pregnancy. 
It has been demonstrated an increase in expression of inducible NOS mRNA in rat 
uteri and a small increase in expression of endothelial NOS and neuronal NOS mRNA 
during late pregnancy (Ali et al., 1997). Immunohistochemistry study show that 
there is expression of inducible NOS and endothelial NOS in myometrium on days 
17–18 of pregnancy and that expression decreased at term in rats in labour (Riemer 
et al., 1997). It is suggested that the increase in inducible NOS expression in may be 
important in the maintenance of uterine quiescence during pregnancy (Kaya et al., 
1998, Izumi and Garfield, 1995) and that a decrease in its activity is coincident with 
the beginning of the uterine contractions that are necessary for labour (Farina et al., 
2001). 
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1.6 Preterm birth and labour 
Labour is the physiologic process by which a foetus is expelled from the uterus. The 
process involves regular, painful uterine contractions which increase in intensity, 
duration and become more frequent leading to cervical dilation (Kota et al., 2013). 
Normal labour occurs around 37 to 42 weeks of pregnancy. 
Preterm birth is defined as birth before 37 weeks of pregnancy. It is the largest 
cause of perinatal morbidity and mortality, and the high incidence has remained 
unchanged (Leal et al., 2016). In 2010, 14.9 million babies were born preterm 
accounting for 11.1% of all births worldwide (Boyle et al., 2017). The rates of 
spontaneous preterm birth range from about 5% in European countries to 18% in 
African countries (Blencowe et al., 2012). Preterm birth is a leading cause of 
neonatal deaths (Rubens et al., 2014) and morbidity in children less than 5 years old 
(Harrison and Goldenberg, 2016).  The cost of preterm birth to the public sector is 
substantial; accounting for more than £2.9 billion (Mangham et al., 2009). Much of 
the cost is attributed to neonatal intensive care, continued heath care of preterm 
infants and educational requirements (Howson et al., 2013).  
Preterm birth can be spontaneous or medically indicated. Spontaneous preterm 
births account for about 70% of preterm births, with women presenting with 
cervical dilation or preterm premature rupture of membranes (PPROM) (Rubens et 
al., 2014, Boyle et al., 2017). The underlying cause of spontaneous premature 
labour is often unknown; however certain risk factors may contribute to preterm 
labour and birth. They include: drug abuse, previous late miscarriages, low maternal 
weight at time of conception, maternal smoking, uterine abnormalities, cervical 
incompetence, antepartum haemorrhages, multiple gestations, previous preterm 
labour and infection (Vause and Johnston, 2000). The medically indicated preterm 
births are often precipitated by clinical conditions such as preeclampsia, diabetes, 
maternal medical conditions, and foetal problems (Moutquin, 2003) and are not the 
focus of my research since they are not normally labouring.  In the western world, 
about one-third of infants born preterm are delivered by caesarean section or 
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induction of labour because of pregnancy complications, and these deliveries 
contribute to the growing incidence of late PTB (Rubens et al., 2014).  
Several mechanisms could lead to preterm labour including inflammation, infection, 
ischaemia, haemorrhage or stress (Goldenberg et al., 2008). Increased maternal risk 
of preterm birth is associated with extremes in maternal age, multiple pregnancies, 
history of previous preterm births, assisted reproductive technology, family history, 
substance abuse, cigarette use, low socioeconomic status, low maternal pre-
pregnancy weight, bacterial vaginosis, periodontal disease, and poor pregnancy 
weight gain (Institute of Medicine Committee on Understanding Premature and 
Assuring Healthy, 2007). The biological basis for some of these risk factors is poorly 
understood (Rubens et al., 2014). Although many factors including 
sociodemographic, nutritional, biological, and environmental can increase the risk 
of spontaneous preterm birth, the cause is not fully understood (Muglia and Katz, 
2010, Goldenberg et al., 2008). 
Preterm birth is associated with a number of health complications (Rubens et al., 
2014) such as cognitive and neurological impairment such as cerebral palsy, 
respiratory and gastrointestinal complications (Marlow et al., 2005). There is also 
the increased risk of chronic diseases in adulthood, such as obesity, diabetes and 
hypertension (Rubens et al., 2014).  
Clinically preterm labour is diagnosed by confirmation of regular uterine 
contractions and evidence of cervical dilation. Contractions are then managed with 
tocolytics thereby providing time for administration of corticosteroids to reduce 
preterm morbidity and mortality. Despite the high burden of preterm birth on 
childhood mortality, morbidity, and health care expenditure, few strategies are in 
place to effectively prevent preterm delivery. 
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1.7 Treatment of Preterm labour 
Tocolysis, which is the inhibition of myometrial contractions, is currently the 
primary treatment for preterm labour and/or birth. Since uterine contractions are 
one of the most recognised signs of preterm labour, researchers have focused on 
development of tocolytics to inhibit uterine contractions, thereby preventing 
preterm birth. Quantitative studies have demonstrated that all tocolytic drugs are 
able to delay delivery for 48 hours and 7 days, although not at delaying delivery 
until 37 weeks (Haas et al., 2009). The delay is sufficient for antenatal 
corticosteroids to be administered or for the mother to be transferred to tertiary 
care facility (Haas et al., 2009, Haas et al., 2012). Unfortunately, no single tocolytics 
has been able to effectively and optimally inhibit myometrial contractions without 
causing maternal and foetal side effects (Gyetvai et al., 1999). The 2012 World 
Health Organisation report Born Too Soon highlighted the need for effective 
tocolytics (Howson et al., 2013). 
A range of tocolytics has been used to delay labour or treat preterm labour 
including: calcium channel antagonists e.g. nifedipine; magnesium sulphate; 
cyclooxygenase inhibitors e.g. indomethacin and nimesulide; β-adrenergic receptor 
agonists e.g. terbutaline and ritodrine; oxytocin receptor antagonists e.g. atosiban 
and barusiban; and others. Each tocolytic   a unique mechanism of action (Figure 
1.6), side effects and degree of complexity of administration (Goldenberg, 2002). 
1.7.1 Calcium channel antagonists 
Calcium channel antagonists act on the L-type calcium channels preventing calcium 
influx and the spread of action potential required for the myometrium to contract in 
a coordinated manner (Arrowsmith et al., 2010). This leads to a reduction in 
intracellular calcium, inhibiting MLCK phosphorylation, followed by decreased 
myosin-actin interaction promoting myometrium relaxation. 
Nifedipine is a smooth muscle relaxant which reduces the intracellular influx of 
calcium ions. It acts by binding to the inside of the L-type VGCCs causing them to 
remain closed. Though not a licensed tocolytic, nifedipine is recommended by the 
NICE as first line tocolytic (NICE, 2015). Studies have shown that nifedipine is able to 
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delay labour for up to 7 days (van Geijn et al., 2005). A systematic review of 12 
randomised controlled trial involving 1029 women (King et al., 2003) revealed that 
in comparison to other tocolytics, calcium channel blockers reduced the number of 
deliveries within 7 days and prior to 34 weeks gestation.  
Although nifedipine is able to delay labour and is more cost effective than other 
tocolytics, its cardiovascular side effects remain a major concern and therefore not 
recommended for patients with cardiovascular morbidity (Jaju and Dhabadi, 2011). 
1.7.2 Magnesium sulphate 
Magnesium, a bivalent cation is the fourth most common cation in the human body 
(Mercer and Merlino, 2009). Although the effect of MgSO4 on the duration of 
uterine contraction was first described about six decades ago (Hall D, 1959), the 
exact mechanism of magnesium as a tocolytic is not fully understood. Magnesium is 
thought to inhibit contractility by competing with Ca (Arrowsmith et al., 2010). 
Magnesium hyperpolarises the plasma membrane and inhibits myosin light-chain 
kinase activity by competing with intracellular calcium, which in turn reduces 
myometrial contractility (Simhan and Caritis, 2007). Magnesium is thought to act via 
both intracellular and extracellular mechanisms, leading by blocking L-type calcium 
channel entry and blocking agonist-stimulated IP3 channels (Mercer and Merlino, 
2009). 
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Figure 1.6: The mechanism of tocolytics on myometrial 
contractionsOxytocin binds GPCR leading to the activation of G-protein, 
and the cascade of events lead to contractions. Atosiban, an oxytocin 
receptor antagonist competes with oxytocin for its receptors. 
Indomethacin inhibits the enzyme responsible for converting arachidonic 
acid to prostaglandin –cyclooxygenase. Indomethacin may also act by 
blocking calcium channels. Nifedipine and Magnesium are both classed 
calcium channel blockers, blocking L-type calcium channels and calcium 
entry. Nifedipine prevents the reuptake of calcium ions through. 
Magnesium sulphate (MgSO4) inhibits myometrial contractions by 
competing with calcium ions for the calcium channel. Ritodrine, a β-
agonist, acts by increasing cyclic adenosine monophosphate (cAMP), 
leading to relaxation. 
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1.7.3 Cyclooxygenase inhibition 
Cyclooxygenase (COX) inhibitor, also known as prostaglandin synthase inhibitors are 
drugs that inhibit uterine contractions by preventing PG synthesis, e.g. 
indomethacin. Prostaglandins have been proposed to play an important role in the 
onset and maintenance of labour, acting as myometrial stimulant (Olson and 
Ammann, 2007). Both term and preterm labour are associated with increased 
prostaglandin synthesis within the uterus (Skinner and Challis, 1985). COX enzymes 
are fundamental to the production of prostaglandins and inhibitors reduce uterine 
contractions (Doret et al., 2002). There are two COX isoforms, COX-1 and COX-2 
which convert arachidonic acid to PGH2. PGH2 serves as a substrate for the 
production to the alternative prostaglandins and prostacyclins.  
In vitro data have demonstrated the inhibition of uterine contractions with COX 
inhibitors (indomethacin and nimesulide), but not inhibition of PG; however, they 
reduced the Ca2+ channel current in human myometrium (Sawdy et al., 1998). This 
study also concluded that, as there was no relationship between myometrial 
inhibition and PG production. 
1.7.4 β-adrenergic receptor agonists 
The β-adrenergic receptor (β-AR) agonist inhibits myometrial contractions by 
binding to β-AR. Once β-AR is bound, it in turn activates adenylate cyclase by 
stimulating a G protein. The adenylate cyclase enzyme converts ATP to cAMP, 
leading to the increase of intracellular cAMP levels, which in turn activates protein 
kinase A (PKA). This ultimately leads to the inactivation of myosin-light chain kinase, 
thereby reducing contractions. 
With the activation of PKA, there is decreased influx and increased efflux of calcium 
ions, and since [Ca2+]i is the major regulator of the actin-myosin cross bridge, the 
effect of the reduce [Ca2+]i levels is myometrial relaxation. Thus, through activation 
of protein kinase A, the beta agonist causes muscle relaxation in two ways: 
inhibition of myosin light chain phosphorylation and decreasing [Ca2+]i levels (B. 
Caughey and T. Parer, 2001). 
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Of the sub-types β-AR, β2-AR is the most predominant making up to about 80%; 
moreover, this changes depending on the expression at different gestations and 
physiological differences. It has been postulated that a down regulation of β2-AR 
may play a role in the onset of preterm labour, although the mechanism is unclear 
(Arrowsmith et al., 2010). 
1.7.5 Oxytocin receptor antagonists 
As the name implies, oxytocin receptor antagonists are drugs that act as antagonists 
to OTR. They block the activation of the receptors, preventing the stimulatory effect 
of oxytocin, leading to myometrial relaxation. Following activation, Gαq stimulates 
PLC, which then generates DAG and IP3 through the cleavage of PIP2. IP3 is then 
released and binds to calcium channels located on the SR; this results in increased 
[Ca2+]i levels and ultimately smooth muscle contraction (Gimpl and Fahrenholz, 
2001). 
Atosiban is a synthetic analogue of oxytocin and therefore a competitive antagonist. 
It competes with oxytocin for binding to the receptors in myometrium and decidua 
and prevents the increase in [Ca2+]i.  A Cochrane review showed that atosiban is 
effective at delaying birth but did not improve the incidence of preterm births 
before 37 weeks nor improve neonatal outcome (Papatsonis et al., 2005). 
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1.8 Dual Tocolysis 
Although studies show that tocolytics prolong pregnancy in threatened preterm 
labour, the use of tocolytics is not without severe concentration-dependent side 
effects (Berkman et al., 2003). Drugs like calcium channel blockers or prostaglandin 
synthesis inhibitors have high efficacy with low cost, but result in many side effect 
(Maitra et al., 2007, Olson and Ammann, 2007). On the other hand, oxytocin 
receptor antagonist, even though are safe and effective agents, are also very 
expensive (Wex et al., 2009, Al-Omari et al., 2006). As shown in Figure 1.3, each 
tocolytic acts via a unique intracellular pathway, creating opportunities to explore 
combining tocolytics especially those acting via different pathways.  
The combination of tocolytics has been investigated in both animal and human 
myometrium. A recent Cochrane review (Vogel et al., 2014a) pointed that in 
comparison to single agents, combining tocolytics especially those acting via 
different mechanistic pathways may have a greater potential in increasing efficacy. 
Furthermore, combined tocolytics may result in reducing dosage and frequency of 
administration thereby reducing side effects of each agent. The authors also 
suggested the urgent need to explore the effect of combining tocolytics compared 
to single agents (Vogel et al., 2014a). In agreement with their suggestion, this work 
focuses on combining magnesium with most commonly used tocolytics in the UK.   
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1.9 Aims of the Thesis 
Due to the steady rise in preterm birth, and the lack of efficacy of single tocolytics, a 
recent Cochrane review suggested combining tocolytics. In this thesis, I will 
investigate the hypothesis that combining two agents acting via different 
mechanism may produce a synergistic relaxant effect on myometrial contractions. 
Therefore, the aims of my thesis were to: 
(i) investigate the effect of magnesium on spontaneous contractile activity in 
mouse myometrial contractility, 
(ii) compare the effect of magnesium in oxytocin-induced contractions, and 
(iii) investigate how the tocolytic efficacy of magnesium is altered with 
gestational changes, 
(iv) determine if the tocolytic efficacy in different gestations is altered in the 
presence or absence of oxytocin; 
(v) To determine the effect of indomethacin, atosiban, and nifedipine on 
spontaneous and oxytocin-induced contractions, and calculate their respective IC50 
values; 
(vi) To examine the effect of magnesium in combination with  indomethacin 
compared to Mg alone; 
(vii) To examine the effect of magnesium in combination with  atosiban 
compared to magnesium alone; 
(viii) To examine the effect of magnesium in combination with  nifedipine on 
term pregnant mouse uterine contractility compared to Mg alone; 
(ix) To determine which combination of tocolytic is most effective in reducing 
term pregnant mouse uterine contractions; 
(x) determine if  L-type calcium subunits (Cav 1.1 and 1.2) are expressed across 
different gestations of the mouse uterus;  and if present, 
(xi) quantify the mRNA expression of L-type calcium subunit at different 
gestational states using real time qPCR; 
(xii) examine the most commonly used reference genes in mouse uterus; and 
(xiii) identify the most stable housekeeping genes for qPCR across mouse 
gestational states. 
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Chapter 2 
General Materials and Method 
This chapter will provide a general description of the apparatus and methods used 
in this thesis. A more detailed explanation of the methods and chemicals used will 
be given in the relevant chapters. 
2.1 Animals and Tissue Preparation 
2.1.1 Animal Housing 
 Only female CBL57/6J mice (Charles River, UK), were used in the work 
performed in this thesis. Pregnant mice were individually housed in open cage while 
non-pregnant mice were kept in a group of four. The animals were on a 12-hour 
light/dark cycles (7am to 7pm), with access to standard laboratory food; CRM 
pelleted (SDS Ltd, UK), and animals were provided with water ad libitum. Room 
temperature was kept at 21 oC ± 2 oC, and the humidity was kept relatively between 
40-55% as specified by Home Office regulations, UK. 
 
2.1.2 Animal Ethics and Regulation 
 All animals were handled and killed according to the code of practice for 
humane killing of animals under the Schedule 1 (Scientific Procedures) Act 1986. 
The mice were placed in a chamber and anaesthetised with rising concentration of 
CO2. Death was then confirmed by cervical dislocation. If pregnant mice were used, 
the pups were delivered by caesarean section and killed by cervical dislocation. 
2.1.3 Uterine Tissues 
In this study, mice tissues were used as they are easier to obtain at different 
gestations. Uterine tissues were obtained from non-pregnant (weighing 175-200g, 
age of approximately 8-10 weeks), 14-day pregnant, 16-day pregnant, term-
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pregnant (18-19 days gestation), or postpartum day 1 mice. (Parturition in mice 
occurs between days 19 to 20 of gestation). 
Female CBL57/6J mice (Charles River, UK) were time-mated with the male mice 
taken in/taken out of the cage being classed as Day 0/1. When pregnant, mice at 
different gestational ages were humanely killed and dissected accordingly. Term 
tissue was taken from mice that were within 24 hours of labour (Day 19/20).   
Uterine tissues were obtained at approximately the same time (usually between 
8.30am- 9.30am). Non-pregnant uterine tissue was obtained from virgin CBL57/6J 
mice. 
2.1.4 Collection, Dissection and Storage of Uterine Tissue 
The uterus was removed and immediately placed in a buffered physiological saline 
solution (PSS).  
After isolating the uterus, it was then placed on a petri dish containing PSS under a 
light microscope. The uterus was cut open with the endometrium side facing 
downwards. Any excess blood, fat, placenta or connective tissue was cleaned from 
the uterus.  Longitudinal uterine strips measuring approximately 1mm x 2mm x 
10mm were then dissected. Each strip contained endometrium, perimetrium and 
myometrium.  
If the strips were to be used for RNA extraction, they were weighed and placed in 
RNAlater (Thermo Fischer Scientific, US) at 4oC. After about 24 hours, the strips 
were taken out from the RNAlater and placed in cryo-vials. They were then stored in 
-80oC until enough samples were collected to begin RNA extraction. If uterine strips 
were used in contractility, each strip was tied at both ends with surgical silk.  
2.2 Chemicals and Solutions 
 All solutions were purchased from Sigma (Poole, Dorset UK) unless 
otherwise specified. 
2.2.1 Physiological Saline Solution (PSS) 
The PSS/Krebs was prepared freshly daily and had the following composition: 
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Table 2. 1: Components and Composition of Physiological saline Solution 
Using 4M Sodium Hydroxide (NaOH), the pH of the solution is then adjusted to 7.4.  
 
2.2.2 Acidic PSS 
This was made using the same composition as PSS, however the pH was adjusted 
using 1M Hydrochloric acid (HCl). The buffer was not changed as HEPES buffer is 
effective between pH 6.8 and 8.2. The Acidic pH needed in this work was 6.9. 
2.2.3 PSS with Increased Concentrations of MgSO4 
For magnesium and combined tocolytics experiments, increasing concentrations of 
MgSO4 were added to PSS. Table 2.2 shows the concentration of MgSO4. Cumulative 
doses (2-10 mM) of MgSO4 were added to PSS on spontaneous contractions while 
2-12 mM of MgSO4 was applied on oxytocin-induced contractions. Details of 
magnesium’s application for the different protocols are explained within the 
relevant result chapters 3 and 4. 
Composition Concentration Mass 
concentration 
Sodium chloride (NaCl) 154mM 9.00 g/L 
Potassium chloride (KCl) 5.6mM 0.42 g/L 
Magnesium sulphate heptahydrate 
(MgSO4 7H2O) 
0.12mM 0.29 g/L 
4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid buffer 
(HEPES) 
10.9mM 2.60 g/L 
 
Glucose 8mM 2.10 g/L 
Calcium chloride (CaCl2) 2.0mM 2ml/L 
Distilled H20 (dH20)  1L 
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2.3 Drugs and Agents 
Preparation of drugs used in the contractility experiments and the methods of 
application to the organ bath are described in this section. Application of all drugs 
was done after a steady state of contraction was reached. 
  
 
 
 
 
 
 
Table 2. 2: Concentration of MgSO4 added to PSS 
 
2.3.1 Oxytocin 
Oxytocin was dissolved in dH20 to make a stock of 10mM concentration. It 
was then aliquoted in small vials and stored at -20oC, defrosted and diluted in PSS as 
needed on day of experiment. The PSS was then diluted to the desired 
concentrations. For non-pregnant myometrium, a concentration of 1.0nM was used 
while 0.5nM was used for pregnant uterine tissues. A lower concentration of 
oxytocin was chosen in pregnant mouse myometrium, as previous work in mouse 
showed that less was required to produce optimal stimulation (unpublished data). A 
1.0nM concentration in pregnant myometrium would produce tonic contractions in 
most strips. 
Concentration Mass concentration (g/100ml) 
2mM 0.0196 
4mM 0.0686 
6mM 0.1176 
8mM 0.1666 
10mM 0.2156 
12mM 0.2646 
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2.3.2 Atosiban 
Atosiban was dissolved in Bovine Serum Albumin (BSA) to produce 1mM stock 
solution, as per manufacturer’s protocol. It was then aliquoted into small vials and 
stored at -20⁰C until used. 1mM working concentration was used for experiments 
by diluting the stock solution with Krebs and oxytocin. At the beginning, I was trying 
to find the best physiological concentration of atosiban that could block the OTRs 
but not affecting the spontaneous uterine activity. A concentration response was 
carried out between 10nM -3µM and the IC50 value was determined. Consequently, 
I decided to use 500nM final working concentration of Atosiban in my experiments 
to block the OTRs but not affecting the overall uterine activity. 
2.3.3 Indomethacin 
Indomethacin was dissolved in dimethyl sulfoxide (DMSO) to produce 100mM stock 
solution and then stored at room temperature according to manufacturer’s guides. 
A concentration response was carried out from 1 µM -100 µM and IC50 was 
determined for both spontaneous and oxytocin-induced contractions. 3 µM and 30 
µM working concentration for spontaneous and oxytocin-induced contractions 
respectively was used for experimentation by diluting the stock with Krebs’ 
solution. This concentration was chosen carefully, so that should have the 
maximum effect on cyclooxygenase without affecting the overall uterine activity. 
2.3.4 Nifedipine 
Nifedipine (Sigma, UK) was dissolved in ethanol to produce a 1mM stock solution. 
The stock solution was stored at 4oC until required. A concentration response test 
was carried out from 0.1 nM – 30 nM to determine the IC50 values.  
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Figure 2. 1: Recording of contractile activity using an organ bath 
Uterine strips, measuring 1mm x 2mm x 10mm in size, are dissected from mouse 
(A). Surgical strings are tied to the strips (B) with one end attached to a fixed hook 
and the other to a force transducer of an organ bath (C). This was superfused with 
physiological saline solution at 37o C, pH 7.4. Contractility was then measured. 
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2.4 Isometric Tension Measurements 
Firstly, force was calibrated in Newtons (N) using a weight (1g). The 1g 
weight was suspended on the hook connected to the force transducer and the 
deflection was measured.  A 1g weight is 9.81 mN (N is kg/ms2). 
Tissues were tied with surgical silk with one end attached to a fixed hook and the 
other to the force transducer in 5ml organ bath (Linton Instruments, UK) containing 
PSS (Figure 2.1). The tissue strips were then stretched by 5mN. Strips were 
continually superfused with PSS solution, and the temperature was adjusted and 
maintained at 37⁰C throughout the entire experiment using Thermostatic bath 
(Grant Instruments Ltd, Cambridge). The force transducer (World Precision 
Instruments (WPI), UK) was attached to a Digidata acquisition package and Datatrax 
software (WPI instruments, UK). These strips were left to equilibrate for at least 45 
minutes before any experiments began. I established that mouse myometrial tissue 
could sustain contractions for many hours (Figure 2.2). 
During periods of control and application of drugs, four contractile parameters were 
analysed. These parameters were force amplitude, frequency, duration and area 
under the curve (AUC). Figure 2.3 shows how these parameters were measured. 
The analysis of these parameters was done using the Origin Pro Software (Origin 
version 2016).  These parameters were normalised against the control (100%) 
values.   
Force amplitude  
The force amplitude of contractions was determined by measuring the baseline 
value of each contraction and subtracting it from the value of the peak of that 
contraction. The force amplitude is recorded in mN.  If there were no contractions, 
the force was taken as ‘0’. 
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Figure 2. 2: Control contractility trace  
Representative isometric trace showing over 2 hours of spontaneous contractions 
from mouse myometrium at 37oC with perfusion rate 4ml/min 
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Frequency 
The frequency of contractions is a measurement of how many contractions happen 
over a given period. The frequency of contractions is recorded as number of 
contractions/ x minutes, where x was often 10 minutes. If there were no 
contractions, the frequency was taken as ‘0’. 
Duration 
The duration is the amount of time each contraction lasted for. This was measured 
by recording the time at half-maximal height of contractions (50% of force 
amplitude). The duration of contractions was recorded in minutes. If there were no 
contractions, the duration was not measured. 
Area under the curve (AUC) 
The AUC is also referred to as mean force integral. The AUC takes into account all 
the other contractile parameter together. This parameter was measured using the 
Origin Pro 2015 software (Origin Lab Corporation, MA, USA) . If there were no 
contractions, it was recorded as ‘0’. 
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Figure 2. 3: Illustration of the measurement of contractile parameters 
(A) Amplitude measured from baseline to peak of contraction (mN); (B) 
frequency measured by the time difference between the peak of contractions 
(number of contractions/minutes); (C) duration measured by time taken from 
the beginning of a contraction till it relaxes; and (D) force integral determined 
by the area under the curve of a contraction. 
 
 
  
(C) (A) 
(B) 
(D) 
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2.5 Polymerase Chain Reaction (PCR) 
2.5.1 RNA extraction 
Preparation of RNA was achieved using TRIzol reagent (Invitrogen TRIzol® Plus RNA 
Purification kit), a solution that contains phenol and guanidine isothiocyanate, 
which helps to maintain the integrity of the RNA, while allowing for complete 
dissociation of nucleoprotein complexes. This procedure was carried out as per 
manufacturer’s protocol with a few changes. 
TRIzol (1mL) was added directly to uterine samples (~100mg) and homogenization 
was carried out using a tissue homogenizer. The sample lysate was incubated at 
room temperature for 5 minutes to allow complete dissociation to occur, then 
0.2mL chloroform was added, mixed vigorously by hand for 15 seconds and 
incubated for a further 2-3 minutes at room temperature. After centrifugation 
(12,000g) for 15 minutes at 4o C, there was a 3-layer separation consisting of a 
lower, red phenol-chloroform phase, a middle phase and the colourless aqueous 
upper phase (containing the RNA) which was transferred to a fresh tube.  
RNA was precipitated from the supernatant by addition of equal amount of 70% 
ethanol and vortexing. Following centrifugation at 12,000g for 15 seconds at room 
temperature, the supernatant was then removed and discarded. This step was 
repeated until the entire sample was processed.  0.7mL of wash buffer was added 
and centrifuged at 12,000g for 15 seconds, while discarding the supernatants. 
0.5mL of wash buffer II (mixed with ethanol) was also added, and centrifuged at 
12,000g for 15 seconds at room temperature, discarding the supernatant.  
To dry the membrane, the spin cartridge and collection tube (provided in the kit) 
were centrifuged at 12,000g for 1 minute at room temperature. This collection tube 
is then discarded and spin cartridge was then placed in a recovery tube. 30µL of 
RNase free water was added to the spin cartridge and allowed to incubate at room 
temperature for 1 minute. This is followed by centrifugation at no less than 12,000g 
for 2 minutes at room temperature. The spin cartridge was discarded while the flow 
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through was placed immediately on ice if used within a few hours or at -80oC for 
long term storage.  
2.5.2 RNA Quantification  
Following the isolation of RNA, quantification of RNA was carried out using a 
nanodrop ND-1000 spectrophotometer (Thermo Fischer). This step was done to 
determine the purity and integrity of the RNA samples. 
2.5.3 DNase Treatment 
 This procedure was carried out using the TURBO DNA-free Kit (Ambion by 
life technologies). This kit included all reagents used (TURBO DNase, 10X TURBO 
DNase buffer, DNase inactivation reagent and nuclease free water). DNase 
treatment aids the removal of genomic DNA contamination from the RNA 
preparation before reverse transcription. It also helps removal of divalent cations 
that could increase RNA degradation when heated. According to the manufacturer’s 
protocol, a reaction size of between 10 - 100µL was recommended, therefore in this 
thesis, a 50µL reaction size was used.  
 Using the concentration of RNA samples gotten from the nanodrop data, the 
volume of RNA for 10µg in 50µL reaction was calculated. 10x TURBO DNase buffer 
(5µL) and TURBO DNase (1µL) were then added to the predetermined volume of 
RNA and mixed gently. The remaining volume was made up with RNase free water. 
Following incubation of the mixture at 37o C for 20-30 minutes, 5mL of the 
resuspended inactivation reagent was added and mixed. This was then incubated 
for 5 minutes at room temperature while flicking occasionally. The mixture was 
then centrifuged at 10,000g for 1.5 minutes and the supernatant (containing the 
RNA) was carefully transferred into a fresh tube.   
2.5.4 cDNA Synthesis or Reverse Transcription 
Reverse transcription (RT-PCR) utilises the ability of the enzyme reverse 
transcriptase to synthesize DNA from an RNA template. The resulting 
complementary DNA (cDNA) fragments represent the population of genes which 
are expressed in the tissue from which the RNA was extracted. Since the messenger 
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RNA molecules will have been processed and introns excised from the sequence, 
cDNA can be used to study the transcripts present in a given tissue type. cDNA was 
prepared using the AMV First Strand cDNA Synthesis Kit (BioLabs Inc.). The kit was 
stored at -200 C and experiment was carried out as per manufacturer’s protocol. The 
AMV kit composed of AMV enzyme mix, AMV reaction mix, Oligo d(T)23 VN, random 
primer mix and nuclease free water. 
A total of 5ul of RNA was added to 2 µL of Random primer mix (60 µM). The 
reaction volume was made up to 8µL with nuclease free water. To another tube, 10 
µL of AMV reaction mix was added to 2 µL of AMV enzyme mix. The 8 µL of ample 
mix was then added to this tube to make a total of 20 µL reaction. To a separate 
tube (negative control), 10 µL of AMV reaction mx was added to 2 µL of nuclease 
free water.  Again, this was added to the 8 µL of sample mix.  
The 20 µL cDNA synthesis reaction was then incubated at 25o C for five minutes 
before being incubated further at 420 C for one hour. Following this, the reaction 
was terminated by inactivating the enzyme at 800 C for five minutes. The reaction 
volume was made up to 50 µL by the addition of 30 µL nuclease free water and 
stored at -20o C. 
2.5.5 Primers  
The sequence of calcium channel subunit primers (Sigma Aldrich Co.) used in the 
conventional PCR stage was obtained from the literature (Xu et al., 2003). Each 
primer was initially at 100µM of forward and reverse (separately).  A combination of 
forward and reverse primers was done, reconstituting primers to 5µM working 
stock.  When used in PCR reaction, a concentration of 0.5 µM was used.   
For establishing the optimal housekeeping genes, a commercial kit geNorm 
reference gene selection kit was purchased from Primer design UK. The kit contains 
12 genes which have been determined from over 13000 microarray experiments to 
be stably expressed across different tissues, experimental conditions, and different 
disease condition. The kit includes classically used housekeeping genes for 
comparison.  
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Primers for Cav 1.2 were also designed by Primer Design UK. The forward and 
reverse primers were reconstituted and 0.3 µM  concentration (F+R) was used in 
qPCR reaction.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
2.5.6 End-Point or Conventional PCR 
For end-point PCR, the HotStarTaq® Master Mix kit (Qiagen®) was used. 
HotStarTaq® Master Mix is supplied at 2x final concentration, with the final reaction 
concentrations as follows: 2.5 units HotStarTaq DNA polymerase, 1x PCR buffer 
(contains 1.5 mM MgCl2) and 200 µM of each dNTP.  The forward and reverse 
primers were added to the master mix at a final concentration of 0.2µM of each 
primer and template DNA at < 1 µg/ 50 µL reaction. The exact concentrations of 
primer and templates were adjusted to optimise the reaction. The remainder of the 
reaction volume was made up with nuclease free water. An example of the volumes 
used a typical reaction using HotStarTaq® Master Mix is shown in Table 2.3. For my 
experiments, a 10 µL reaction mix was made. 
 
Components Volume used for 
10 µL reaction 
Final concentration 
HotStarTaq master mix 5µL 2x 
Primer mix: includes forward primer 
(10µM) + reverse primer (10 µM) 
1 µL (F+R) 5 µM 
Template DNA  1 µL 200ng/10 µL reaction 
RNase free water  3 µL - 
 
Table 2. 3: Preparation of a 10µL PCR reaction using HotStarTaq® Master Mix 
 
The PCR tubes containing the 10 µL reaction were placed in Bio-Rad T100 Thermal 
cycler (Bio-Rad Laboratories Inc. USA) and PCR conditions were adjusted to optimise 
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the reactions. Table 2.4 shows the optimized cycling conditions used in my 
experiments.  
 Step Time Temperature 
1. Initial heat 
inactivation 
15 minutes 95o C 
2. Denaturation 1 minute 95o C 
3. Annealing  1 minute 50-70o C 
4. Extension 2 minutes 72o C 
5. Number of cycles Repeat steps 2 to 4 (34 times) - 
6. Final extension 10 minutes 72o C 
 
Table 2. 4: PCR conditions for DNA amplification 
The thermocycler ends the amplification process by entering a state of indefinite 
cooling at 4oC. Samples were stored at 2 - 8o C for use the following day. 
 
2.5.7 Agarose Gel Electrophoresis 
 Agarose gel electrophoresis was used in my research to determine the 
presence and size of PCR products.  1% agarose (Sigma) was made by adding 1 gram 
of agarose powder to added to 100ml of 1X TAE buffer (consisting of 4.84g Tris 
base, 1.14ml glacial acetic acid, 2ml 0.5M EDTA, pH 8). Using a microwave, the 
mixture was allowed to heat and melt on medium power and 10 µL SYBR™ safe DNA 
gel stain (Thermo Fischer Scientific) was added to allow visualisation of DNA 
fragments under long-wave ultraviolet light. The melted agarose solution is the 
poured in gel casting tray and the appropriate combs inserted. After the gel was 
cooled and become solid, the combs were then carefully removed and the gel trays 
placed in the electrophoresis chamber. The 1x TAE buffer was poured into chamber 
so that there is about 2-3mm of buffer over the gel. 
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In loading the gel, 2µL of 6x sample loading buffer (BioLabs Inc.) was added to each 
10 µL PCR reaction. 5 µL of sample was pipetted in separate wells.  To provide a 
reference for size, 1.5 µL of DNA ladder standard was pipetted in at last one well on 
each row on the gel. For this thesis, 50bp and 100bp ladder were used (BioLabs 
Inc.).  
Electrophoresis was carried out at 110 volts for about 60-90minutes depending on 
the size of products being resolved. Following electrophoresis gels were visualised 
on an ultraviolet transilluminator and images were captured using the capture 
feature of the software, UVP Chemi TS software (Analytik Jena, US). 
2.5.8 Choice of reference or housekeeping genes 
Several statistical tools, including geNorm, Normfinder and Bestkeeper are available 
to identify the most stably expressed genes. Studies have shown that in most cases 
there is no significant difference between the different tools (De Spiegelaere et al., 
2015, Wang et al., 2002) as studies using them have shown very similar results. The 
geNorm software (geNorm package v 3.5) was selected and used in this thesis to 
select the most stable genes. 
GeNorm is an algorithm that determines the most stable reference genes from a set 
of tested candidate genes in a given sample panel. A gene expression normalisation 
factor can be calculated for each sample based on the geometric mean of a user 
defined number of reference or housekeeping genes.  
Pairwise variation (Vn/n+1) of each gene is determined as standard deviation of the 
logarithmically transformed expression ratios. This is calculated to evaluate the 
minimum number of reference genes required for normalization. A pairwise 
variation of 0.15 is considered the cut-off value below which the inclusion of 
additional reference gene will not be required (Vandesompele et al., 2002).  An M 
value is calculated for a particular gene as the arithmetic mean of pairwise variation 
with all other genes in the same panel. Genes that are stably expressed are 
characterised by the lowest M value. Stepwise exclusion of the least stable genes 
results in combination of two constitutively expressed reference genes 
(Vandesompele et al., 2002) 
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My qPCR results were normalised to reference or housekeeping genes, and 
therefore results are an expression of the relative quantification of the gene of 
interest in relation to the endogenous control. 
2.5.9 Quantitative real-time PCR 
Quantitative real-time PCR assay is a reliable and fast technique for the 
quantification of transcription levels in gene expression studies, and are used 
frequently in many areas of modern research. This technique provides 
quantification of input templates over a broad linear range, low sample 
consumption, rapid throughput of large sample numbers, and low risk of 
contamination (Gibson et al., 1996, Livak et al., 1995).  
Using SYBR green chemistry, real-time PCR was performed with CFX Connect Real-
time system (BioRad laboratories, Hercules, CA, USA). Details on the amplification 
mixture are specified within chapter 5. 
Relative standard curves for target genes and housekeeping genes were 
constructed from a serial dilution of cDNA template. Both samples and standards 
were run in triplicates on 96-well Hard Shell® PCR thin-wall plates (Bio-Rad 
laboratories Inc. USA), with every run including a no template control (NTC or no 
cDNA). An optimized volume of cDNA was used for the amplification of each gene. 
Precision ® FAST qPCR Master Mix was used for qPCR and the samples were treated 
according to the manufacturer’s instructions (Primer Design, UK). The reaction 
components are detailed in the result chapter.  
 
2.5.10 Analysis and determination of target gene expression relative to 
housekeeping gene 
Accurate normalisation is fundamental to obtaining sound results. Normalisation is 
usually achieved by simultaneous amplification of housekeeping genes along with 
the target gene. 
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For every sample, the cycle threshold (Ct) value was determined using the CFX 
Software (Bio-Rad laboratories Inc. USA). The threshold value indicates background 
level of fluorescence. The Ct value indicates the number of cycles at which the 
fluorescence passes the set threshold value and is therefore a way to determine the 
concentration of the gene of interest.  
Since my samples were run in triplicate, the Ct values were then determined for 
each well and the mean Ct value was used, and where Ct values differed by more 
than 1.2, they were excluded and samples repeated. The expression of target gene 
was then determined relative to the housekeeping gene value for each sample. 
Generally, the lower the Ct values, the greater the amount of gene expression. 
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2.6 Sample Size in this Thesis  
The sample size is the number of uterine strips used from each mouse. In this 
thesis, there is variation in the samples size between different protocols. We 
considered using power calculation; however determination of n numbers was 
taken from previous animal studies by us and others. Power calculations are more 
generally used in clinical studies, where there can be very large sample sizes and 
small, but important, effects. In biomedical science experiments, previous 
knowledge of statistical variation in control parameters, e.g. amplitude of 
contraction, and estimates of effect size, guide the choice of n numbers. Generally, 
the focus was to do the experiments by using as large a number as needed for 
significance and to uphold the guidelines set by the UK home office legislation for 
animal use. As a result, it is important to kill the smallest number of animals 
consistent with obtaining meaningful data The sample size was calculated 
retrospectively using the formula: n= 2(Z2 σ2/E2) where Z is the value from the 
standard normal distribution reflecting the confidence level that will be used (e.g., Z 
= 1.96 for 95%), σ is the standard deviation of the outcome variable and E is the 
desired margin of error. The formula used generates the minimum number of 
samples required to ensure that the margin of error in the confidence interval does 
not exceed E. Therefore with an error of 0.05 (5%) with a power of 0.5, an alpha 
significance level of 0.05 with a 95% Confidence interval, power analysis indicated 
similar sample size as that used: at least an n of 4 in pH and nifedipine protocols and 
the others at least an n of 8. 
2.7 Data and Statistical Analysis 
Cumulative concentration-response curves were fitted to the logistic equation using 
non-linear regression.  The 50% inhibition concentration (IC50) was calculated for 
each tocolytic using the sigmoidal dose–response equation “log [inhibitor] vs. 
response – variable slope”. The –log IC50 values between groups were compared on 
the basis of the extra sum of squares F-test. The top plateau of the curve was 
constrained, and the effects of the drugs on Log IC50 values and steepness of the 
curve (Hill slope) for AUC activity were analysed by GraphPad Prism 6.0 (GraphPad 
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Inc) using a sigmoidal dose response (variable slope) to test the null hypothesis that 
log IC50 and Hill slope are the same for each data set.  Statistical significance 
between the values was calculated using ANOVA and the appropriate post hoc test 
for multiple comparisons was chosen (Bonferroni comparison for multiple pairs) at 
each individual concentration of the tocolytics (antagonist) used.  
In general, graphs and tables were constructed using Microsoft Excel 2016, Origin 
Pro 2016, and GraphPad Prism 6.0. Data were represented as Mean ± standard 
error mean (SEM). For all tests, significance was taken as a p value less than 0.05 
(p<0.05*).The specifics of statistics for each chapter are discussed within the results 
chapter. 
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Chapter 3 
Gestational and Hormonal effects on Magnesium 
Sulphate’s Ability to Inhibit Mouse Uterine Contractility. 
3.1 Abstract 
 Magnesium sulphate is used as a tocolytic, but clinical efficacy has been seriously 
questioned (Grimes and Nanda, 2006). The main objective was to use controlled ex 
vivo conditions and known pregnancy stages, to investigate how two key factors, 
hormones and gestation, affect Magnesium’s tocolytic ability. It was hypothesised 
that these factors could underlie the varying clinical findings around Magnesium’s 
efficacy. Myometrial strips were obtained from non-pregnant (n=10), mid-term 
(n=12) and term-pregnant (n=11) mouse uterus. The strips were mounted in organ 
baths superfused with oxygenated physiological saline at pH 7.4 and 37 °C.  The 
effect of different concentrations of MgSO4 (2 – 20mM) was examined on 
spontaneous and oxytocin-induced (0.5-1nM) contractions. Contractile properties 
(amplitude, frequency and area under the curve, AUC) were measured before and 
after application of Magnesium.  Magnesium sulphate had a concentration-
dependent inhibitory effect on both spontaneous and oxytocin-induced 
contractions but was less effective in the presence of oxytocin. In spontaneous 
contractions, Magnesium was more potent as gestation progressed (P<0.0001).  In 
the presence of oxytocin however, there were no significant gestational differences 
in its effects on contraction.  The rapid onset and reversal of Magnesium’s effects 
suggest an extracellular action on Calcium entry. Taken together I can conclude that 
Magnesium’s actions are influenced by both gestational state and hormones, such 
that, at least in mice, it is least effective in early gestation with oxytocin present and 
most effective at term in the absence of oxytocin.  That Magnesium is least effective 
preterm and oxytocin decreases its effectiveness throughout gestation, may explain 
its disappointing clinical effects as a tocolytic. 
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3.2 Introduction 
The high incidence of preterm birth, >10% of births worldwide, remains unchanged 
despite much research effort and advancement in understanding uterine physiology 
(Cypher, 2012). It is the single largest cause of mortality and morbidity in newborns. 
Several tocolytics including oxytocin-receptor antagonists e.g. atosiban, 
prostaglandin synthesis inhibitors e.g. indomethacin, calcium channel blockers e.g. 
nifedipine, beta-2 agonists e.g. ritodrine, and magnesium sulphate (MgSO4) have 
been developed to help prolong pregnancy, by reducing or slowing uterine 
contractions when preterm labour threatens. Unfortunately, it remains the case 
that none are ideal in terms of either efficacy or side effects, and perhaps not 
surprisingly there is little international consensus on which tocolytic to use to help 
manage spontaneous preterm labour.  
Magnesium sulphate was described as a tocolytic in 1959 (Hall D, 1959) and shortly 
after became the preferred drug in treating preterm labour. More recently 
however, studies including Cochrane systemic reviews (Crowther et al., 2014) 
(Crowther et al., 2002) have suggested that MgSO4 is ineffective in the treatment of 
preterm labour. For example Crowther et al., (2014) concluded that it was no better 
than placebo for the primary outcome of giving birth within 48 hours of trial entry, 
and nor was there any significant difference for the primary outcome of serious 
infant morbidity (Crowther et al., 2014). In contrast, MgSO4 has been shown to be 
the drug of choice in treatment of seizures in eclampsia (Lucas et al., 1995) and 
prevention of preeclampsia in hypertensive pregnant women (Duley et al., 2010). 
Additionally, MgSO4 has been shown to have neuroprotective effects in preterm 
foetuses at delivery, reducing the risk of death, cerebral palsy, and gross motor 
dysfunction (Doyle et al., 2009).  
In contrast to clinical findings, in vitro studies have consistently found that 
Magnesium has a relaxant effect on smooth muscles including airway 
(Gourgoulianis et al., 2001) and vascular (D'Angelo et al., 1992).  Studies in 
myometrial smooth muscle show it to be a relaxant in several species (Kantas et al., 
2002, Kawarabayashi et al., 1989, Tica et al., 2007, Popper et al., 1989); it 
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significantly inhibits contractions in a concentration-dependent manner(Tica et al., 
2007, Arrowsmith et al., 2016).  
In smooth muscles, Magnesium inhibits contractility via multiple mechanisms 
including effects on extracellular calcium entry, intracellular calcium release and 
calcium oscillations (Phillippe, 1998). It primarily acts by competing with Ca2+  at the 
L-type, voltage-gated Calcium channel (VGCC), resulting in a decrease in 
intracellular calcium concentration (Phillippe, 1998)   The channel is comprised of 
four subunits, of which α-1 is the pore forming, voltage sensitive and conducting 
component, and the others modulate its activity. Progression of gestation has been 
linked to an increase in α-1 expression, and VGCC activity increases close to term 
(Tezuka et al., 1995, Mershon et al., 1994, Collins et al., 2000). These findings 
suggest that Calcium channel density and expression increases with gestation.  As 
Magnesium’s main action is at the calcium channel, the question arises: could these 
changes in Calcium channel density and expression alter the effectiveness of 
Magnesium at different gestational ages?  
Of the hormonal changes around labour, oxytocin has a pivotal role (Arrowsmith 
and Wray, 2014). Oxytocin stimulates myometrial activity via a variety of 
mechanisms, including increasing Ca2+ entry into the myometrium via L-type 
channels and stimulating Calcium release from the sarcoplasmic reticulum 
(SR)(Luckas et al., 1999, Matthew et al., 2004b).  Oxytocin stimulation would 
therefore be expected to mitigate the actions of Magnesium.  Thus if women with 
threatened preterm labour had differing levels of oxytocin or differences in levels of 
expression of its receptor (Blanks et al., 2007), this may also alter responsiveness to 
Magnesium tocolysis in vivo.  
It would be of benefit if the in vivo and in vitro findings concerning Magnesium’s 
effects on uterine contractility could be reconciled. This could then enable a 
stratification of which threatened spontaneous preterm labours may benefit from 
its use as a tocolytic. The approach was to consider if there may be physiological 
factors which affect Magnesium’s efficacy in vivo.  Preterm births are defined as 
those before 37 completed weeks of gestation, and thus cover a very large 
gestational age range and much change in myometrial physiology and hormonal 
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conditions(Byrns, 2014, Shynlova et al., 2009, Breuiller-Fouche et al., 2007, Garfield 
et al., 1998). These changes can be anticipated to also affect Magnesium‘s tocolytic 
ability. 
While the effect of Magnesium in animal and human term-pregnant myometrium 
on spontaneous (Tica et al., 2007, Popper et al., 1989, Arrowsmith et al., 2016) and 
oxytocin induced contractions (Tica et al., 2007, Phillippe, 1998, Arrowsmith et al., 
2016), has received some attention, the effect of Magnesium at different 
gestational stages has not been systematically investigated. In addition, neither has 
the influence of oxytocin on Magnesium’s action been studied throughout 
gestation. Furthermore, much can be learnt from mouse animal models, but only 
one study was found where they have been used to look at Magnesium’s relaxant 
effect, and that was on day 14 of pregnancy in lipopolysaccharide (LPS)-treated 
animals (Sugawara et al., 2007).   
The aims of this study therefore were to: 
 
(i) investigate the effect of magnesium on spontaneous contractile activity in 
mouse myometrial contractility, 
(ii) compare the effect of magnesium in oxytocin-induced contractions,  
(iii) investigate how the tocolytic efficacy of magnesium is altered with 
gestational changes, and 
(iv) determine if the tocolytic efficacy in different gestations is altered in the 
presence or absence of oxytocin; 
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3.3 Methods 
 
3.3.1 Solutions  
All study solutions were prepared fresh at the start of each experiment by direct 
dissolving of MgSO4 or MgCl2 in buffered physiological saline solution (PSS) 
composed of (mM): NaCl 154, KCl 5.6, MgSO4 1.2, CaCl2 2, Glucose 8 and HEPES 
10.2 (Jones et al., 2004). Basal or control MgSO4 therefore was 1.2mM. Oxytocin 
was prepared in distilled water and added to the PSS to give a final concentration of 
0.5nM (pregnant tissues) or 1nM (non-pregnant tissues). A 1nM concentration of 
oxytocin was used for non-pregnant tissues to ensure a similar stimulation to that 
seen in pregnant tissues was achieved. The concentration of water did not exceed 
0.01%. All chemicals were obtained from Sigma UK. 
 
3.3.2 Tissue collection and preparation  
Uterine tissues were collected and prepared as previously described by our group 
(Arrowsmith and Wray, 2014). Non-pregnant, 14- and 16- day (referred to as mid-
pregnant) and 18 day (term) pregnant mice were humanely killed using CO2 
anaesthesia and cervical dislocation, in accordance with UK Home Office 
regulations. All mice used were between 8-10 weeks old. The uterus was removed, 
cleaned of placentas and membranes (where applicable) and full-thickness 
(endometrium intact) myometrial strips (1 x 2 x 10 mm) were dissected along the 
longitudinal axis (Matthew et al., 2004b). Using surgical thread, individual strips 
were mounted between a fixed support and a 10g isometric force transducer 
(World Precision Instruments, UK) within a 5ml tissue bath (Linton Instruments, UK) 
under a resting tension of 5mN and were continuously superfused with oxygenated 
(95% O2, 5% CO2) PSS at pH 7.4, at a rate of 5mL/min and maintained at 37oC to 
mimic physiological conditions(Babiychuk et al., 2004). 
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3.3.3 Experimental protocol 
For spontaneous contractions, strips were allowed to equilibrate for 45-60 minutes 
until regular, frequent and equal amplitude contractions were observed. For 
oxytocin-induced contractions, strips achieved regular spontaneous activity as 
above, ahead of addition of oxytocin which remained in the superfusate 
throughout. The uterine strips were then exposed to increasing concentrations of 
MgSO4 from 2 – 10 mM (spontaneous) and 2 – 12 mM (oxytocin-induced) for 15 
minutes or MgSO4 or MgCl2 (10mM and 20mM), either in the presence or absence 
of oxytocin.  
 
3.3.4 Analysis and statistics 
Myometrial contractions were continuously recorded via the force transducer 
connected to a data acquisition system equipped with Labtrax software (World 
Precision Instruments, UK)(Babiychuk et al., 2004). For each recording, the 
amplitude, frequency and force integral (area under the curve, (AUC) of contraction 
were measured, both during the control period (contractions occurring in the ten 
minutes immediately preceding the first application of Magnesium) and during the 
final ten minutes of each step in the concentration-response period.  Data were 
analysed using Origin Pro 2015 (Origin Lab Corporation, MA, USA) and are 
presented as percentage of control to reflect the effect of Magnesium, where the 
control period is taken as 100%. Values given are mean ± standard error of the 
mean (SEM) unless stated otherwise and were compared by ANOVA, n is the 
number of myometrial tissue strips, each one from a different animal, N.   
Concentration-response curves for AUC were fitted to the logistic equation with the 
use of non-linear regression.  The concentration at which MgSO4 caused a 50% 
reduction (IC50) in overall contractile activity (AUC) was calculated. Log IC50 values 
were compared by the extra sum of squares F test or ANOVA followed by 
Bonferroni post-hoc analysis.
 
All statistical analysis was carried out using GraphPad Prism 6.0, significance was 
taken as P<0.05. Summary of analyses performed: 
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1) Effect of MgSO4  vs. MgCl2 - compared using t tests. 
2) Tables 1 and 2- ANOVA with Bonferroni post hoc correction. 
3) Comparison of LogIC50 values for Magnesium on spontaneous or oxytocin 
contractions between gestational groups – ANOVA with Bonferroni post hoc 
correction. 
4) Comparison of LogIC50 values for effect of magnesium on spontaneous vs. 
oxytocin simulated contractions at each gestation - Extra sum of squares F-test. 
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3.4 Results 
3.4.1 Control data and effects of Magnesium on late-pregnant mouse 
myometrium. 
As there were little or no data concerning the actions of Magnesium on mouse 
myometrium, initial experiments were performed to, determine that Magnesium 
affected contractility, that the effects of MgSO4 were due to Magnesium and not 
the anion, and to obtain an indicative concentration for concentration-response 
curves.  
As shown in Figures 3.1A and 3.1B, stable, control contractions from pregnant 
mouse myometrium could be obtained for several hours without decrement in 
spontaneously active (A) and oxytocin-stimulated (B) tissues (typical of 9 
preparations). Figure 1 also shows typical traces obtained using either 10 mM or 20 
mM MgSO4, (Figure 3.1C) or, MgCl2 (Figure 3.1D), from three paired experiments 
(different animals), on oxytocin-stimulated pregnant myometrium. No significant 
differences were found between the effect of 10mM MgSO4 and MgCl2: amplitude: 
70 + 14% and 77 + 9%; AUC: 50 + 7 and 58 + 2%, respectively, nor were any 
significant differences found between MgSO4 or MgCl2 during spontaneous activity 
(data not shown). Based on these data, the remaining experiments were performed 
using MgSO4 as it is the sulphated form which is used clinically, and the effects of 
different concentrations and gestation were examined. 
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Figure 3.1 The effects of magnesium on contractions of mouse myometrium 
Typical records showing contractions obtained from term-pregnant mouse 
myometrium. In this and all subsequent figures, data were obtained at 37°C and pH 
7.4, with tissues superfused with physiological saline (containing 1. 2 mM MgSO4), 
in the absence (A & B)  and presence of increased  (10 or 20 mM) magnesium as 
sulphate (C ) or chloride (D) salt. Traces B, C & D, were in the presence of oxytocin 
(0.5 nM). 
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Figure 3.2: The effect of magnesium sulphate on spontaneous contractions of 
non-pregnant mouse myometrium. 
Figure showing (A) representative isometric trace showing the effect of 
increasing concentrations of magnesium sulphate in non-pregnant. Bar charts 
show the effect of magnesium sulphate on (B), amplitude, (C), frequency (D) 
duration and (E) the area under the curve (AUC). Significant difference was 
found using ANOVA with Bonferroni post hoc test. The coloured bars indicate 
the 15-minute period when magnesium sulphate was added. 2mM (blue), 4mM 
(orange), 6mM (red), 8mM (green), and 10mM (purple). 
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3.4.2 Effects of Magnesium on spontaneous contractions of non-pregnant 
myometrium. 
The inhibitory effect of Magnesium on spontaneous contractions of non-pregnant 
mouse myometrium was examined. Increasing concentration of magnesium (2-
10mM) was applied to spontaneously contracting myometrial strips for 15 minutes 
(Figure 3. 2A) and its effect on contractility parameters was determined (Figures 3. 
2 B-E). In comparison to control, magnesium caused a concentration dependent 
decrease in force and frequency of contractions. There was a significant decrease of 
amplitude at 6mM and higher. At the highest concentration used, magnesium 
reduced amplitude of contractions to 81.5% ± 3.5 (relative to control, 100%), P< 
0.01. At 4mM and higher, magnesium significantly reduced the frequency of 
contractions, reducing it to 31.2% ± 2.9 (P<0.01). There was no significant effect on 
duration of contractions even at the highest concentration. A concentration 
response curve was plotted to show the AUC of spontaneous contraction and the 
IC50 value was determined as 7.06mM ± 0.32.  
3.4.3 Effects of Magnesium on spontaneous contractions of day 14 pregnant 
myometrium. 
The concentration-dependent effect of magnesium on day 14 pregnant 
myometrium was examined. As described for non-pregnant myometrium, 
increasing concentrations of magnesium (2-10mM) was added to the strip (Figure 
3.3A). Bar charts showing magnesium’s effect on spontaneous contractions are 
represented in Figures 3.3B-E. Magnesium caused a significant reduction in 
contraction amplitude from 8mM onwards. At 10mM, magnesium reduced 
amplitude to 42.4% ± 12.5 (relative to control, 100%), p < 0.001.  From 4mM 
onwards, the frequency of contractions was also significantly decreased.  The 
duration of contractions was significantly decreased at 8mM and 10mM of 
magnesium’s application. At 10mM, duration was reduced to 61.6% ± 13.6 (p<0.05) 
relative to control. From the concentration response curve plotted with AUC values, 
the IC50 was determined as 4.75mM ± 0.21.  
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3.4.4 Effects of Magnesium on spontaneous contractions of day 16 pregnant 
myometrium. 
In day 16 pregnant mouse, MgSO4 reduced spontaneous contractions in a 
concentration-dependent manner. Figure 3.4 shows a representative trace of 
magnesium’s 15-minute application of each concentration.  The bar charts showing 
magnesium’s effect on amplitude, frequency and duration are represented in Figure 
3.4B-E. Magnesium decreased contraction amplitude at 8mM and higher. At 10mM, 
contractions were reduced to 66.0% ± 15.0 (P<0.01). The frequency of contractions 
were also greatly reduced from 6mM onwards and reached 23.3% ± 11.7 at 10mM 
(P<0.01). There was no significant effect on the duration of spontaneous 
contractions.  The IC50 value determined from AUC was 5.50mM ± 0.26.  
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Figure 3.3: The Effect of Magnesium sulphate on spontaneous contractions 
of day 14 pregnant mouse myometrium 
Figure showing (A) representative isometric trace showing the effect of 
increasing concentrations of magnesium sulphate in non-pregnant.  
Bar charts showing magnesium sulphate’s effect on (B), amplitude (C), 
frequency (D), duration and (E) the area under the curve (AUC).  
Significant difference was found using ANOVA with Bonferroni post hoc test. 
The coloured bars indicate the 15-minute period when magnesium sulphate 
was added. 2mM (blue), 4mM (orange), 6mM (red), 8mM (green), and 10mM 
(purple). 
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Figure 3. 4: The effect of magnesium sulphate on spontaneous contractions of 
day 16 pregnant mouse myometrium. 
Figure showing (A) representative isometric trace showing the effect of increasing 
concentrations of magnesium sulphate in non-pregnant. Bar charts showing 
magnesium sulphate’s effect on (B) amplitude, (C), frequency (D) duration and (E) 
the area under the curve (AUC).  
Significant difference was found using ANOVA with Bonferroni post hoc test. 
The coloured bars indicate the 15-minute period when magnesium sulphate was 
added. 2mM (blue), 4mM (orange), 6mM (red), 8mM (green), and 10mM (purple). 
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3.4.5 Effects of Magnesium on spontaneous contractions of day 18 (term) 
pregnant myometrium. 
 Increasing concentrations of magnesium was added to spontaneously contracting 
term pregnant myometrium for 15 minutes (Figure 3.5A). Magnesium caused a 
concentration-dependent reduction and abolition of contractile activity (Figure 
3.5B-D). Once magnesium was removed and perfused with normal PSS, contractions 
resumed. There was a significant decrease in contractile parameters- amplitude, 
and frequency of contractions when compared to control. The amplitude of 
spontaneous contraction was significantly reduced at concentration ≥ 4mM. The 
frequency of contractions was significantly reduced from the first application of 
magnesium (2mM). There was no significant effect on the duration of contractions. 
From the AUC values, a concentration-dependent curve was plotted (Figure 3.5E) 
and the IC50 value was determined as 3.08mM ± 0.16. 
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Figure 3. 5: The effect of magnesium sulphate on spontaneous contractions of day 
18 pregnant mouse myometrium. 
Figure showing (A) representative isometric trace showing the effect of increasing 
concentrations of magnesium sulphate in non-pregnant. Bar chart showing 
magnesium sulphate’s on (B) amplitude, (C), frequency (D) duration and (E) the area 
under the curve (AUC). Significant difference was found using ANOVA with Bonferroni 
post hoc test. 
The coloured bars indicate the 15-minute period when magnesium sulphate was 
added. 2mM (blue), 4mM (orange), 6mM (red), 8mM (green), and 10mM (purple). 
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3.4.6 Comparing the effects of Magnesium on spontaneous contractions at 
different gestational states. 
The effects of the application of increasing concentrations of MgSO4 in the 
superfusate bathing the spontaneously contracting myometrial strips were 
examined and compared at day 14, 16 and 18 of pregnancy, and non-pregnant. 
Concentration-dependent inhibitory effects of Magnesium were found at each 
gestational state investigated as well as non-pregnant tissues.  For all preparations, 
there was a decrease in frequency of contractions followed by a reduction in 
contraction amplitude.  The mean data show that Magnesium reduces spontaneous 
activity of the myometrium in all tissue groups (Tables 3.1- 3.4), with its effect 
becoming more marked (and significant) as term approaches: In non-pregnant and 
day 14-pregnant tissues, contractions in the presence of 10mM MgSO4 still 
persisted, with the AUC being 40% and 18% of control respectively. In term-
pregnant myometrium 10mM MgSO4 further and significantly reduced the AUC to 
negligible values (6%, Figure 3. 5A).  The increased effects of Magnesium with 
gestation can also be appreciated from the fact that, in non-pregnant, day 14 and 
16 tissues, contractions were abolished in just 1/22 preparations (on day 16), 
whereas at term, Magnesium abolished contractions in over half the tissues (6/11 
preparations).  In all preparations however, including those where contractions 
were abolished (e.g. Figure 3.5A), spontaneous contractions recovered to control 
values upon return to normal physiological saline (MgSO4 1.2mM). 
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Figure 3. 6:  The effects of magnesium sulphate on spontaneous contractions of 
mouse myometrium. 
The concentration-response curves showing the effect of magnesium sulphate on 
force area under the curve (AUC) at different gestational states (non-pregnant:  
green circle, 14-day: blue square, 16-day: red diamond, term pregnant: purple 
triangle). The concentration-response curves significantly shifted to the left as 
gestation increased (P<.0001). Significant difference was found using ANOVA with 
Bonferroni post hoc test. 
10- 4 10- 3 10- 2 10- 1 100
0
60
120 Non-pregnant
14-day
16-day
18-day
Spontaneous contractions
Log [MgSO4] (M)
%
 c
o
n
tr
o
l 
A
U
C
*** 
110 
 
Plotting AUC concentration-response curves and calculating the IC50 values for 
Magnesium confirmed the mean data findings. The order of potency for MgSO4 on 
spontaneous contractions was term-pregnant>mid-pregnant>non-pregnant, (Figure 
3.6).  The IC50 values fell from 7.06mM ± 0.32 (non-pregnant, n=10) to 4.75mM ± 
0.21 (d 14, n=9) to 3.08mM ± 0.16 (term, n=11, P<0.001). There was no significant 
difference between the IC50 values for MgSO4 at 14d and 16d gestation (4.75mM ± 
0.21 and 5.50mM ± 0.26 respectively, P>0.05).  
 
3.4.7 Effects of Magnesium on oxytocin-induced contractions of non-pregnant 
myometrium. 
The effect of increasing concentrations (2-12mM) of magnesium on oxytocin-
induced contractions of non-pregnant myometrium was examined (Figure 3.7A). 
1nM oxytocin was added to PSS and applied to strips. Magnesium produced a 
concentration-dependent decrease in contractile parameters (Figures 3.7B-E). The 
amplitude of contractions was significantly inhibited at 10mM and higher. The 
frequency of contractions was significantly decreased at 4mM and higher. At 
12mM, the frequency of contraction was reduced to 36.1% ± 4.1. There was no 
significant reduction in duration of contractions. The IC50 value from the 
concentration-response curve was determined as 8.07mM ± 0.40.  
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Figure 3. 7:  The effects of magnesium sulphate on oxytocin-induced contractions of non-
pregnant mouse myometrium. 
Figure showing (A) representative isometric trace showing the effect of increasing 
concentrations of magnesium sulphate in non-pregnant in the presence of 1nM oxytocin. 
Bar charts show the effect of magnesium sulphate on (B) amplitude force, (C), frequency (D) 
duration and (E) the area under the curve (AUC). Increasing concentration of magnesium 
sulphate (2-12mM) caused gradual reduction in amplitude and frequency of contractions.  
The short, coloured bars indicate the 15-minute period where magnesium sulphate was 
added. 2mM (blue), 4mM (orange), 6mM (red), 8mM (green), 10mM (purple) and 12mM 
(brown). 
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3.4.8 Effects of Magnesium on oxytocin-induced contractions of day 14 pregnant 
myometrium. 
Increasing concentrations of MgSO4 (2-12mM) were added to oxytocin-induced 
contracting strips (Figure 3.8A). Magnesium produced a concentration dependent 
effect on oxytocin-induced contractions (Figure 3.8B-E) and its effect on contractile 
parameters was calculated. Magnesium significantly reduced amplitude at 12mM to 
67.0 % ± 11.1 (P<0.001). The frequency of contractions was reduced at 
concentration ≥ 10mM. The duration was not significantly reduced. The IC50 value 
was determined as 10.25mM ± 0.24. 
 
3.4.9 Effects of Magnesium on oxytocin-induced contractions of day 16 pregnant 
myometrium. 
The response to MgSO4 (2-12mM) when applied to contracting myometrium, in the 
presence of oxytocin (0.5nM), was a decrease in contractility (Figure 3.9 A-E). As 
reflected in Figure 3.9, compared to the control period, the amplitude was 
significantly decreased at ≥ 10mM. There was no significant decrease in the 
frequency and duration of contractions. The IC50 value for MgSO4 in oxytocin-
induced contractions, taken from the AUC concentration response curve, is 9.35m ± 
0.38 (Figure 4.9 E). 
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Figure 3. 8:  The effects of magnesium sulphate on oxytocin-induced contractions of day 14 
pregnant mouse myometrium 
Figure showing (A) representative isometric trace showing the effect of increasing 
concentrations of magnesium sulphate in day 14 pregnant mouse myometrium in the 
presence of 0.5nM oxytocin. Bar charts show the effect of magnesium sulphate on (B) 
amplitude, (C), frequency (D) duration and (E) the area under the curve (AUC).  
The short, coloured bars indicate the 15-minute period where magnesium sulphate was 
added. Increasing concentration of magnesium sulphate (2-12mM) caused gradual reduction 
in amplitude and frequency of contractions.  
 Increasing concentration of magnesium sulphate (2-12mM) caused gradual reduction in 
amplitude and frequency of contractions.  
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Figure 3. 9:  The effects of magnesium sulphate on oxytocin-induced contractions 
of day 16 pregnant mouse myometrium. 
Figure showing (A) representative isometric trace showing the effect of increasing 
concentrations of magnesium sulphate in day 16 pregnant mouse myometrium in 
the presence of 0.5nM oxytocin. Bar charts show the effect of magnesium sulphate 
on (B) amplitude, (C), frequency (D) duration and (E) the area under the curve 
(AUC).  
The short, coloured bars indicate the 15-minute period where magnesium sulphate 
was added. Increasing concentration of magnesium sulphate (2-12mM) caused 
gradual reduction in amplitude and frequency of contractions.  
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3.4.10 Effects of Magnesium on oxytocin-induced contractions of day 18 pregnant 
myometrium. 
In the presence of oxytocin, MgSO4 had a concentration-dependent effect on day 18 
pregnant tissue (Figure 3.10A-E). The amplitude of contraction was significantly 
reduced at 8mM and higher. At 12mM, magnesium reduced the contractions to 
71.0 ±4.9 (P<0.0001). The frequency of contractions was significantly reduced at ≥ 
6mM, reaching 58.0 ± 3.9 (P<0.0001). There was no significantly effect on the 
duration of contraction. The IC50 value from the AUC is determined as 9.75mM ± 
0.21. 
 
3.4.10 Comparing the effects of magnesium on oxytocin-induced contractions at 
different gestational stages. 
Having found significant effects of Magnesium on spontaneous contractility I next 
investigated whether these effects were altered when the tissues were stimulated 
with oxytocin. Using the same protocol as for spontaneous contractions, the data 
obtained in the presence of oxytocin also showed a concentration-dependent 
decrease in all parameters of contraction. This was evident in all tissue groups. 
Representative traces showing the effect of MgSO4 in the presence of oxytocin are 
given in Figures 3.3A-D. 
Unlike spontaneous activity, in the presence of oxytocin, the myometrium was still 
producing significant amounts of force at 10mM Magnesium in all preparations. In 
order therefore to accurately plot concentration-response curves, assist with curve 
fitting and better understand the response of the tissue, Magnesium was increased 
to 12 and 20 mM.  Typical responses to 20mM Magnesium are shown in Figure 
3.1C.   
As is clear in the example traces in Figure 3.3, for all pregnant tissues, a less potent 
inhibition with Magnesium was found in the presence of oxytocin compared to its 
application to spontaneous contractions, i.e. without oxytocin (Figure 3.2). 
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Figure 3. 10:  The effects of magnesium sulphate on oxytocin-induced contractions 
of day 18 pregnant mouse myometrium 
Figure showing (A) representative isometric trace showing the effect of increasing 
concentrations of magnesium sulphate in day 18 pregnant mouse myometrium in 
the presence of 0.5nM oxytocin. Bar charts show the effect of magnesium sulphate 
on (B) amplitude, (C), frequency (D) duration and (E) the area under the curve 
(AUC). The short, coloured bars indicate the 15-minute period where magnesium 
sulphate was added. Increasing concentration of magnesium sulphate (2-12mM) 
caused gradual reduction in amplitude and frequency of contractions.  
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Additionally, in pregnant tissues, concentration-response curves for Magnesium in 
the presence of oxytocin were also shifted to the right compared to spontaneous 
contractions (Figure 3E and 4B-D), resulting in significantly greater IC50 values with 
oxytocin stimulation. The greatest shift in IC50 values was seen for term-pregnant 
tissues from 3.08mM ± 0.16 in spontaneous conditions to 9.75mM ± 0.21 with 
oxytocin (P<0.0001). A significant shift in IC50 values was also seen for day 14 
gestation tissues from 4.75mM ± 0.21 in spontaneous conditions to 10.25mM ± 
0.24 in oxytocin (P<0.0001) and day 16 gestation tissues from 5.50mM ± 0.26 in 
spontaneous conditions to 9.35m ± 0.38 in oxytocin (P=0.0031). In contrast, in non-
pregnant tissues, the presence of oxytocin (even at 1nM) did not significantly alter 
the IC50 values for Magnesium: 7.06mM ± 0.32 in spontaneous to 8.07mM ± 0.40 in 
the presence of oxytocin (Figure 3.4A, P=0.3236), hence in non-pregnant tissues, 
Magnesium is equipotent in the presence and absence of oxytocin. 
My data showed that, a consequence of oxytocin significantly increasing the IC50 
values in all pregnant tissues was that there were no longer any gestational 
differences between them, in the effects of Magnesium (Figure 3.4).  In other 
words, there was no significant difference in the inhibitory effect of Magnesium as 
pregnancy progressed, unlike what had been found above for spontaneous 
conditions. Instead, in the presence of oxytocin, the potency of MgSO4 was reduced 
such that it was similar to its potency in non-pregnant tissues irrespective of 
pregnancy. 
Tables showing the mean values ± SEM for all results in this chapter are in the 
appendix section. 
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Figure 3. 11:  The effects of magnesium sulphate on oxytocin-induced contractions 
of mouse myometrium. 
 
The concentration-response curves show the effect of magnesium sulphate on AUC of 
contraction at different gestational states (non-pregnant :  green circle, 14-day: blue 
square, 16-day: red diamond, term-pregnant: purple triangle). There was no 
significant difference between the concentration-response curves for the different 
gestational states, determined using ANOVA with Bonferroni post hoc test.  
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Figure 3. 12:  The effect of magnesium sulphate between spontaneous and 
oxytocin-induced contractions at different gestational states. 
The concentration-response curves show the effect of magnesium sulphate on 
force integral (AUC) of contraction in spontaneous (green circles) and oxytocin-
induced contractions (purple squares). There was no significant difference 
(P=0.062) between the concentration-response curves of non-pregnant 
myometrium (A). For 14-day (B), 16-day (C) and term-pregnant myometrium (D), 
the concentration-response curves were significantly shifted to the right in the 
presence of oxytocin (P<.0001, P<0.01 and P<0.0001 respectively). Significant 
difference in activity was determined using F-test. 
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3.4 Discussion 
 
Magnesium has been reported to suppress myometrial contractions and for this 
reason has been used over the last five decades in the treatment of preterm labour. 
Many clinical studies however, including Cochrane reviews (Crowther et al., 2014), 
conclude or suggest that MgSO4 is ineffective at delaying labour. Thus, the clinical 
use of MgSO4 in the treatment of preterm labour is questioned (Grimes and Nanda, 
2006, Hacivelioglu et al., 2007, Keirse, 2003b), highlighting the need for further 
studies. This study was conducted to better understand the effects of Magnesium 
on uterine contractility. It was designed to examine if physiological changes, namely 
gestational state and hormonal background, could influence myometrial responses 
to Magnesium.  In this way, a better understanding of the disappointing clinical 
findings will be obtained and perhaps suggest a more stratified approach to its use 
as a tocolytic, to help prevent preterm labour. Magnesium’s effects as a tocolytic 
may synergise with its use and action to treat eclampsia. This data provide fresh 
insights, as they show that preterm myometrium is much less sensitive to the 
relaxant effects of Magnesium than term myometrium, which could explain its lack 
of clinical efficacy. If oxytocin was present, its efficacy was further decreased, at all 
gestational stages. Thus, taken together I conclude that Magnesium’s actions are 
influenced by both gestational state and hormones, such that, at least in mice, it is 
least effective in early gestation with oxytocin present and most effective at term in 
the absence of oxytocin.   
In vitro Mouse myometrium 
This study was conducted on mouse myometrium so that myometrial preparations 
at several stages of gestation as well as non-pregnant tissue could be obtained. 
Myometrium from pregnant mouse has previously been reported to produce 
rhythmic spontaneous contractions in vitro for many hours(Matthew et al., 2004b).  
Consistent with this, I found all the uterine strips generated spontaneous 
contractions which were stable within a period of 45 -60 minutes, and remained 
regular without significant reduction in amplitude or frequency for many hours. This 
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therefore allowed the effect of incremental concentrations of Magnesium to be 
examined and concentration-response curves to be fitted. There has been just one 
previous report of Magnesium's actions on mouse myometrium, in a 
lipopolysaccharide model of preterm birth (Sugawara et al., 2007). These authors 
only studied mid-gestation (14 day) uterus and reported inhibition of spontaneous 
contractions with Magnesium; an effect which was decreased by 
lipopolysaccharide.  The findings of an inhibitory effect on term-and non-pregnant 
myometrium are consistent with findings in other species(Phillippe, 1998, 
Arrowsmith et al., 2016, Onwochei et al., 2017, Tica et al., 2007, Kantas et al., 2002) 
including humans. Future studies should attempt to obtain human biopsies at 
different stages of gestation to confirm these findings, although obtaining preterm 
biopsies is challenging.  In addition, to reflect the somewhat heightened state of 
contraction that may be associated with preterm labour compared to the non-
labouring strips used here, a preterm labour mouse model, such as that induced by 
LPS or other agents, could be used to investigate the in vivo therapeutic effect of 
MgSO4.    
Magnesium’s mechanism of action in myometrium. 
The effect of MgSO4 on contractions at different gestational stages was investigated 
and my data shows that regardless of gestational age or pregnancy status, it can 
reduce myometrial contractions. This inhibitory effect was reversible and the 
prompt recovery after washout suggests no ill effects of Magnesium on 
myometrium, even at high concentrations. The concentrations of MgSO4 used by us 
in vitro were empirically determined, and in the case of oxytocin-evoked 
contractions, going in to pharmacological rather than physiological concentrations, 
to enable maximal effects to be obtained.  
It is unlikely that intracellular Magnesium will have risen during the course of the 
experimental protocol,  due to the activity of  Na+ - Mg2+ exchangers and 
intracellular buffers(Fomin et al., 2006), as well as Magnesium's  slow penetrability 
through cell membranes (Martin et al., 1987). That the effects of Magnesium on the 
myometrium are relatively rapid and reversible, suggests that its main mechanism 
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of action is likely to be extracellular. The rapid reversal of Magnesium’s effect is 
clinically useful, for example if delivery is by cesarean section, as it reduces the risk 
of postpartum haemorrhage (Lau et al., 2001). Magnesium use in preeclampsia has 
been associated with increased post-partum haemorrhage in some studies (Szal et 
al., 1999), but in another study, its use was not associated with additional blood loss 
(Graham et al., 2016).  
The major mechanism of Magnesium’s action to relax uterine smooth muscle is, as 
with other excitable tissues, due to its cationic competition with Calcium (Phillippe, 
1998).  In myometrium, contractions, whether spontaneous or agonist induced, are 
critically dependent upon Calcium entry through L-type Calcium channels (Wray et 
al., 2001, Wray et al., 2003).  Thus when increased Magnesium competes with 
Calcium, entry of Calcium falls and hence contractions reduce and can even be 
abolished, as our group and others have shown (Popper et al., 1989). The fall in 
intracellular Calcium will also lead to a fall in the Calcium content of the 
sarcoplasmic reticulum (SR)(Shmigol et al., 2001). This reduced SR Calcium available 
when agonists such as oxytocin produce IP3, will reduce their ability, to increase 
myometrial contractility(Phillippe, 1998). In this way, Magnesium will be expected 
to reduce the force of spontaneous and oxytocin-induced contractions. Fomin et al., 
(2006) showed that MgSO4 reduced spontaneous, oxytocin- and KCl-induced 
myometrial contractility and all were associated with a decrease in intracellular 
Calcium (Fomin et al., 2006). In addition, they found no shift in the force-Ca 
relationship in the myometrium. Together this provides strong evidence that 
Magnesium’s effects are predominantly extracellular and on Calcium entry.  
At all gestations and in non-pregnant tissue, my data show a significant reduction in 
force and frequency of contractions with addition of MgSO4. A reduction in force is 
most likely because of Magnesium’s antagonistic effect with Calcium at L-type 
calcium channels, as discussed above. Frequency of contractions is mainly 
dependent on excitability and membrane potential, hence a reduction in frequency 
suggests the pacemaker activity may also be affected by MgSO4 (Kawarabayashi et 
al., 1989). For example, should differences in the resting membrane potential of 
some pacemaker cells exist, it may make them more susceptible to the effects of 
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Magnesium leading to fewer action potentials being triggered (Wray et al., 2015). 
The figures throughout show that a decrease in the frequency of contractions, 
usually preceded a fall in force. This finding is consistent with observations on 
human myometrium (Tica et al., 2007, Tang et al., 2014). Additionally, although not 
yet tested in uterus, Magnesium may affect inter-cellular coupling such as via gap 
junctions (Matsuda et al., 2010, Rimkute et al., 2018), hence reducing the likelihood 
of frequent, synchronous contractions being produced.   
 
Gestational effects 
In spontaneous contractions, the effect of MgSO4 was most potent at term, and 
least potent in non-pregnant tissues. The latter group were not staged for oestrous 
and should therefore be treated as a mean of any cyclical, oestrous changes (Dodds 
et al., 2015, Wray and Noble, 2008). I found that even on day 16 of gestation, 
Magnesium’s effect on the myometrium was significantly less than at term, 
suggesting that the changes in sensitivity are on-going throughout pregnancy. Given 
that the underlying mechanism of Magnesium’s effects is via decreasing excitability 
and Calcium entry, then these findings point to a difference in the Calcium channels 
with gestation. There have been surprisingly few studies of L-type Calcium 
expression with gestation in the myometrium.  The work that has been done 
suggests an increase in expression and changes of subunits from mid-gestation 
onwards.  Tezuka et al (1995) found a marked increase in α1 expression in 
pregnancy, especially in the last half of gestation until term, followed by a decrease 
during labour (Tezuka et al., 1995).  Similarly, Mershon et al (1994) studied the 
expression of α1 subunit and showed a gradual increase in the mRNA towards term 
followed by a decrease during parturition (Mershon et al., 1994). They also showed 
an increase in the number of dihydropyridine binding sites (markers for L-type 
channels) in the last half of gestation. Thus, a simple effect on Calcium entry is 
difficult to propose to explain gestational differences, unless the switch to increased 
α-1 subunits confers an increased susceptibility to Magnesium blockade.  Rather, 
my data suggests that at term the effect of Magnesium is enough to reduce 
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excitability and make action potential firing less likely, as occurs with its use in 
neuronal tissues to protect the brain.   
Oxytocin and Magnesium 
To determine if MgSO4 can affect contractile parameters in the presence of an 
agonist, its effect on oxytocin-evoked contractions was determined. Oxytocin was 
used due to its particular importance to labour.  Oxytocin can directly and indirectly 
stimulate myometrial contractions (Arrowsmith and Wray, 2014). This data show 
that a greater concentration of Magnesium is needed to inhibit oxytocin-stimulated 
contractions compared to spontaneous contractions in pregnant tissues.  This is in 
agreement with data from other studies including human myometrium (Arrowsmith 
et al., 2016, Onwochei et al., 2017).  However, oxytocin did not significantly change 
the IC50 for Magnesium in non-pregnant tissues, from that found for spontaneous 
contractions. We found this to be the case even when oxytocin was used at 1nM i.e. 
double the oxytocin concentration used in pregnant tissues. There was no 
difference in the potency of MgSO4 on oxytocin-stimulated contractions between 
the different gestational groups. The greatest shift in Magnesium's potency with 
oxytocin was observed for term-pregnant myometrium; this shifted the IC50 from 
around 3 mM in spontaneous conditions to almost 10 mM.  In terms of clinical 
applications, the effect of oxytocin is to shift the concentration from therapeutic to 
lethal. Therapeutic concentrations of Magnesium are reported at 2.5 mM (5 mEq/L ) 
or below (Tica et al., 2007), and for  seizure management in preeclampsia, 3 mM 
(Onwochei et al., 2017).  
Although oxytocin acts via several mechanisms, an important mechanism is 
increasing membrane potential (resulting in opening of the L-type Ca2+ channels and 
increased Calcium entry), releasing Calcium from the sarcoplasmic reticulum and 
preventing Calcium exit (Arrowsmith and Wray, 2014). These mechanisms will 
counteract Magnesium’s actions and may explain why a greater concentration of 
MgSO4 is needed to inhibit oxytocin induced contractions close to term. The lipid 
environment around the oxytocin receptor  influences its affinity for oxytocin 
(Arrowsmith and Wray, 2014, Gimpl and Fahrenholz, 2001, Noble et al., 2006) , an 
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effect attributed to its partitioning into lipid rafts and their effect on signal 
transduction (Smith et al., 2005, Draeger et al., 2005). It was also reported that as 
well as high cholesterol, the high affinity form of the oxytocin receptor requires 
Magnesium, working as an allosteric modulator. Thus, when Magnesium is 
increased it may increase the oxytocin signalling and further counter the relaxant 
effect of Magnesium on Calcium entry.  
Transition to labour in humans is associated with increased oxytocin receptor 
expression (Kimura et al., 1992), which increases the sensitivity of the uterus 
towards oxytocin (Kubota et al., 1996). An increase in oxytocin receptor expression 
towards term in mouse, has also been shown (Kubota et al., 1996).  Consistent with 
this is the finding that little, if any, contractility stimulation to 0.5nM oxytocin was 
observed in non-pregnant tissues and hence the use of 1nM, to assess the effect of 
oxytocin on the potency of MgSO4 (control data, not shown). Although not 
accounting for the lack of gestational differences, the increased drive on 
contraction produced by oxytocin, and the increased number of receptors, and 
increased affinity, may also partly explain why a greater concentration of MgSO4 is 
needed to inhibit contractions in its presence.   
3.5 Study Limitations 
Although, as indicated above and in chapter 1, there is much that is similar between 
mouse and human, nevertheless the effect of magnesium should be further 
explored in human tissues.  
This study did not use strips from labouring mouse tissues as they were much more 
difficult to obtain. Studies testing magnesium on labouring tissues may prove 
helpful. 
I have focussed on the most plausible mechanisms of magnesium’s tocolytic effect, 
based on the literature and our understanding of EC coupling. Other mechanisms 
however may have operated in this model, such as Calcium-independent pathways 
which may have additionally been affected by elevated Magnesium. However, the 
role of Ca-sensitisation in the mouse uterus is thought to be minor (Wray, 2007). 
However, this work, and studies by others have not considered possible effects of 
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magnesium on potassium channels. Finally, in vitro studies will always be a step 
removed from in vivo conditions, although I optimised the experimental conditions 
to near-physiological, in vivo conditions to aid translation. 
3.6 Conclusion 
This in vitro study shows that MgSO4, acting extracellularly, concentration-
dependently inhibits spontaneous and oxytocin-induced myometrial contractions in 
both the pregnant and non-pregnant mouse, with greater efficacy observed in 
term-pregnant tissues. However, oxytocin decreases the potency of MgSO4 in 
pregnant tissues, due to its stimulation of contraction and perhaps due to 
Magnesium allosterically increasing the affinity of the oxytocin receptor, which may 
underlie its lack of efficacy as a relaxant i.e. tocolytic, in vivo. 
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Chapter 4 
The Effect of Combining Magnesium with Other Tocolytics 
4.1 Abstract 
Several uterine tocolytics have been investigated in the treatment of preterm 
labour: oxytocin receptor antagonist e.g. atosiban, calcium channel blockers, e.g. 
nifedipine, prostaglandin synthetase inhibitor e.g. indomethacin, β- adrenoceptor 
agonist e.g. ritodrine and Magnesium sulphate (MgSO4).  Studies have shown 
tocolytics to only delay labour for 48 hours and at best 7 days.  They however delay 
labour long enough for administration of corticosteroids. MgSO4 though not a 
tocolytic used in the UK is administered in threatened preterm birth cases (<30 
weeks). Since these tocolytic agents act via different pathways, I hypothesized that 
a combination of MgSO4 with other tocolytics may produce a greater inhibitory 
effect than the individual drugs used alone. The aim of the study was to investigate 
the dual effect of magnesium (Mg) plus other tocolytics in vitro.  
Longitudinal uterine strips were obtained from term pregnant C57BL/6J mice (19 
days gestation).  After spontaneous contractile activity reached a steady state, 
0.5nM oxytocin was added. Contractile activity was recorded using digital software 
(Labtrax). The concentration-dependent effect of indomethacin, atosiban and 
nifedipine was examined with the IC50 value (concentration at which there is a 50% 
reduction) determined for each drug. Magnesium sulphate was then applied either 
alone or in combination with (i) 3 µM (spontaneous) and 30 µM (oxytocin) 
indomethacin, (ii) 500 nM atosiban or (iii) 0.03 nM nifedipine at their 
predetermined IC50 values. Control contractile activity and activity after addition of 
each combination were measured using the last 10 minutes of activity and the 
changes expressed as a percentage of control (100%).  
All tocolytics investigated (Mg, indomethacin, atosiban and nifedipine) inhibited 
myometrial contractions when used alone.  In spontaneous contractions, Mg + 
indomethacin reduced the area under the curve (AUC) of contractions to 4.6% ± 3.1, 
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compared to 62.7% ± 8.0 with indomethacin alone (P<0.001). With the addition of 
oxytocin, the efficacy of Mg plus indomethacin was reversed. The combination 
reduced AUC of contractions to 70.6% ± 3.1 compared to 38.4% ± 5.8 with 
indomethacin alone (P<0.01). The combination of Mg plus Atosiban (n=8) greatly 
reduced AUC of oxytocin-induced contractions to 1.3% ± 1.0 compared to 56.2% ± 
7.0 with atosiban alone (P<0.0001). In spontaneous contractions, Mg plus nifedipine 
(n=7) reduced the AUC to 46.4% ± 6.7. Similarly in oxytocin-induced experiments, 
Mg + nifedipine (n=6) reduced AUC of contractions to  
This in vitro data suggest that Mg plus atosiban produced a greater inhibitory effect 
than either the drugs alone or the other combinations.  
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4.2 Introduction 
 Preterm birth is defined as birth before 37 weeks of pregnancy. Globally, 
preterm births affect almost 15 million people yearly and currently accounts for 
about 11.1% of all births (Howson et al., 2013). It is generally thought that about 65 
to 70% of preterm births are spontaneous which could either be due to 
spontaneous preterm labour or births following a premature rupture of membranes 
(Goldenberg et al., 2008). The precise cause of spontaneous preterm labour is 
unknown; however, it could result from a range of factors and varies with 
gestational stages (Carvajal et al., 2017).These factors could include history of 
preterm birth, maternal age, race, urinary tract infections, poor nutrition, etc. 
(Goldenberg et al., 2008, Vogel et al., 2014b). 
 A wide range of drugs are used to suppress or reduce uterine contractions, 
known as tocolytics. Since the discovery of the first tocolytic, relaxin, many other 
tocolytics have been developed.  One major factor that contributed to the 
development of tocolytics was to improve perinatal mortality (Keirse, 2003a). 
However, with the development of these drugs, an actual reduction in preterm 
birth has not been evident and there hasn’t been an improvement in infant 
outcome following tocolytic therapy (Keirse, 2003a). Even though the 
administration of tocolytics prolongs labour, several studies have also shown that 
they are not without their side effects which may be foetal or maternal (Olson et al., 
2008) (de Heus et al., 2009). 
 As detailed in chapter 3, uterine contractions is regulated by the increase in 
intracellular Ca2+ in the myometrium. Ca2+ binds to calmodulin, activating myosin 
light chain kinase (MLCK), and resulting in the phosphorylation of myosin light 
chains and initiation of cross-bridge cycling in contractile proteins (Gáspár and 
Hajagos-Tóth, 2013, Wray et al., 2003). Calcium influx is therefore a major pathway 
for myometrial contraction. Agonists (e.g. oxytocin and prostaglandins) by binding 
to their receptors result in augmentation or stimulation of the pathway 
(Arrowsmith et al., 2010). These agonists could also initiate other intracellular 
mechanisms which may influence force. Oxytocin acts by activating OTRs, causing 
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the activation of phospholipase C-β (PLCβ), which controls hydrolyses of 
phosphatidylinositol bisphosphate (PIP2) leading to the formation of inositol 
triphosphate (IP3) and diacylglycerol (DAG). Intracellular calcium is then mobilized 
from the SR leading to stimulation of the uterus. Besides this mechanism, there are 
other more complex pathways via which oxytocin acts. Prostaglandins, which act by 
binding to different G-protein coupled produces different cascades of intracellular 
pathways as a result of each of them having individual receptors. This stimulation 
causes an increase in free intracellular calcium concentration in myometrial cell. 
There is evidence that stimulation with oxytocin results in an upregulation of 
cyclooxygenase-2 (COX-2) and prostaglandin synthesis in other uterine tissues (e.g. 
epithelium and amnion), (Chibbar et al., 1993, Wilson et al., 1988, Terzidou et al., 
2011). Oxytocin also increases COX-1 and COX-2 activity leading to PGE2 formation  
(Blanks and Thornton, 2003). 
Tocolytics, however, cause uterine inhibition or relaxation by acting on these 
contractile pathways (Figure 4.1). The different classes of tocolytics: magnesium 
sulphate, oxytocin receptor antagonists (e.g. atosiban), prostaglandin inhibitor (e.g. 
indomethacin), calcium channel blockers (e.g. nifedipine), beta-adrenergic receptor 
(AR) agonists (e.g. ritodrine) all have a unique mechanism of action. Magnesium 
acts both extra- and intracellularly causing decreased Ca influx and Ca release from 
the SR (Arrowsmith et al., 2010). It acts mainly by antagonising Ca entry at the L-
type Ca channel thereby decreasing intracellular calcium concentration. Atosiban is 
the only selective oxytocin receptor antagonist currently used in clinical practice 
(Hubinont and Debieve, 2011) although there have been others developed including 
barusiban. Atosiban acts by competing with oxytocin from binding to its receptors 
in the myometrium and decidua (Mattison, 2013). 
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Figure 4. 1:  Schematic showing the mechanism of action by different stimulants 
and relaxants on myometrial contractions 
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Ritodrine is a non-selective β–AR agonist whose tocolytic effect is mediated through 
the cAMP pathway. It acts by binding to β-AR, leading to increased levels of the 
cyclic AMP which activates protein kinase. Indomethacin, a prostaglandin-synthase 
inhibitor act via this pathway of inhibiting the contractility stimulator: 
prostaglandin. They inhibit cyclooxygenase COX-1 and COX-2, the relevant enzymes 
for the conversion of arachidonic acid to prostaglandins, leading to the reduced 
synthesis of prostaglandins thereby leading to reduced uterine contractions. 
Nifedipine, a calcium channel blocker acts by blocking the influx of Ca through the 
cell membrane and prevents the spread of action of action potential required for 
coordinated contractions of the myometrium. 
The efficacy of tocolysis in stopping preterm labour has been greatly questioned. 
These tocolytics stop labour for a maximum period of 48 hours, allowing time for 
the administration of corticosteroids and maternal transfer to care centres to 
improve neonatal outcomes (Witcher, 2002). Even though the survival rate of very 
preterm babies (<30 weeks) has improved over the years, there is still a prevalence 
of neurodevelopmental challenges in these children (Usman et al., 2017). The risk of 
cerebral palsy, which is the general term used to describe the different types of 
motor and posture disabilities, increases with reduced gestation. 
In 1988, a study revealed that preterm babies born to women with preeclampsia 
(and administered magnesium) previously had fewer germinal matrix haemorrhages 
(Leviton et al., 1988). A more recent study (Rouse et al., 2009), which involved 2,241 
pregnant women between 24 – 31 weeks of gestation were either given magnesium 
sulphate or placebo. Results showed that infants were free of moderate or severe 
cerebral palsy at 2 years. These findings and many more findings recently led the 
Royal College of Obstetricians and Gynaecologists (RCOG) and National Institute for 
Health and Care Excellence (NICE) to recommend that magnesium sulphate is given 
to women who are likely to deliver before 30 weeks of gestation (NICE, 2015) This 
means that magnesium sulphate (which has a calcium antagonism mechanism) is 
currently given for neuroprotection in very preterm cases in combination with a 
tocolytic (e.g. indomethacin, nifedipine or atosiban). 
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Currently, there is the absence of substantial evidence to affirm that any tocolytic is 
more effective than another; the choice of any tocolytic is mainly on its safety over 
others (de Heus et al., 2009). Since tocolytics act via different signalling 
mechanisms, it was therefore hypothesized that a combination of magnesium and 
another tocolytic agent could result in a greater inhibitory effect (additive or 
synergistic), especially with drugs that target different pathways. In addition, this 
could lead to a lesser dosage needed and potentially decrease the rate of adverse 
effects seen with tocolytics whilst maintaining efﬁcacy. 
The aims of this chapter, therefore, were, in term pregnant mouse myometrium: 
(v) To determine the effect of indomethacin, atosiban, and nifedipine on 
spontaneous and oxytocin-induced contractions, and calculate their 
respective IC50 values; 
(vi) To examine the effect of magnesium in combination with  indomethacin 
compared to Mg alone; 
(vii) To examine the effect of magnesium in combination with  atosiban 
compared to magnesium alone; 
(viii) To examine the effect of magnesium in combination with  nifedipine on 
term pregnant mouse uterine contractility compared to Mg alone; 
(ix) To determine which combination of tocolytic is most effective in reducing 
term pregnant mouse uterine contractions. 
During parturition, myometrial contractility is affected by several factors including 
hormonal changes, hypoxia, pH changes, lactate and stretch (Wray, 2007). 
Alterations in pH play a major role in myometrial contractions and the effect of 
these changes have been widely studied in human and animal models but the 
outcome hasn’t been consistent. During pregnancy, plasma pH has been shown to 
increase while normal labour is associated with acidemia (Cerri et al., 2000). This 
may be explained by the occlusion of blood vessels resulting from strong uterine 
contractions (Brinkman, 1990). Since labour is affected by pH changes and reduced 
pHo may affect force, it is important to investigate how this change may affect 
tocolytic efficacy. Therefore, a further aim of this chapter was to determine: 
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(x) The effect of reduced extracellular pH (pHo) on uterine contraction and 
combined tocolytic efficacy. 
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4.3 Methods 
4.3.1 Tissue and force measurement 
 All uterine strips used in this chapter were obtained from term 
pregnant mouse. As described in chapter 2, uterine strips were cleaned, dissected 
and prepared for force measurement. Uterine strips measuring 1 x 2 x 10mm were 
dissected and tied using a surgical thread on both ends. They were then mounted 
between a fixed hook and a force transducer and continuously perfused with PSS at 
37o C, bubbled with 95% O2 and 5% CO2 at a flow rate of 4ml/min and contractile 
activity was seen almost immediately the tissue was mounted. A 5mN stretch was 
applied on the tissues at the start of each experiment. 
 This chapter consists of:  investigating the concentration-dependent effect 
of indomethacin alone (n=6); investigating the effect of magnesium and 
indomethacin (n=13); investigating the concentration-dependent effect of atosiban 
alone (n=4); investigating the effect of magnesium and atosiban (n=11); 
investigating the effect of nifedipine alone (n=7); investigating the effect of 
magnesium and nifedipine (n=7) and investigating the effect of acidification on Mg 
and Atosiban (n=7). 
4.3.2 Solutions 
 Solutions including PSS were made as described in chapter 2. Oxytocin was 
used at 0.5nM concentration for all experiment in this chapter. Atosiban was used 
at 500nM concentration, indomethacin was used at 3nM for spontaneous and 
30nM for oxytocin-induced experiments while Nifedipine was used at 0.01nM for 
both spontaneous and oxytocin-induced experiments. Details on how these drugs 
were made are detailed in Chapter 2. 
4.3.3 Experimental protocol 
 In all uterine strips, contractile activity was observed immediately or after a 
few minutes of perfusion with HEPES buffered PSS. The strips were allowed to 
contract spontaneously until stable contractions were obtained before application 
of any drugs.  
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Concentration-dependent Experiments 
The first part of this study investigated the effect of individual tocolytics on 
uterine contractions. Concentration-dependent experiments were carried out to 
determine a suitable concentration of indomethacin, atosiban and nifedipine in 
combination with magnesium. These experiments were also performed to 
determine the suitability of the vehicle time controls and the length of experiments. 
For spontaneous contractions, myometrial strips were left to equilibrate for a 
period of 45 – 60 minutes or until stable contractions were achieved. For oxytocin-
induced contractions, once stable contractions were achieved as previously 
described, contractions were then stimulated with 0.5nM oxytocin. Increasing 
concentrations of each drug was then added at 15 minute interval. Indomethacin 
was examined at concentrations of 1, 3, 10, 30, 100, and in some cases 300µM, 
atosiban was examined at concentrations of 10nM, 30nM, 100nM, 300nM, 1µM, 
and 3 µM, and nifedipine was examined at concentrations of 3pM and 10pM (in 
some cases), 30pM, 100pM, 300pM, 1nM and 3nM. For oxytocin-induced 
experiments, all drugs were applied in the continuous presence of 0.5nM oxytocin. 
For all indomethacin experiments, the concentration of DMSO did not exceed 0.3% 
(v/v). 
Combination Experiments 
For spontaneous contractions, after recording control activity, the effect of 
the application of Mg and either of the drugs was examined. When combining Mg 
with indomethacin, Mg was applied in increasing concentrations (2-10mM) in the 
presence of indomethacin, at its predetermined IC50 value. Each concentration of 
Mg was applied for a 15-minute period as explained in Chapter 2. With Mg and 
nifedipine, the IC50 of Mg in spontaneous contractions was chosen (4mM) in 
combination with 0.01nM nifedipine. This protocol is different from indomethacin 
due to nifedipine’s effect on contractions (details explained in the results section– 
3.4.4). With Mg and atosiban, no experiments were carried out on spontaneous 
contractions. 
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In oxytocin-induced contractions, after stable spontaneous contractions were 
obtained, oxytocin (0.5nM) was applied. A stable control period with oxytocin was 
then recorded before application of reagents. When combining Mg with atosiban, a 
single concentration of atosiban was used (500nM) with increasing concentration of 
magnesium (2-12mM). Each concentration of Mg was applied for a 15-minute 
period. This protocol was the same for Mg and indomethacin (30µM). With Mg and 
nifedipine, the approximate IC50 value of Mg in oxytocin-induced contractions was 
used (10mM) in combination with 0.01nM nifedipine. Control experiments for all 
manoeuvres were carried out simultaneously. Traces are shown in Chapter 2. 
The Effect of extracellular acidification 
After obtaining stable spontaneous contractions, the tissue was stimulated with 
0.5nM oxytocin and allowed to equilibrate. Once the contractions had contractions 
reached steady state, the combination Mg + atosiban pH 7.4 was added to the 
tissue for 15 minutes followed by Mg + atosiban pH 6.9 for another 15 minutes.  The 
amplitude, frequency, duration and AUC of contractions were then calculated. 
4.3.4 Data analysis and statistics 
 Data were analysed using Origin Pro 2015 and n is the number of 
myometrial tissue strips each from a different animal. Amplitude and duration of 
each contraction were measured during the 10 minutes of solution application and 
the mean calculated. Frequency was measured as the number of contractions 
within the 10-minute period. If there were no contractions during Mg application, 
amplitude and frequency of contractions were recorded as ‘0’ and excluded from 
duration analysis. The area under the curve (AUC) was also measured using the last 
10 minutes of solution application or control period. All data are presented as % of 
control period (100%).  Values given are mean ± SEM unless stated otherwise. 
Significance was taken as P<0.05. 
Concentration-response curves for AUC were fitted to the logistic equation with the 
use of non-linear regression. The concentration at which there was a 50% reduction 
in force integral (AUC) was calculated. The log IC50 values were calculated and 
139 
 
compared using the extra sum of squares F test or ANOVA followed by Bonferroni 
post-hoc analysis. All statistical analysis was carried out using GraphPad Prism 6.0.  
Summary of statistical analyses performed are: 
1) Tables 4.1 to 4.5- ANOVA with Bonferroni post hoc correction 
2) Comparison of IC50 values for the effect of indomethacin alone on 
spontaneous and oxytocin-induced contractions – F-test  
3) Comparison of IC50 values for spontaneous vs oxytocin in Mg + indomethacin 
combination – F-test 
4) Comparison of IC50 values for Mg alone and Mg + indomethacin, Mg alone 
and Mg + atosiban - ANOVA with Bonferroni post hoc correction 
5) Comparison of IC50 values between the combinations (Figure 4.10) – ANOVA 
with Bonferroni post hoc correction 
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4.4 Results  
4.4.1 The Effect of Indomethacin on uterine contractions of term pregnant 
mouse 
Concentration-response experiments were carried out to establish the 
concentration at which indomethacin caused a 50% reduction (IC50) in spontaneous 
(n=7) and oxytocin-induced (n=6) contractions. In both spontaneous and oxytocin-
induced experiments, indomethacin produced a concentration-dependent 
inhibitory effect on the force, frequency and AUC of contractions in all uterine strips 
examined. Representative isometric traces demonstrating the effect of 
indomethacin and vehicle time control (DMSO) on contractions are shown in Figure 
4.2A-D. Mean data were used to plot bar charts and concentration-response curves 
representing the effect of indomethacin on force, frequency, duration and AUC on 
spontaneous (Figure 4.3A-D) and oxytocin-induced contractions (Figure 4.4 A-D). 
With the use of DMSO, there was no significant effect on spontaneous and 
oxytocin-induced contractions.  
The IC50 values for AUC of spontaneous and oxytocin-induced contractions 
were 3.6 µM and 30.2 µM respectively. Statistical comparison of the IC50 values 
showed a significant difference between both groups (P<0.001). The concentration-
response curves for the effect of indomethacin on oxytocin’s activity when plotted 
against spontaneous activity, was shifted to the right (Figure 4.4E), indicating a 
higher IC50 value. For subsequent experiments, the approximated IC50 values of AUC 
were then used in combination with Mg (3µM and 30 µM for spontaneous and 
oxytocin-induced experiments respectively). 
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Figure 4. 2: The effect of Indomethacin on term mouse uterine contractions. 
Representative isometric traces showing A, the effect of the vehicle control (DMSO) on 
spontaneous contractions, B, the effect of increasing concentration  of indomethacin on 
spontaneous contractions, C, the effect of DMSO on oxytocin-induced contractions, 
and D, the effect of increasing concentration of indomethacin on oxytocin-induced 
contractions. The short coloured bars indicate the 15 minute period where increasing 
concentrations of DMSO or indomethacin were added. The blue (0.001% or 1µM) orange 
(0.003% or 3µM) red (0.01% or 10µM), green (0.03% or 30µM), purple (0.1% or 100µM) and 
brown (0.3% or 300µM) of DMSO or indomethacin respectively. 
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Figure 4. 3:  Concentration dependency of Indomethacin on spontaneously 
contracting mouse myometrium 
Average mean data ±  SEM showing the concentration-dependent effect of 
Indomethacin on A, force, B, frequency, C, duration and D, AUC of spontaneously 
contracting strips.  
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Figure 4. 4: Concentration dependency of Indomethacin on oxytocin-induced 
contracting term mouse uterus 
Average mean data ±  SEM showing the concentration-dependent effect of 
Indomethacin on (A), force, (B), frequency, (C), duration and (D), AUC of oxytocin-
induced contractions. Figure E shows concentration-dependent curves for the effect 
of indomethacin on AUC of both spontaneous (green) and oxytocin-induced 
contractions (purple). A significant difference in activity was found using ANOVA 
with Bonferroni post hoc. *denotes p<0.05, ** p<0.01, ***p<0.0001. 
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4.4.2 The Effect of Mg + Indomethacin on uterine contractions of term pregnant 
mouse. 
The inhibitory effect of Mg plus Indomethacin on spontaneous contractions was 
examined. Increasing concentration of Mg (2-10mM) were applied to spontaneously 
contracting myometrial strips for 15 minutes each in the presence of a 
predetermined single concentration of indomethacin (3µM) (Figure 4.5) and its 
effect on contractility was determined (Figure 4.6). Magnesium + Indomethacin on 
in spontaneously contracting myometrium, caused a concentration-dependent 
reduction of force amplitude, frequency and AUC of contraction in all samples 
examined (n=8). There was a significant decrease in the contractile parameters 
measured- force amplitude, duration, frequency and AUC of contractions when 
compared to the control period (see Table 4.1, ANOVA with Bonferroni post hoc 
analysis). At 2mM and higher, there was a significant decrease in the force of 
contractions. At 10mM Mg concentration, the force was reduced to 17.2% ± 11.3 
(relative to control, 100%), P<0.0001. At 4mM or higher, a sudden and marked drop 
or abolition of contraction force was observed I n 7 of 8 tissues. There was also a 
marked decrease in contraction frequency with increased Mg concentrations which 
was significant from the first concentration (2mM) onwards. At 10mM Mg, the 
frequency of contractions was reduced to 10.9% ± 6.7 (P<0.0001). The duration of 
contractions at 10mM was reduced to 26.0% ± 12.7 (P<0.05) compared to control. 
The AUC however, which integrates all three parameters showed a significant 
concentration-dependent decrease. At 10mM Mg, the AUC was reduced to 4.6% ± 
3.1 compared to control (n=8).  
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Figure 4. 5: The effect of MgSO4 and Indomethacin on spontaneously contracting 
mouse myometrium. 
Representative isometric traces showing A, spontaneous time 
control B, indomethacin (3uM) alone, C, the effect of increasing concentration of 
magnesium sulphate on spontaneous contractions, and D, the effect of magnesium 
sulphate in combination with indomethacin on spontaneous 
contractions. Magnesium concentration dependently reduces the contraction and 
this inhibitory effect is enhanced when combined with indomethacin. The short 
coloured bars indicate the 15 minute period where magnesium was added. 2mM 
(blue), 4mM (orange), 6mM (red), 8mM (green), and 10mM (purple). 
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Figure 4. 6: Concentration dependency of MgSO4 + Indomethacin on 
spontaneously contracting mouse myometrium 
Mean data ± SEM showing the concentration-dependent effect of 
MgSO4+Indomethacin in A, force, B, frequency, C, duration and D AUC of 
spontaneously contracting strips. A significant difference in activity was found 
using ANOVA with Bonferroni post hoc. *denotes p<0.05, **p<0.01, ***p<0.001, 
**** p<0.0001 
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Table 4. 1: A comparison of the effect of Magnesium alone and Mg + indomethacin 
on spontaneous contractions. 
 Mean data ± SEM showing concentration dependent decrease in (A) amplitude force 
(B) frequency (C) duration and (D) AUC in spontaneously contracting term pregnant 
mouse uterine strips. Significance level was determined by ANOVA Bonferroni post hoc 
analysis. * indicates P<0.05, **P<0.01, P<0.001, P<0.0001 
 
Table 4.1: A comparison of the effect of Magnesium alone and Mg + indomethacin on 
spontaneous contractions. 
 Mean data ± SEM showing concentration dependent decrease in (A) amplitude force 
(B) frequency (C) duration and (D) AUC in spontaneously contracting term pregnant 
mouse uterine strips. Significance levels was determined by ANOVA Bonferroni post 
hoc analysis. * indicates P<0.05, **P<0.01, P<0.001, P<0.0001 
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A concentration response curve was plotted to show the AUC of spontaneous 
contractions and the IC50 (the concentration at which contractile activity is reduced 
by 50%) value for Mg + Indomethacin was determined as 2.6 ± 0.4 mM compared 
with 3.08 ± 0.16 mM for Mg alone.   
Different contractile properties could be affected under agonist stimulated 
conditions; therefore, the effect of Mg + Indomethacin on oxytocin-induced 
contractions was also examined. 0.5nM oxytocin was applied to stable spontaneous 
contractions. 
Increasing concentrations of Mg (2-12mM) were added to oxytocin-induced 
contracting tissues (Figure 4.7). As observed in spontaneous contractions, Mg + 
Indomethacin produced a concentration-dependent decrease in oxytocin-induced 
contractions in all tissues, however.  In contrast to spontaneous contraction, this 
was not sudden in onset, but a gradual decline in activity. Myometrium from a total 
of 8 mice was used in investigating the effect of Mg + Indomethacin on oxytocin-
induced contractions and its effect on contractile parameters were calculated (see 
Table 4.2).   
At 2mM and higher, there was a significant decrease in the force of contractions. At 
12mM Mg concentration, the force was reduced to 70.6% ± 0.2 (P<0.001). There 
was also a marked decrease in contraction frequency with increased Mg 
concentrations which was significant from 4mM onwards. At 12mM Mg, the 
frequency of contractions was reduced to 69.6% ± 0.3 (relative to control, 100%), 
p<0.0001. The duration of contractions at 12mM was reduced to 89.7% ± 10.7 and 
wasn’t statistically significant. The AUC however, which integrates all three 
parameters showed a significant concentration-dependent decrease.  
At 12mM Mg, it was reduced to 1.4% ± 1.0 compared to control (n=8). 70.6% ± 3.1 
(P<0.001). The AUC values were used to plot a concentration-response curve as a 
percentage of control activity. The changes in contractile parameters are 
represented in the bar charts and concentration-response curve shown in Figure 
4.8. From this concentration-response curve, the IC50 for Mg + Indomethacin in the 
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presence of oxytocin was calculated and determined as 12.3 ± 1.5 mM compared to 
9.8 ± 0.2 mM for Mg alone. 
To determine the concentration at which contractions are completely abolished, a 
separate experimental manoeuvre was carried out. A concentration of 10mM and 
20mM Mg was applied in combination with 30µM Indomethacin.  At 20mM, there 
was the complete abolition of contractions (Figure 4.7E). Its effect on different 
contractile parameters is indicated in the bar charts and concentration-response 
curve in Figure 4.8. 
In comparison between spontaneous and oxytocin-induced contractions, it was 
observed that a greater effect of the combination was seen in spontaneous 
contractions (Figure 4.9). When the concentration-response showing the effect of 
Mg + Indomethacin on oxytocin is plotted against that of spontaneous activity, it is 
observed that the curve is significantly shifted to the right demonstrating a higher 
IC50 value (P<0.0001). 
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Figure 4. 7:  The effect of MgSO4 and Indomethacin on oxytocin-induced 
contractions of mouse myometrium 
Representative traces showing A, oxytocin time control, B, indomethacin (30µM) 
time control, C, the effect of increasing concentration of magnesium sulphate in 
oxytocin-induced contractions, D, the effect of magnesium sulphate and 
indomethacin on oxytocin-induced contractions and E, the effect of magnesium 
sulphate (10mM and 20mM) and 30µM indomethacin in all traces were in the 
presence of oxytocin. The short coloured bars indicate the 15-minute period where 
different concentrations of magnesium were added. 2mM (blue), 4mM (orange), 
6mM (red), 8mM (green), 10mM (purple) and 12mM (brown). 
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Table 4. 2: A comparison of the effect of Magnesium alone and Mg + indomethacin 
on oxytocin-induced contractions. 
 Mean data ± SEM showing concentration dependent decrease in (A) amplitude force 
(B) frequency (C) duration and (D) AUC in oxytocin-induced contracting term 
pregnant mouse uterine strips. Significance levels were determined by ANOVA 
Bonferroni post hoc analysis. * indicates P<0.05, **P<0.01, P<0.001, P<0.0001 
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Figure 4. 8: Concentration dependency of MgSO4 + Indomethacin on oxytocin-
induced contracting mouse myometrium 
Mean data ± SEM showing the concentration-dependent effect of MgSO4+ 
Indomethacin in (A) force (B) frequency (C) duration and (D) AUC of oxytocin-
induced contracting strips. A significant difference in activity was found using 
ANOVA with Bonferroni post hoc test. **denotes p<0.01, ****p<0.0001 
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Figure 4. 9: A comparison of MgSO4 + Indomethacin in spontaneous and 
oxytocin-induced contractions 
Mean data ±  SEM showing the dose-dependent effect of MgSO4+Indomethacin in 
(A) force (B) frequency (C) duration and (D) AUC of spontaneously (green) and 
oxytocin-induced (purple) contracting strips. A significant difference in activity 
was found using ANOVA with Bonferroni post hoc. *denotes p<0.05, ** p<0.01, 
***p<0.0001 
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4.4.3 The Effect of Atosiban on uterine contraction of term pregnant mouse. 
   Increasing concentrations of atosiban (10nM -3µM) was applied to oxytocin-
induced contractions. Representative isometric traces demonstrating the effect of 
increasing concentration of atosiban and time control (oxytocin alone) are shown in 
Figure 4.10A-B.  Data showing atosiban’s effect on force, frequency and duration 
are represented on bar charts (Figure 4.11A-C), while its effect on AUC is 
represented in a concentration-response curve (Figure 4.11D).  
The force of contractions was significantly reduced at 300nM and higher. The 
frequency was significantly reduced from 30nM and higher. Atosiban had no 
significant effect on the duration of contractions. The AUC values were used to plot 
a concentration response curve and the IC50 value for atosiban was determined as 
376 nM ± 20.1. The IC50 (approximated) value used for subsequent combination 
experiment was 500nM. 
4.4.4 The Effect of Mg plus Atosiban on uterine contractions of term pregnant 
mouse. 
 The effect of Mg plus atosiban was not determined in spontaneous 
contractions as our group has previously shown that atosiban had little or no effect 
on spontaneous contractions (Arrowsmith et al., 2015), therefore only oxytocin-
induced contractions were investigated. Figure 4.12 shows typical recording of 
myometrial contractions stimulated with 0.5nM oxytocin (Figure 4.12A), inhibited 
by 0.5µM atosiban (Figure 4.12B), showing the effect of increasing concentrations 
of Mg (Figure 4.12C), and the inhibitory effect of Mg + atosiban (Figure 4.12D).  
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Figure 4. 11: The effect of Atosiban on oxytocin-induced contractions of term mouse 
myometrium 
Isometric representative traces showing (A), the effect of 0.5nM oxytocin on term 
pregnant mouse myometrium which continued contracting without loss of force and 
frequency over a long period of time and, (B), the inhibitory effect of increasing 
concentrations of atosiban (10nM- 3µM) on oxytocin-induced contractions. 
The short coloured bars indicate the 15-minute period where increasing concentrations 
of atosiban were added: 10nM (blue), 30nM (orange), 100nM (red), 300nM (green), 
1µM (purple) and 3µM (brown). 
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Figure 4. 12:  Concentration dependency of Atosiban on oxytocin-induced 
contracting term mouse uterus 
Average mean data ± standard error mean (SEM) showing the concentration-
dependent effect of atosiban on (A), force, (B), frequency, (C), duration and (D), 
AUC of oxytocin-induced contractions. A significant difference in activity was found 
using ANOVA with Bonferroni post hoc. *denotes p<0.05, *** p<0.001, **** 
p<0.0001. 
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Figure 4. 13: The combined effect of Magnesium and atosiban on oxytocin-
induced contractions 
Representative isometric traces showing (A) oxytocin time control (B) atosiban 
time control (C) the effect of Magnesium on oxytocin-induced contractions and 
(D), the effect of Magnesium + Atosiban on oxytocin-induced contractions. 
Magnesium alone slowly reduced the contractions, but when atosiban was 
added, contractions were inhibited and in almost all cases, completely 
abolished. 
The short coloured bars indicate the 15-minute period where magnesium was 
added. 2mM (blue), 4mM (orange), 6mM (red), 8mM (green), 10mM (purple) 
and 12mM (brown). 
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In the presence of oxytocin, Mg + Atosiban caused a concentration-dependent 
decrease on force, frequency and AUC. At 2mM and higher, there was a significant 
decrease in the force of contractions (Table 4.3). At 12mM Mg concentration, the 
force was reduced to 9.7% ± 9.7 with of 6 of 8 samples completely abolished. There 
was also a marked decrease in contraction frequency with increased Mg 
concentrations which was significant from the first concentration (2mM) onwards. 
At 12mM Mg, the frequency of contractions was reduced to 2.3% ± 2.8 (relative to 
control, 100%), p<0.001. The duration of contractions at 12mM was reduced to 
11.12% ± 10.4 compared to control. The AUC however, which integrates all three 
parameters showed a significant concentration-dependent decrease. At 12mM Mg, 
the AUC was reduced to 1.4% ± 1.0 compared to control (n=8).  
 The concentration-dependent reduction in oxytocin-induced contractions is 
represented in the bar charts (Figure 4.13) for force (Figure 4.13A), frequency 
(Figure 4.13B), and duration (Figure 4.14C). To determine the IC50 value, a 
concentration-response curve was plotted using the AUC values (Figure 4.13D) of 
Mg alone and in combination with atosiban. Mg + atosiban caused a leftward shift 
of the concentration-response curve compared with Mg alone. The IC50 values for 
Mg + Atosiban were 3.2 mM ± 0.04 compared with 7.4 mM ± 1.4 for Mg alone 
(p<0.001). 
4.4.5 Comparison between Mg + Indomethacin and Mg + Atosiban 
In oxytocin-induced contractions, the same experimental procedures were used to 
test the tocolytic efficacy of Mg + Atosiban and Mg + Indomethacin on pregnant 
mouse myometrium; therefore it was possible to make a direct comparison 
between these drug combinations.  
159 
 
  
Table 4. 3: A comparison of the effect of Mg alone and Mg + atosiban on oxytocin-
induced contractions 
 Mean data ± SEM showing concentration dependent decrease in (A) amplitude force 
(B) frequency (C) duration and (D) AUC in oxytocin-induced contracting term 
pregnant mouse uterine strips. Significance levels were determined by ANOVA 
Bonferroni post hoc analysis. * indicates P<0.05, **P<0.01, P<0.001. 
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Figure 4. 14: Concentration dependency of MgSO4 + Atosiban on oxytocin-induced 
contracting mouse myometrium 
Bar charts showing the concentration-dependent effect of MgSO4 + atosiban on 
force (A), frequency (B) and duration (C). D, shows concentration response curves 
depicted for the effect of MgSO4 alone (green) and when combined with atosiban 
(blue). The concentration response curve for atosiban time control (red) is also 
plotted. With the combination, the curve is significantly shifted to the left for AUC 
(P<0.0001). A significant difference in activity was found using ANOVA with 
Bonferroni post hoc. **denotes p<0.01, *** p<0.001, **** p<0.0001. Data are 
presented as mean ± SEM.  
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The mean data for both drug combinations are indicated in Table 4.5 and these 
values were used to plot bar chart for force, frequency and duration (Figure 4.14A-
D) while a concentration-response curve was plotted to reflect the changes in AUC 
(Figure 4.14D). The IC50 values for Mg + Atosiban and Mg + Indomethacin were 3.2 
mM ± 0.04 and 12.2 mM ± 1.5 respectively. There was no significant difference 
between the drug combinations in force (Figure 4.14A), and duration (Figure 4.14C), 
from 2-10mM Mg, however, a significant difference was observed at 12mM Mg. The 
difference seen in frequency was significantly different at all concentrations of Mg 
(Figure 4.14B). The concentration-response of Mg + Indomethacin was significantly 
shifted to the right (P<0.001) indicating a higher IC50. 
4.4.6 The Effect of Nifedipine on Uterine Contractions of term pregnant mouse. 
To determine the IC50 value of nifedipine on spontaneous and oxytocin-
induced contractions, a similar protocol to indomethacin and atosiban was used. 
Increasing concentrations of nifedipine (3pM- 3nM) were used for both 
spontaneous (Figure 4.15A) and oxytocin-induced (Figure 4.15B) experiments. At 
very small concentrations (10 pM and above), it was observed that the contractions 
were abolished (Figure 4.15A-B). Therefore, single concentrations (10pM and 
30pM) were used to determine the effect on contractions (Figure 4.15C-D). It was 
observed that contractions were slowly decreased and if left for a long time, 
completely abolished. 
As depicted in Figure 4.15, nifedipine was shown to be time-dependent on 
the strips and once completely abolished; its effect was not reversible even after 
one hour of washout.  
  
162 
 
 
  
F o r c e
M g S O 4  C o n c e n tr a t io n
%
 
o
f
 
c
o
n
t
r
o
l
 
f
o
r
c
e
C
o
n
tr
o
l
2
m
M
4
m
M
6
m
M
8
m
M
1
0
m
M
1
2
m
M
0
5 0
1 0 0
1 5 0
M gS O 4 + A to s ib a n
M gS O 4 + In d o m e th a c in
(A)
* **
F r e q u e n c y
M g S O 4  C o n c e n tr a t io n
%
 
o
f
 
c
o
n
t
r
o
l
 
f
r
e
q
u
e
n
c
y
C
o
n
tr
o
l
2
m
M
4
m
M
6
m
M
8
m
M
1
0
m
M
1
2
m
M
0
5 0
1 0 0
1 5 0
M gS O 4 + A to s ib a n
M gS O 4 + In d o m e th a c in
(B)
** ** ** ** **
D u ra tio n
M g S O 4  C o n c e n tr a t io n
%
 o
f
 
c
o
n
t
r
o
l
 d
u
r
a
t
i
o
n
C
o
n
tr
o
l
2
m
M
4
m
M
6
m
M
8
m
M
1
0
m
M
1
2
m
M
0
5 0
1 0 0
1 5 0
M gS O 4 + A to s ib a n
M gS O 4 + In d o m e th a c in
(C)
**
1 0 -4 1 0 -3 1 0 -2 1 0 -1 1 0 0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0 M gS O 4  +  A to s ib a n
M gS O 4 +  In d o m e th a c in
L o g  [M g S O 4 ]  (M )
%
 c
o
n
t
r
o
l 
A
U
C
(D)
Figure 4. 15: A comparison of MgSO4 plus Atosiban and MgSO4 plus 
Indomethacin on oxytocin-induced contractions 
 
Mean data ± SEM showing the concentration-dependent effect of MgSO4+ 
Atosiban (blue) and MgSO4 + Indomethacin (purple) in (A) force, (B) 
frequency, (C) duration, and (D) AUC of oxytocin-induced contracting strips. 
MgSO4+ Atosiban significantly shifts the curve to the left (P<0.001) indicating 
less magnesium to inhibit contractions compared to MgSO4 + Indomethacin. 
A significant difference in activity was found using ANOVA with Bonferroni 
post hoc. *denotes p<0.05, ** p<0.0001 
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Figure 4. 16 The effect of nifedipine on uterine contractions of term 
pregnant mouse. 
Representative isometric traces showing the effect of increasing 
concentration of nifedipine on (A) spontaneous contractions, and (B), 
oxytocin-induced contractions). (C and D) showed the effect of a single 
concentration of nifedipine on contractions. With a single concentration, 
nifedipine reduced both spontaneous and oxytocin-induced contractions over 
time until contractions were completely abolished. 
The short coloured bars indicate the 15 minute period where increasing 
concentrations of nifedipine were added- 3pM (black), 10pM (blue), 30pM 
(orange), 0.1nM (red), 0.3nM (green), 1nM (purple) and 3nM (brown). 
 
(A) 
 
(B) 
 
(C) 
 
(D) 
 
0 
 
20 
 
Force 
(mN) 
 
0 
 
13 
 
Force 
(mN) 
 
Nifedipine (Time control) 
 10pM 
Nifedipine 
0 
 
18 
 
Force 
(mN) 
 
Nifedipine (Time control) 
 
30pM 
Nifedipine 
OT  
 
0 
 
15 
 
OT 
 
Force 
(mN) 
 
15 mins 
 
15 mins 
 
164 
 
For spontaneous contractions, the time-dependent effect of 10pM nifedipine is 
depicted in the bar charts (Figure 4.16A- D). Over a 1-hour period of nifedipine’s 
application, there was a time-dependent reduction in force of contractions which 
reach significance at 40 minutes and higher. Although there was an observed 
reduction in frequency and duration of contractions, this didn’t reach significance as 
the error bars were very high, resulting from a small n value (n=2), however, the 
AUC was significantly reduced at 30 minutes and higher.  
Bar charts showing the time-dependent effect of 30pM nifedipine on oxytocin-
induced experiments (n=4) are represented in Figure 4.17A-D. Nifedipine caused a 
significant reduction of contractions in force at 20 minutes and higher. The duration 
was also significantly reduced at 30 minutes and higher. The frequency of 
contractions was significantly increased at 50 minutes and higher.  The overall 
activity (AUC) showed a significant decrease at 20 minutes and higher. 
As a result of the time-dependency of higher nifedipine concentrations, I, therefore, 
chose a lower concentration of nifedipine (3pM) to be combined with the IC50 
values of Mg for spontaneous (4mM) and oxytocin-induced contractions (10mM). At 
this concentration, contractions remained stable for a long period of time. Also, the 
concentration-dependent experiments were not carried out with nifedipine. 
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Figure 4. 17: Time-dependent effect of nifedipine on spontaneous 
contractions 
Bar charts showing the time dependent effect of 10pM nifedipine on 
spontaneous contractions of term pregnant mouse during a 1-hr period of 
application. Nifedipine gradually decreased (A) force, (B) frequency, (C) 
duration and (D) AUC 
Data represents mean values ± SEM (n=2). The asterisks on the vertical bars 
indicate a significant difference compared to control (ANOVA, p< 0.05).  * 
denotes p<0.05. 
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Figure 4. 18:  Time-dependent effect of nifedipine on oxytocin-induced 
contractions 
Bar charts showing the time dependent effect of 30pM nifedipine on oxytocin-
induced contractions of term pregnant mouse during a 1-hr period of 
application. Nifedipine caused a change in (A) force, (B) frequency, (C) duration 
and (D) AUC.  
Data represents average mean values ± SEM (n=4). The asterisks on the vertical 
bars indicate a significant difference compared to control (ANOVA, p< 0.05).  * 
denotes p<0.05, *** p<0.0001. 
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4.4.7 The Effect of Mg plus nifedipine on uterine contractions of term pregnant 
mouse. 
Having established a robust protocol (4.4.6), I proceeded to examine the effect of 
combining Mg + nifedipine in both spontaneous and oxytocin-induced contractions 
(Figure 4.18). Unlike in atosiban and indomethacin experiments, increasing 
concentrations of Mg have not used in Mg + Nifedipine experiments for reasons 
explained in section 4.4.6.  
In spontaneous contractions (n=7), 4mM Mg + 3pM nifedipine reduced the force of 
contractions to 62.1% ± 14.0 of control, however, this reduction did not reach 
statistical significance. When this effect was compared to that seen with 4mM Mg 
alone (86.5% ± 6.5), there was again no significant difference (P=0.06). The 
frequency of contractions, however, was affected by Mg + nifedipine causing a 
significant reduction (56.2% ± 4.5, P<0.01) compared to control (100%). There was, 
however, no significant difference when the effect of the combination was 
compared to Mg alone (P=0.07). The duration of contractions was not significantly 
affected (91.3% ± 26.2, P =0.76). The AUC of contractions was significantly reduced 
to 46.4% ± 6.7 of control (p<0.001) while Mg alone caused the AUC to be 
significantly reduced to 64.6% ± 5.6 of control (p<0.001).  Bar charts to represent 
the mean percentage compared to control ± SEM for force, frequency, duration and 
AUC are shown in Figure 4.19 A-D. 
To determine the tocolytic efficacy of the combination of Mg + nifedipine under the 
hormonal influence of oxytocin, the effect of Mg (10mM) + nifedipine (3pM) was 
also examined in oxytocin-induced contractions (n =6). In the presence of oxytocin, 
Mg + nifedipine still produced a decrease in myometrial contractions: The force of 
contractions was significantly reduced to 61.5% ± 6.3 of control (P<0.01) while Mg 
alone reduced the force to 81.1% ± 5.1 (P<0.05) of control. The frequency of 
contractions was significantly reduced b to 50.4% ± 10.1 (P<0.01). The duration of 
contraction was not significantly reduced with either Mg alone (P=0.69) or in 
combination with nifedipine (P= 0.72). The AUC was significantly reduced by Mg + 
nifedipine to 34.6% ± 6.8 compared to control (P<0.001). When the effect of Mg in 
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the presence of nifedipine was compared to that of Mg alone (51.0% ± 7.7, P<0.01), 
there was a significant difference (P<0.05). Figure 4.20 (A-D) shows bar charts to 
represent the percentage change in force, frequency, duration and AUC of 
contractions.  
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Figure 4. 19: The effect of MgSO4 plus Nifedipine on spontaneous and 
oxytocin-induced contractions 
Isometric traces showing (A), the effect of 3pM nifedipine on contractions; (B), 
the effect of 4mM Mg alone on spontaneous contractions; (C) the effect of 
4mM Mg and 3pM nifedipine on spontaneous contractions; (D), the effect of 
10mM Mg on oxytocin-induced contractions and (E) the effect of10mM Mg 
and 3pM nifedipine on oxytocin-induced contractions. 
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Figure 4. 20: The effect of MgSO4 and MgSO4 plus Nifedipine on spontaneous 
contractions. 
Bar charts showing the effect of MgSO4 alone (green) and in combination with 
nifedipine (orange) on (A), force (B) frequency, (C) duration and (D) AUC of 
spontaneous contractions. The difference in activity was found by ANOVA using 
Bonferroni post hoc test. *denotes p<0.05, ** p<0.01 ***p<0.001. 
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Figure 4. 21:  The effect of MgSO4 and MgSO4 plus Nifedipine on oxytocin-
induced contractions. 
Bar charts showing the effect of MgSO4 alone (green) and in combination with 
nifedipine (orange) on (A), force (B) frequency, (C) duration and (D) AUC of 
oxytocin-induced contractions. The difference in activity was found by ANOVA 
using Bonferroni post hoc test. *denotes p<0.05, ** p<0.01, *** p<0.001 
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4.4.5 Comparison between combined tocolytics 
 To determine which tocolytic in combination with Mg is most efficacious, I, 
therefore, chose one concentration of Mg (10mM) which was used in all procedures 
and in the presence of oxytocin which could, therefore, be used to compare 
responses across the different tocolytic combinations with Mg. (Figure 4.21). 
 Mean data for Mg and the combinations on all contractile parameters of 
contractility were plotted together and statistical analysis between groups 
performed. In the force of contractions (Figure 4.21A), there was a significant 
difference between all groups (p<0.05). There was also a significant difference 
between all groups in frequency (Figure 4.21B) and AUC (Figure 4.21D) of 
contractions (p<0.0001). The duration of contractions (Figure 4.21C) between 
groups did not reach statistical significance (p=0.57). The mean values ± SEM for all 
parameters are represented in Table 4.5.  My data suggests the order of combined 
tocolytic potency to be: Mg + atosiban > Mg + nifedipine > Mg + indomethacin. 
4.4.6 The Effect of Acidification on the efficacy of combined tocolysis. 
 Since my investigations revealed that the most effective combination of 
tocolytic with magnesium is Atosiban, I wanted to investigate how acidification 
could affect the efficacy of this combination. To determine the effect of 
extracellular acidification (pHo), the pH of the Mg + atosiban solution (pH 7.4) was 
changed to an acidic solution (pH 6.9). This was applied for 15 minutes and the 
change in contractile properties compared to pH 7.4 was measured. A typical trace 
is shown in Figure 4.22A. All contractions were induced with 0.5nM oxytocin while 
4mM Mg plus 500nM atosiban were used as inhibitors. 
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Figure 4. 22: The effect of MgSO4 alone and in combination with Atosiban, 
Indomethacin and Nifedipine on oxytocin-induced mouse myometrium. 
Bar charts showing the effect of MgSO4 alone (black) and in combination with 
atosiban (blue), nifedipine (orange) and indomethacin (purple) on (A), force (B) 
frequency, (C) duration and (D) AUC of oxytocin-induced contractions. The 
difference in activity was found by ANOVA using Bonferroni post hoc test. 
*denotes p<0.05, ** p<0.01, *** p<0.001. 
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Figure 4. 23: The effect of extracellular acidification on MgSO4 plus atosiban 
(A) Representative isometric recording showing the effect of MgSO4 + atosiban 
on oxytocin-induced contracting strips at pH 7.9 and 6.9 (n=8). Bar charts show 
the effect of extracellular acidification on MgSO4 + atosiban. Mean data ± SEM 
(denoted by error bars) showing decrease in (B) amplitude (C) duration (D) 
frequency (E) AUC in response to pH 7.4 (green) and pH 6.9 (yellow) when 
compared to the control (black). Significant difference was calculated using 
ANOVA. ** denotes p<0.01, *** P<0.001, ****P<0.0001. 
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It was observed that acidification caused an increase in force, frequency and AUC of 
contractions resulting in reduced efficacy of the combination. Analysis of AUC 
values showed significant differences between Mg + atosiban (pH 7.4) compared to 
control (32.2% ± 3.5, n=7; p<0.0001) and Mg + atosiban (pH 6.9) compared to 
control (60.7% ± 8.3, n=7; p<0.01). Comparison between the effects of the two 
groups (pH 7.4 and pH 6.9), showed the reduction in activity to be significantly 
greater under pH 7.4, P=0.005. Bar charts comparing the effect before and after 
acidification in comparison to control are shown in Figure 4.22 B-E. 
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4.5 Discussion    
Tocolytics have been shown to relax myometrial contractions and they act via 
different mechanisms. Many studies including a Cochrane review (Vogel et al., 
2014a) conclude that the combination of tocolytics, especially those affecting 
different pathways, could have a greater effect compared to single agents and could 
also reduce dosage used, thereby reducing side effects.  
To the best of my knowledge, this chapter is the only study that has extensively 
investigated the effect of Mg in combination with the most commonly used 
tocolytics (indomethacin, atosiban and nifedipine) in pregnant mouse uterus. This 
study was conducted to investigate the inhibitory effect of individual tocolytics, 
investigate the effect of combining Mg with these tocolytics and to examine how 
extracellular acidification and hormonal influences such as oxytocin could affect its 
efficacy. My data showed that all drugs studied (Mg, atosiban, indomethacin and 
nifedipine) individually had a tocolytic effect in vitro on pregnant mouse uterus. 
The effect of indomethacin on uterine contractility 
This experiment showed that indomethacin has a concentration-dependent 
inhibitory effect on mouse uterine contractions which confirms work previously 
described in human myometrium (Baumbach et al., 2012).  Indomethacin arrests 
and completely inhibits spontaneous contractions, with complete abolition of 
contractions at 100 µM.  
To mimic the hormonal milieu in labour, the effect of indomethacin on oxytocin-
induced contractions was also investigated. As shown in Table 4. 2, the effects of 
indomethacin were less in the presence of oxytocin compared to spontaneous 
contractions, which may be due to the increased contractile activity with oxytocin 
stimulation. These data also revealed that the response to indomethacin under 
oxytocin is shifted to the right, indicating a greater concentration needed to 
suppress oxytocin’s effect on contractions. At higher concentrations, indomethacin 
drastically abolished contractions, suggesting that indomethacin may be acting via 
another mechanism other than inhibiting COX and prostaglandin production. Similar 
rapid inhibition was found in human myometrium by our group (Arrowsmith et al., 
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2016) and others (Sawdy et al., 1998). They suggested that indomethacin may partly 
act via calcium channel blockade, thereby reducing calcium entry (Sawdy et al., 
1998). They and others (Vane and Williams, 1973, Riendeau et al., 1997) also 
showed that indomethacin had more of an inhibitory effect on contractility than on 
calcium currents, suggesting that calcium blockage may be one of several 
mechanisms by which indomethacin acts. In this study, indomethacin only arrested 
contractions at >30 µM, which is higher than the therapeutic plasma concentrations 
(1-2 µM). It is however uncertain if this effect of indomethacin is of any relevance in 
vivo.    
The effect of atosiban on uterine contractility 
Under oxytocin stimulation, atosiban caused a concentration-dependent reduction 
in contractions. The force and frequency of contractions were affected, including 
the force integral which takes into account the whole contractile activity. At the 
highest concentration used (3µM), atosiban inhibited contractions to less than 
spontaneous activity.  This may be as a result of atosiban’s agonistic action on 
oxytocin and vasopressin receptors or perhaps by an unknown mechanism. Similar 
response to atosiban has been shown in term pregnant women (Büscher et al., 
2001).  
Atosibans’s effect seemed more potent in the frequency than force of contractions. 
The effect of nifedipine on uterine contractility 
This study has shown that nifedipine significantly inhibits spontaneous and 
oxytocin-induced contractions even at very low concentration (10pM). This finding 
supports other published work confirming nifedipine as a potent tocolytic 
(Moynihan et al., 2008b, Forman et al., 1982). This study is the first to show a time-
dependent inhibitory effect of nifedipine on mouse uterine contractility. Due to the 
inhibitory effect observed at very low concentrations, it is clear that nifedipine may 
be a potent tocolytic. 
My data clearly reveals that nifedipine was able to inhibit contractions even when 
induced by oxytocin. This may partly be as a result of one of oxytocin’s mechanisms 
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which involve depolarizing and increasing calcium entry via the L-type calcium 
channel (Wray, 2007). There was greater tocolytic effect of nifedipine in 
spontaneous contractions than in oxytocin-induced, which may be due to the 
increased uterine activity with the stimulant. 
Spontaneous uterine contractions are produced by changes in membrane potentials 
resulting in the burst of action potentials (Kawarabayashi et al., 1989), and L-type 
calcium channel opening (Wray et al., 2003, Shmigol et al., 1998). My data shows 
reduced force and duration of contractions, which indicates a decrease in 
intracellular calcium caused by inhibition of L-type calcium channels. In 
spontaneous contractions, a decrease in frequency was also noted suggesting that 
the pacemaker activity is affected. When stimulated with oxytocin however, an 
increase in frequency was observed which may suggest that there is a quick 
recovery of the membrane to resting potential in the presence of oxytocin. 
Regardless of the increase in force and decreased force and duration of oxytocin-
induced contractions, the overall contractile activity (AUC) was still reduced. 
The effect of combined tocolytics 
According to the NICE guidelines 2011, women who are at risk of preterm birth 
before 30 weeks of pregnancy are to be administered MgSO4 to help reduce the risk 
of cerebral palsy. So, although MgSO4 is not currently used for the treatment of 
preterm labour, it is being administered clinically in combination with a tocolytic 
which in the UK could either be indomethacin, nifedipine, or atosiban. This means 
that in certain preterm cases (<30 weeks), a dual tocolytic therapy may be given.  
The idea of combined tocolytics has been studied in animals and human. Nifedipine 
has been studied in combination with ritodrine (Carvajal et al., 2017), β-adrenergic 
agonists (Hajagos-Toth et al., 2010), sildenafil citrate (Chiossi et al., 2010); 
indomethacin has been studied in combination with nifedipine (Kashanian et al., 
2019), and ritodrine (Katz et al., 1983); while atosiban has been studied in 
combination with nimesulide (Grigsby et al., 2000), and magnesium in human 
myometrium (Arrowsmith et al., 2016).  Nonetheless, there are only few studies 
that have investigated the effect of dual tocolysis involving MgSO4 in combination 
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with atosiban, indomethacin or nifedipine, and comparing the inhibitory effects of 
the combination. In fact, a recent Cochrane review pointed out the lack of 
combination studies which involved the widely used tocolytics (Vogel et al., 2014a). 
Therefore, finding the best combination could help halt the increasing rate of 
preterm birth. However, owing to the time-dependent effect of nifedipine on 
myometrial contractions and atosiban having no effect on spontaneous 
contractions, different experimental procedures were used in the three 
combinations examined; Mg + atosiban, Mg + Indomethacin, and Mg + nifedipine. 
This study shows the effect of each tocolytic alone and in combination with Mg. The 
combination of Mg with indomethacin caused a concentration-dependent decrease 
in mouse myometrial contractility in both spontaneous and oxytocin-induced 
contracting tissues, but less reduction was seen in the presence of oxytocin. The 
tocolytic effect on the spontaneously contracting tissue was additive, however, in 
oxytocin induced contractions; the effect on contractions was antagonistic as the 
combination reduced the tocolytic effect of both drugs individually. Indomethacin, 
which is a non-selective COX inhibitor, acts by blocking prostaglandin production 
and hence reduces uterine stimulation, while MgSO4 acts by hyperpolarising the 
plasma membrane and competing with extracellular calcium or entry leading to a 
reduction in the availability of calcium required for myosin light chain kinase 
activation, thereby reducing myometrial contractility (Simhan and Caritis, 2007). 
This finding supports the finding by  (Vane and Williams, 1973) who investigated the 
effect of indomethacin on both non-pregnant and pregnant rat uteri and reported 
that in pregnant myometrium, oxytocin-induced contractions were not antagonized 
by indomethacin but caused a significant reduction in the spontaneous 
contractions.  
With Mg + atosiban combination, a concentration 3 times higher than Mg 
alone was needed to obtain the same effect as seen with the combination. This 
indicates that the effect of MgSO4 + Atosiban on myometrial contractions was 
synergistic. This result is similar to previous findings from our lab which investigated 
the effect of MgSO4 and atosiban on strips obtained from term pregnant women 
undergoing caesarean section (Arrowsmith et al., 2016). This combination 
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potentiates the inhibitory effect of each drug on its own. This may be as a result of 
the two drugs acting via different intracellular pathways which enhance the 
inhibitory effects of each other. Magnesium interferes with the Ca2+ entry into the 
cell while atosiban plays a significant role as an antagonist at the site of the oxytocin 
receptors. However, it should be noted that atosiban had little if any effect on 
spontaneous contractions in humans (Arrowsmith et al., 2016) and hence the effect 
of atosiban on spontaneous contractions in mouse was not tested.   
The combination of Mg and nifedipine has been reported to cause high side effects, 
owing to the potential interaction leading to hypotension and neuromuscular 
blockade (Magee et al., 2011). This combination has however been investigated in 
this chapter. Despite the maternal and neonatal side effects that result from dual 
tocolytic therapy, the NICE guidelines on preterm labour and birth (November 2015) 
provided no information on the safety of using MgSO4 in combination with a 
tocolytic especially nifedipine which acts via a similar mechanism (RCOG, 2016), 
hence the need for this study. 
In both spontaneous and oxytocin-induced contractions MgSO4 + Nifedipine 
significantly inhibited contractions. When the combination was compared to 
magnesium alone, the difference did not reach statistical significance.  This was true 
for both spontaneous and oxytocin-induced contractions. 
The effect of Mg plus Atosiban and Mg plus Indomethacin on oxytocin-induced 
contractions was compared and there was a significant difference between them. 
Although the Mg plus Indomethacin combination caused a concentration-
dependent decrease in contractile parameters, its effect was significantly lower 
than Mg + Atosiban. The concentration response curve for Mg + Indomethacin was 
shifted to the right as indicated by the IC50 values.  When the effect of all three 
combinations were compared at a given Mg concentration, the greatest tocolytic 
effect was Mg plus Atosiban followed by Mg plus Nifedipine with Mg plus 
Indomethacin showing the least tocolytic effect. 
As seen in Figure 4.1, there are 2 major pathways to contractility and the different 
tocolytics act on them to facilitate relaxation. Tocolytics may either stimulate 
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relaxatory pathways e.g. those involving cAMP signaling or inhibit stimulatory 
pathways, typically those involving IP3 formation or calcium (Kuć et al., 2011). IP3 
stimulate the release of calcium ions from sarcoplasmic reticulum and increases the 
intracellular calcium concentration. Most tocolytics (e.g. magnesium, atosiban, 
nifedipine and indomethacin) would normally have an effect on the second 
pathway. Magnesium which is an L-type calcium channel blocker acts by inhibiting 
calcium entry, intracellular calcium release and cytosolic calcium oscillations 
(Phillippe, 1998). Nifedipine, an L-type calcium channel inhibitor acts also by 
blocking of the inflow of calcium ions from extracellular stores, which is 
independent of IP3 pathway. Atosiban, an oxytocin receptor antagonist, prevents 
IP3 pathway stimulation by competitively inhibiting oxytocin binding to myometrial 
cell receptors. Atosiban binds oxytocin membrane receptor and directly blocks G-
protein signalling. Through this mechanism, it inhibits inositol triphosphate 
synthesis. Indomethacin, a prostaglandin synthesis inhibitor blocks cyclooxygenase 
(COX) pathway. Prostaglandins are other stimulants which play a major role in 
maintenance of pregnancy and the beginning of labour. They also modulate 
myometrial contractions during labour as well as during reproduction (Hertelendy 
and Zakar, 2004) 
The greatest tocolytic effect seen with Mg plus Atosiban may be as a result of the 
blockage of two different pathways which lead to increased intracellular calcium 
concentration. This combination results in inhibition of extracellular Ca2+ inflow via 
Mg and reduced calcium release from the SR. In addition, atosiban blocks IP3 
synthesis and it blocks the cooperation with diacylglycerole in prostaglandin 
synthesis.  Oxytocin and prostaglandin play major roles in influencing induction and 
sustenance of myometrial contractions. In these experiments, oxytocin was used to 
stimulate the contraction, hence the greatest inhibition was seen when Mg was 
combined with Atosiban. The least tocolytic effect seen with Mg plus Indomethacin 
may be because of oxytocin’s effect, as the combination caused great inhibition in 
spontaneous contractions. A study which investigated the effect of Indomethacin in 
pregnant rats showed that Indomethacin did not suppress myometrial contractions 
in the presence of oxytocin (Fuchs et al., 1976). The inhibitory effect seen with Mg 
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plus Nifedipine was additive and this may be as a result of the blockage of the influx 
of extracellular calcium. Nifedipine and Mg act via similar mechanism and in 
addition Mg increases cAMP level which reduces intracellular calcium (Ben-Ami et 
al., 1994). Intracellular magnesium reduces calcium available for contraction by 
stimulating calcium dependent ATPase. Because of the similarity in mechanism of 
action between Mg and nifedipine, there have been questions regarding the safety 
of using both drugs in combination. Thorp et al demonstrated in isolated rat heart 
model that nifedipine caused a concentration dependent myocardial depression 
which increased the effect of magnesium (Thorp et al., 1990). Other studies (Snyder 
and Cardwell, 1989) have shown similar findings pointing to increased incidence of 
magnesium-related neuromuscular blockade and other maternal side effects. Other 
studies however have also demonstrated that the drug combination does not 
increase the risk of neuromuscular weakness and blockade (Magee et al., 2005). 
Effect of pH change on tocolytic efficacy 
Changes in extracellular and intracellular pH alter uterine contractions in guinea 
pigs, rats and women (Parratt et al., 1994, Taggart and Wray, 1993, Naderali et al., 
1997).  Despite the fact that pH changes have been widely studied in the uterus, the 
regulatory mechanism at the level of ion channels is poorly understood. This section 
of the study was designed to establish the effect of extracellular acidification and its 
influence on tocolytic efficacy. Previous reports in rats and human have shown 
acidification to decrease contractions while alkalinisation increased contractions 
(Parratt et al., 1994, Taggart and Wray, 1993). My data however, indicates that 
extracellular acidification produces a marked increase in the force and frequency of 
myometrial contractions, hence reducing the tocolytic efficacy of Mg plus Atosiban. 
This result is consistent with an increase in contractile force observed in non-
pregnant guinea pig (Naderali and Wray, 1999b) and an increase in contractions of 
uterine circular muscle of pregnant mice (Hong et al., 2016). Previous study from 
our lab (Almohanna et al., 2016) that investigated the effect of pHo on mouse 
myometrium also showed that reduced pHo caused modulation of force and 
frequency of spontaneous contractions. This increase was seen in non-pregnant, 
mid-term (day 14) and term-pregnant (day 19) mice myometrium.  
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Although pH is thought to act via different mechanisms, one possible mechanism by 
which extracellular acidification stimulates force thereby reducing tocolytic efficacy 
may be via the displacement of Ca2+ from intracellular binding sites (Parratt et al., 
1995). It is known that protons and Ca2+ compete for intracellular binding sites 
(Wray, 1988), hence a rise in H+ may lead to an increase in free Ca2+. This mechanism 
may partly explain the reduced efficacy of tocolytics used in clinics. It has been 
shown that changes in pHo can slowly cause changes in pHi and affect cellular 
function (Austin and Wray, 1995, Wray, 1993, Fry et al., 1994); however, this 
interaction with each other makes it difficult to distinguish their effects (Naderali 
and Wray, 1999a). 
In summary, the data in this chapter shows the effect of magnesium sulphate in 
combination with atosiban, indomethacin or nifedipine on mouse myometrium and 
its effect on mouse myometrium. The data shows that magnesium plus atosiban 
was more potent in reducing myometrial contractions compared to the other 
combinations, possibly due to the combination acting via different contractile 
pathways. The data also shows that extracellular acidification caused an increase in 
force and frequency of contractions in the presence of the combination (Mg plus 
atosiban) thereby reducing the efficacy of the combination. Further investigation 
into the mechanism involved in pH and tocolytics may shed further insights into 
these findings.     
4.5.1 Limitations of this study 
- The strips used in this study were obtained from non-labouring mice and since 
tocolytics are normally used in treatment of preterm labour, this data may not 
translate into clinical scenarios. Studies testing the drugs on preterm labouring mice 
would be helpful. 
- There were no mechanistic studies investigating the effect of intracellular pH or 
calcium signaling in this study. These experiments would need to be done to fully 
understand the effects seen in my samples. 
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- In this study, experiments were not performed in human myometrium. It would be 
of great benefit is this work is carried out on human models and ultimately conducts 
pilot studies in women. 
- There were no experiments carried out to determine the safety of the 
combinations. This would need to be done as there may be interactions between 
the drugs which could result in serious maternal and fetal side effects. 
 
4.6 Conclusion 
This study is the first to compare the tocolytic effect of Magnesium plus atosiban, 
magnesium plus indomethacin and magnesium plus nifedipine on uterine 
contractility of mouse. 
In this chapter, I have shown that Magnesium plus indomethacin concentration 
dependently decreased spontaneous uterine contractions and this effect was 
overcome by the application of oxytocin. This suggests that indomethacin may not 
be the best tocolytic in cases where magnesium is administered. 
I also investigated the effect of magnesium plus atosiban on oxytocin-induced 
contractions. The results showed that the combination caused a significant 
concentration-dependent decrease on oxytocin-induced uterine contractions 
compared to atosiban or magnesium alone. Using the IC50 values, the effect seen 
almost mirrored the effect of magnesium on spontaneous tissues (chapter 3), 
indicating that this combination could reverse the effect of oxytocin. 
The effect of Mg plus nifedipine was also investigated in spontaneous and oxytocin-
induced contractions. My data showed that the combination decreased contractility 
compared to magnesium or nifedipine alone.  
When comparing all three combinations, magnesium plus atosiban showed to be 
the best tocolytic combination in my tissues, hence the effect of extracellular pH 
was examined on this combination. My results showed that pHo caused an increase 
in contraction therefore reduced the tocolytic efficacy of the combination.  
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This work suggests a better tocolytic effect with magnesium plus atosiban, 
nevertheless, the effect of certain factors that affect uterine environment during 
labour e.g. lactate production, hypoxia and acidification needs to be explored. 
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Chapter 5 
The Expression of Calcium Channels at Different Gestational 
States of Mouse Uterus 
5.1 Abstract 
In pregnant uterus, calcium influx is essential for excitation-contraction coupling 
and the L-type calcium channels play an important role in calcium influx as well as 
pregnancy and labour onset. This thesis is focused on magnesium and its effect on 
uterine contractility. Since Mg’s main mechanism of action is via antagonism of 
calcium entry at the calcium channels, it is important to investigate whether 
calcium channel expression also changes throughout gestation. The gestational 
regulation of calcium channel expression in the uterus is not yet completely 
understood, and no previous studies have established the expression of L-type 
calcium channel in mouse at different gestational stages. Therefore, the aim of this 
chapter was to determine the expression of L-type calcium channel (Cav 1.2) in 
mouse non-pregnant, pregnant and postpartum uterine tissues. This chapter also 
determined stable reference genes for studying gene expression across mouse 
gestations. 
Uterus samples were collected from C57BL/6 mice at different gestational states 
(non-pregnant, days 14, 18 and 19 of pregnancy and postpartum). Using end point 
polymerase chain reaction (PCR) the presence of the L-type calcium subunits (Cav 
1.1, Cav 1.2 and Cav 1.3) was examined. The mRNA expression levels of T-type 
calcium channel were detected by quantitative Real time PCR. Using geNorm 
analysis, the most stably expressed reference genes from a panel of 12 genes were 
analysed. 
This chapter showed that the presence of Cav 1.2 in mouse myometrium. The 
mRNA expression of Cav 1.2 increased as pregnancy progressed but didn’t reach 
non-pregnant levels and was further increased after labour (postpartum). 
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5.2 Introduction 
During labour, the uterus undergoes certain changes which enable it to 
contract and expel the foetus. Preterm labour is suggested to result from early 
contractions of the uterus. It is well known that contractions of uterine smooth 
muscles are dependent on the rise in the concentration of intracellular calcium 
(Floyd and Wray, 2007, Shmygol and Wray, 2005). In the uterus, the voltage gated 
calcium channels (VGCC) form the main vehicle for calcium entry (Young et al., 
1993) Voltage gated calcium channels are transmembrane proteins which are 
sensitive to changes in cell membrane potential and play a major role in 
transportation of calcium ions into cells. They are formed as complex of different 
subunits: α1, α2δ, β, and γ. However, it is the α1 subunit which forms the 
Ca2+selective pore containing the voltage-sensitive apparatus. The other subunits 
are thought to have important roles in channel gating.  The α2δ subunit is 
composed of an extracellular α2 segment linked to a trans-membrane δ segment, 
which anchors the α2 segment (Felix et al., 1997, Klugbauer et al., 2003). Overall, 
the binding of the α2δ subunit results in increased [Ca2+]i and so again will promote 
myometrial contractility. The β-subunit binds with high affinity to the linker loop 
between repeats I and II in the α1-subunit (Bichet et al., 2000, Dolphin, 2003). It has 
been shown that binding of the α2δ- and β-subunit the to the α1 subunit modifies 
voltage dependence of both activation and inactivation (Bichet et al., 2000) 
(Klugbauer et al., 2003), current amplitude (Gurnett et al., 1996, Felix et al., 1997), 
number of drug binding sites and number of affinity drug binding (Gurnett et al., 
1996).  
There are a number of different types of VGCC including; neural N-type, P/Q-type, 
L-type, R-type and T-type channels.  In the uterus, the two main types which have 
been identified include the L-type also known as dihydropyridine channel 
(dihydropyridine is located on the α1 subunit and characterize the channel) and T-
type channels (Kamkin et al., 2006). In the L-type calcium channel family, four α 
subunits have been classified namely: α1S, (Cav 1.1), α1C, (Cav 1.2), α1D, (Cav 1.3) 
and α1F, (Cav 1.4).These 4 α subunits are known for their expression in skeletal 
muscle, smooth muscle, ventricular myocytes and neuronal dendrites respectively.  
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The T-type VGCC family consist of 3 α subunits: α1G, (Cav 3.1) α1H, (Cav 3.2), and 
α1I (Cav 3.3). T-type channels are known for their expression in neurons and cells 
with pacemaker activity. Cav 3.1 and Cav 3.2 have been shown to be expressed in 
rat myometrium (Ohkubo et al., 2005).  They investigated the mRNA expression of 
the subunits in longitudinal and circular muscle layers, showing variation in both 
muscle layers.  
A few studies have shown that as well as expressing these channels, there are also 
changes in L- and T-type channel expression during gestation in different species 
(Ohkubo et al., 2005, Collins et al., 2000, Zhang et al., 2015). In mouse, Zhang et al 
(2015) investigated the mRNA and protein expression of T-type α1G (Cav 3.1) and 
α1H (Cav 3.2) and showed that both subunits were expressed in the myometrium 
and that the expression levels increased towards term followed by an abrupt 
decrease in labour. Another study examined the expression of the L-type α1C 
subunit throughout gestation in rats (Mershon et al., 1994). They showed a 
significant increase of DHP binding sites at day 14 compared to non-pregnant 
controls which remained elevated through labour, then decreased postpartum. 
Tezuka et al also showed in rat myometrium, a gradual increase in α1 and β subunits 
throughout gestation followed by a sudden decrease during labour for α1, but an 
abrupt increase in the β subunit (Tezuka et al., 1995). In guinea pigs, Collins et al 
investigated the changes in gestational expression of α and β subunits of the L-type 
calcium channel (Collins et al., 2000). Their results show expression of α subunits at 
day 34 (approximately day 10 gestation in mouse) which increased towards term 
while the β subunits were barely detectable at days 34 or 47 but increased at day 54 
and declined at day 64. Interestingly, others have also shown that calcium current 
density during pregnancy remains unchanged (Inoue and Sperelakis, 1991). With all 
the studies on the expression of L- and T-type calcium channels, this thesis focuses 
mainly on the L-type calcium channels as they are known to play a more significant 
role in pregnancy. 
The gestational regulation of calcium channel expression in the uterus is not yet 
completely understood. This study is focused on Magnesium and its effect on 
uterine contractility. I have already shown differences in the efficacy of Mg on 
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myometrium from different gestational states (Chapter 3). Hence, given Mg’s main 
mechanism of action is via antagonism of calcium entry at the calcium channels, it is 
important to investigate whether calcium channel expression also changes 
throughout gestation. I anticipate that this data will aid our understanding of the 
differences in contractile activity observed with Mg as described in chapters 3 and 
4.  
The first aims of this chapter therefore were to: 
viii. determine if  L-type calcium subunits (Cav 1.1,1.2 and Cav 1.3) are 
expressed across different gestations of the mouse uterus;  and if present, 
ix. quantify the expression of L-type calcium α subunits at different gestational 
states using real time qPCR. 
Real-time polymerase chain reaction (quantitative PCR, qPCR) is well established as 
one of the most sensitive and reproducible quantification methods for gene 
expression analysis (VanGuilder et al., 2008). Although qPCR is used to determine 
the fold change of the expression of genes between samples, the selection of an 
internal control or reference gene(s) (previously known as housekeeping genes) is a 
crucial step in the experimental design process. Normalising the expression level of 
target gene/gene of interest to this control is essential to improve expression data 
accuracy and reliability. For example, it enables differences in the efficiency of 
reverse transcription between samples as well as differences in sample 
concentration in the final PCR reaction such as potential pipetting errors to be 
controlled for (Udvardi et al., 2008, Gutierrez et al., 2008). 
The stability of several genes e.g. ACTB, GAPDH, 18S and HPRT in different 
species and tissues has already been experimentally determined and they have 
been widely used as reference genes in studies of gene expression. However, it is 
important that the stability of these genes is maintained across all experimental 
conditions including throughout gestation (Thellin et al., 1999, Bustin, 2000). To 
ensure reliable and repeatable results in gene expression experiments, in February 
2009, the Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) guidelines were published (Bustin et al., 2009). A major key to 
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improving the fidelity of qPCR results of gene expression is by selecting appropriate 
reference genes (Vandesompele et al., 2002, Guo et al., 2014). Therefore, the final 
aims of this chapter were to: 
x. examine the most commonly used reference genes in mouse uterus (all 
gestational states) as published in the literature; and 
xi. identify the most stable reference genes for qPCR across different 
gestational states in the mouse. 
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5.3 Materials and Methods 
5.3.1 Animals and uterine tissues 
Adult non-pregnant (NP), time-mated (d14, d18 and d19) and postpartum 
(PP) mice were used in this chapter.  Mice were humanely killed by a rising 
concentration of CO2 anaesthesia followed by cervical dislocation. The uterus was 
isolated, cleaned of placentas and connective tissues (where necessary) and placed 
immediately in HEPES buffered Krebs solution. Other tissue types including brain, 
kidney, skeletal muscle and heart were also collected which were used as positive 
controls in some experiments. Tissues were weighed and placed in RNA later 
solution for 24 hours at 4°C before being frozen and stored at -70oC until use.  
5.3.2 RNA extraction    
 Tissues for each group (NP, 14d, 18d, 19d and PP) were pooled from at least 
3 mice. Sixty to one hundred milligrams of tissue was homogenized in TriZol 
Reagent (Invitrogen Life technologies) using an ultratraxx homogenizer. RNA was 
extracted using a Trizol plus RNA purification kit (life technologies) which uses a 
silica-cartridge (column-based) method to bind and purify the RNA, from which it 
can be further washed to remove contaminants before being eluted in RNase-free 
water. RNA concentration and purity was determined by measuring the 260/280 
and 260/230 absorbance ratios using a NanoDropTM 1000 spectrophotometer. To 
ensure the viability of the samples and reduced contamination, all samples used 
ranged between 2.0 and 2.2 for the 260/230 ratios and 260/280 ratios. RNA was 
stored at -70oC until used subsequently for DNase treatment.  
 
5.3.3 DNase treatment 
RNA isolates ore extracts are not completely free from DNA contamination, 
therefore DNase treatment is essential to remove traces of contaminants. For this 
thesis, TURBO DNA free kit (Ambion Catalogue number AM 1907) was used.  
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The amount of RNA required (10 µg) was calculated with each sample, with 5 µl of 
the 10X DNase buffer and 1 µl of DNase added to each sample. Each mix was made 
up to 50 µl with nuclease free water (volume individually calculated). This mixture 
was incubated at 37◦ C for 30 minutes followed by addition of resuspended DNase 
inactivation reagent (5 µl) to each sample. This was then incubated at room 
temperature for 5 mins before centrifuging for 10,000g for 1.5 mins. The RNA was 
then transferred into a fresh micro centrifuge tube. The final sample was stored at -
80◦ C until needed. 
 
5.3.4 cDNA synthesis 
Total RNA (1µg) was reverse transcribed using an AMV first strand cDNA synthesis 
kit (New England BioLabs Inc.). Briefly the RNA was denatured for 5 minutes at 70°C 
to remove secondary structures which can impede long cDNA synthesis, before 
adding to the reaction mix containing an enzyme mix (AMV reverse transcriptase 
and murine RNase inhibitor) and a random primer mix (hexamer and d(T)23 VN 
primers).    The cDNA synthesis reaction was incubated at 25°C for 5 minutes 
followed by 42°C for one hour. The enzyme was inactivated at 80°C for 5 minutes. 
The cDNA product was then diluted to 50µL with nuclease free water and stored at -
20°C until use. A ‘mock’ reverse transcription reaction was also carried out in which 
the reverse transcriptase enzyme was omitted to use as a negative (no RT) control. 
This was to enable the absence of genomic DNA contamination to be confirmed 
during later PCR steps.    
 
5.3.5 End point PCR 
The primers used for this study: Cav 1.1,Cav 1.2, Cav 1.3, Cav 3.1 and Cav 3.2 were 
based on those published by (Xu et al., 2003) (Table 5.1).  
Amplification of cDNA was carried out in a reaction mix containing 1µl of cDNA 
(corresponding to 200ng), 5µl Taq polymerase (Qiagen HotStar Taq® Master Mix 
kit), 1µl (F + R) primer and 3µl RNase-free water, giving a total reaction volume of 
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10µl. End-point PCR was conducted using a Bio-Rad T100 Thermal cycler (Bio-Rad 
Laboratories Inc. USA). A positive control sample, no reverse-transcriptase (no-RT) 
and water (no template) controls were included in each PCR experiment. The PCR 
cycles included denaturation at 95oC for 15mins, annealing for 1 min (optimised 
temperatures for each primer are given in Table 5.1) and extension at 72oC for 1 
min for 35 cycles. Using a 1% agarose gel containing SYBR safe, the PCR products 
were separated at 110V for one hour. The gels were imaged using the imaging 
software (UVP Chemi-Doc TS). Product size was estimated using a molecular weight 
DNA marker run simultaneously alongside the samples of interest. 
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Name Primer 5’- 
Location 
(bp) 
Sequence (5’-3’) Annealing 
temperature 
(oC) 
Product 
Size 
(bp) 
 
Cav 
1.1 
F 1233 GCGAGGTCATGGACGTGGACGA  
57.6 oC 
 
200 R 1433 GATCACCAGCCAATAGAAGAC 
 
Cav 
1.2  
F 3527 CAGGAGGTGATGGAGAAGCCA  
62.0 oC 
 
315 R 3842 CTGCAGGCGGAACCTGTTGTT 
 
Cav 
1.3  
F 3217 GGGGTCCAGCTGTTCAAGGGGGAA  
65.9 oC 
 
555 R 3771 GCATGATGAGGACGAACATCATG 
 
Table 5. 1: PCR primer sequence for the amplification of L- and T-type calcium 
channels 
F=forward, R = reverse, bp = base pairs  
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5.3.6 Literature search 
On 17 December 2018, I conducted a literature search of gene expression studies in 
mouse myometrium using PubMed, the MEDLINE database of references and 
abstracts on life sciences and biomedical topics. I used the search term: "mouse 
myometrium gene expression" to identify all papers. The search returned 222 
papers, which was also restricted to papers published within a 15 year period (from 
2003), giving rise to 139 papers.  The papers were manually searched further to 
ensure they met my stringent inclusion criteria:  
(1) the study was conducted in mouse uterus  
(2) the study related to gene expression (not protein) and used relevant methods 
including PCR, RT-PCR, qPCR  
(3) full access to the article and could therefore accurately determine the reference 
genes used. 
These criteria returned 92 papers. 
Of the 92 papers retained, the method section was manually checked to determine 
(1) the species and gestation of mouse used; (2) the identity of the reference genes; 
(3) the number of reference genes used; (4) whether the authors tested a panel of 
genes to select the most stable; and (5) the number of candidate reference genes 
tested prior to selection.  
The full tables of papers used and data extracted are provided in the Appendix.  
Figure 5.1 also shows a flow chart of the process of paper inclusion/exclusion 
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Records identified through keyword 
search in PubMed 
(n=222) 
Papers from 2003 -2018 
(n=139) 
Non mouse studies (n=9) 
Articles selected based on titles and 
relevance (n=92) 
Articles accessed based on eligibility 
as described in the method section 
Non qPCR studies (n=21) 
Studies with no full access (n=12) 
Studies with no full access (n=3) 
Articles used for analysis (n=47) 
Papers published before 2003  
(n=83) 
Figure 5. 1: The process of inclusion and exclusion 
Flow chart shows literature search result for search words “mouse myometrium 
gene expression” from 2003-2018. On the right side of the chart indicates exclusion 
criteria and number of papers excluded based on those criteria. 
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5.3.7 Quantitative real- time PCR 
Using qPCR, the expression levels of 12 reference genes (Table 5.2) and our genes of 
interest were determined across the different gestational states in mouse 
myometrium. 
Primers for reference genes and our genes of interest were designed by and 
purchased from Primer Design (UK). The commercial kit contains 12 genes which 
have been determined from over 30000 microarray experiments to be stably 
expressed across different tissues, experimental conditions, different disease 
condition, etc. (Primer Design (2013)). The kit includes classically used 
housekeeping genes for comparison.  Gene symbols, full name and cellular function 
of the reference genes are shown in Table 5.2 
Using SYBR green chemistry, real-time  qPCR was performed in a 10 µL reaction mix 
that included 5µL 2x Precision® FAST qPCR Master Mix, 0.5 µL of primer (F + R), 2 µL 
of  nuclease free water and 2.5 µl cDNA as recommended by the manufacturer’s 
instructions (Primer Design, UK). Reactions were carried out in triplicate on 96 well 
Hard Shell® PCR thin-wall plates(Bio-Rad Laboratories Inc. USA) and covered with 
microseal ‘B’ seal (Bio-Rad).  For reference gene analysis plate set-up, a sample 
maximization strategy was used in which the number of samples per plate was 
maximized rather than the number of genes per plate. This was done to reduce 
further technical variation.    Real-time PCR was conducted on a CFX Connect Real-
time system (Bio-Rad Laboratories INC. USA). The Amplification protocol involved 
an enzyme activation step of 95oC for 2mins followed by denaturation: 95°C for 
5 seconds and data collection: 60oC for 30 seconds for 40 cycles.  
Standard curves were created for the reference genes (SDHA and ATP5B) as well as 
genes of interest using positive control templates for standard curves (Primer 
Design, UK). Standard curves were produced using serial dilutions (10-6, 10-5, 10-4, 
10-3, 10-2, and 10-1) to check the linearity and efficiency of the PCR reactions.  
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5.3.8 Analysis of reference gene stability and variability   
Ten samples from 10 mice from 5 gestational states were used (NP, 14d, 16d, 18d 
and PP). Threshold cycle (Ct) values from the samples analysed were exported to 
qbasePLUS, which incorporates GeNormPLUS (Biogazelle) analysis program. This 
software was used to analyze the stability and variability of the 12 different 
candidate reference genes, in accordance with the software instructions. To 
examine the most stable reference genes, the software calculates the gene stability 
measure (M value) as the average pairwise variation for that gene as well as the 
other candidate reference genes (Vandesompele et al., 2002). Genes with the 
lowest M value (lower than 1.5) are considered to be the genes with most stable 
expression. Based on pairwise variation (Vn/n+1), the software also calculates the 
minimum number of genes required for RT-qPCR data normalisation between 
successive normalisation factors (+1, +2 and so on).  As explained by Vandesompele 
et al., 0.15 is considered the cut-off value below which the addition of another 
reference gene would not be beneficial (Vandesompele et al., 2002). 
5.3.9 Data analysis 
To determine for gene expression changes in our genes of interest e.g. Cav 1.2 
between gestational groups, data were analyzed using the methods described by 
Livak and Schmittgen (Livak and Schmittgen, 2001). Briefly, efficiency corrected Ct 
values (which take into account the differences in reaction efficiencies for the 
different primers) for our genes of interest in each sample group were normalized 
to the geometric mean of the two reference genes, SDHA and ATP5B. In doing so, 
this controlled for differences in sample input concentration. This normalized 
expression was then expressed relative to zero. 
 
For examination of gene expression between different gestation states, we 
obtained an n of 1 resulting from a pool of 3 samples; therefore, it was not possible 
to determine statistical significance when comparing the expression of the gene of 
interest (Cav 1.2) between gestational groups. 
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Genes Gene names Cellular function 
18S Eukaryotic 18S rRNA Ribosomal RNA 
ACTB Beta-actin Cell migration and structure 
ATP5B ATP synthase ATP production 
B2M Beta-2-microglobulin Histocompatibility complex antigen 
class I receptor activity 
EIF4A2 Eukaryotic translation initiation factor 
4A2 
mRNA binding to ribosome 
YWHAZ Tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein 
signal transduction 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
 Glycolytic enzyme 
SDHA Succinate dehydrogenase complex; 
subunit A; flavoprotein (Fp) 
Dehydrogenase 
CANX Calnexin Retain protein in endoplasmic 
reticulum 
CYC1 Cytochrome c-1 Electron transport chain 
UBC Ubiquitin C ubiquitination 
 RPL13A Ribosomal protein L13A Protein synthesis 
 
Table 5. 2: List of the housekeeping genes and their cellular functions 
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5.4 Results 
5.4.1 Detection of L-type calcium channels in mouse gestation 
Using conventional PCR, the expression of Cav 1.1 (Figure 5.2A) was not detected in 
any of the myometrial samples studied.  Clear expression was observed in skeletal 
muscle however, which was used as a positive control sample. This indicates that 
the PCR conditions were favourable and there were no technical issues with the 
reaction. As expected, Cav 1.2 was expressed at all stages of gestation and in non-
pregnant tissues (Figure 5.2B).  Expression of Cav 1.3 (Figure 5.2C) was not detected 
in any of the samples as well as in positive control. Thus Cav1.2 (α1C) is the only 
subunit expressed in mouse myometrium. Therefore this gene was chosen for 
quantitative analysis by real time qPCR. 
5.4.2 Identification of published reference genes in mouse myometrium 
Of the 47 papers researched, only 4 studies provided evidence that a panel of 
reference genes had been tested to find those that are stably expressed. Amongst 
all included studies, only 7 of them used a second reference gene while 4 studies 
used a third. The most common choice of reference genes were GAPDH (used in 
about 30% of the studies), ACTB (21%) and 18S rRNA (10%) (Figure 5.3). Table 5.3 
shows the number of times each gene was used in the included papers. 
5.4.3 Determination of the stability of a panel of potential reference genes 
The stability of 12 pre-designed candidate reference genes (Primer Design) was 
studied in our samples. The geNorm algorithm produced average expression 
stability (M) values and cycle threshold (Ct) ranges for each gene, which ranked 
them from lowest to highest stability (Table 5.4).  In order to determine the most 
stable genes, the recommended Ct ranges and M values were used. 
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Figure 5. 2: Detection of the different L-type calcium channel (α) subunits 
present in mouse myometrium across different gestational states 
End-point PCR was performed on samples from non-pregnant (NP), pregnant 
(day 14, 18 and 19) and postpartum mouse myometrium (PP). 
Imaging of agarose gel after electrophoresis revealed (A) the absence of Cav 
1.1 in all gestational states (B) the presence of Cav 1.2 in all gestational states, 
and (C) the absence of Cav 1.3 in all gestational states of mouse myometrium.  
The numbers 1-8 represent non-pregnant, day 14, 16, 18, 19, and postpartum 
tissue, positive control, No RT and NTC respectively. 
Positive controls for Cav 1.1 and Cav 1.3 are skeletal muscle and heart 
respectively. 
NTC- no template control (NTC), no RT- no reverse transcriptase, L- 100 base 
pair ladder. 
Cav 1.2 
Cav 1.1 
Cav 1.3 
(A) 
(B) 
(C) 
2 1 3 4 5 6 L 7 8 
2 1 3 4 5 6 L 7 8 
2 1 3 4 5 L 7 8 
500 
200 
203 
 
Given by ranking in all gestations studied, the most stable genes expressed were 
SDHA and ATP5B (Figure 5.4). Genes that were least stable and deemed least 
suitable across mouse gestation were CYC1, 18S and B2M. From literature search 
and as shown in Figure 5.3, 18S is commonly used as reference gene in mouse 
uterine samples. This result again points to the need for gene analysis to determine 
the most stable genes. 
 
As shown in Figure 5.4A, the genes with the lowest M values are most stably 
expressed. Moreover, using geNorm, the optimal number of reference gene was 
estimated. Figure 5.4B shows the effect of adding an (n+1)th gene between two 
normalising factors. In my analysis, V2/3 considers the variation formed by the two 
most stable reference genes (ATP5B and SDHA) and added a third gene (in this case 
EIF4A2). With the addition of a third gene, the normalisation factor still remains 
lower than 0.15. Therefore, the two most stable reference genes (SDHA and ATP5B) 
were deemed optimal and were used in the analysis of Cav 1.2 expression in mouse 
myometrium across the range of gestations. 
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Reference genes used in Papers from 
2003 -2018
GAPDH
ACTB
18S
HPRT
PPIA
TBP
RPL7
β2M
RPL19
RPLP0
TNF-α
m36B4
PGK1
YWHAZ
Figure 5. 3: Reference genes used in published papers from 2003 – 2018 
Histogram showing the frequency reference genes commonly used in published papers. 
GAPDH, ACTB and 18s were the most commonly used genes within the 15 year period. 
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REF GENES USED No of 
papers 
% of 
total 
GAPDH 20 32.78689 
ACTB 14 22.95082 
18S 7 11.47541 
HPRT 4 6.557377 
PPIA 3 4.918033 
TBP 2 3.278689 
RPL7 2 3.278689 
β2M 2 3.278689 
RPL19 2 3.278689 
RPLP0 1 1.639344 
TNF-α 1 1.639344 
m36B4 1 1.639344 
PGK1 1 1.639344 
YWHAZ 1 1.639344    
TOTAL 61 100 
  
Table 5. 3: Table showing published reference genes and the frequency of use 
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(A) 
(B) 
Figure 5. 4: GeNormPLUS analysis of the candidate reference genes. 
(A) Average expression stability (M) and ranking of the 12 candidate housekeeping 
genes. The more stably expressed genes are positioned on the right side of the 
diagram; less stable genes are positioned on the left side. (B) Determination of the 
optimal number of housekeeping genes required for normalisation by pairwise 
variation (V) using GeNorm
PLUS
 software. Each bar indicates a change in the 
normalisation accuracy. An M value of more than 0.15 was the threshold 
(indicated by green line) for eliminating a gene as unstable; hence two genes 
would be satisfactory for normalisation. 
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5.4.5 Expression of Cav 1.2 at different mouse gestation 
Expression of Cav 1.2 gene was determined relative to the geometric mean of the 
reference genes, SDHA and ATP5B.  
The amplification and melt curves for each gene are represented in Figure 5.5A-F. 
The melt curves of all genes exhibited only one specific peak without primer dimers 
and non-specific amplification. The melt temperatures and amplification efficiency 
for Cav 1.2 were 82.0oC and 93.5% respectively.  
Amplification of each gene in the five samples (each sample being a pool of 3 
samples) produced 15 Ct values datasets from triplicates per sample. Amplification 
curves for SDHA and ATP5B are shown in Figure 5.5. The standard deviations for 
each sample were studied and if greater than a threshold, the two replicates closest 
to each other were used and the third discarded from analysis.  
Melt curves for the most stable genes, SDHA and ATP5B were generated (Figure 
5.5B, D and F), which exhibited only one peak indicating no non-specific 
amplification. The melt temperatures were determined as 81.5oC for SDHA and 
84.0oC for ATP5B. Their amplification efficiencies were 100% and 92.4% 
respectively.  
As seen in Figure 5.6, relative expression of Cav 1.2 was lowest in day 14 pregnant 
tissue followed by a steady increase of expression at days 18 and 19 with maximum 
expression in postpartum tissues. Interestingly, non-pregnant samples also had high 
levels of expression.  
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Figure 5. 5: Amplification and melt curves for Cav 1.2, SDHA and ATP5B. 
(A, C and E) show amplification curves for Cav 1.2, SDHA and ATP5B, with efficiency of 
93.5% , 100% and 92.4% respectively.; (B,D and F) show the melt peak of SDHA and 
ATP5B, with melting temperatures  of 82
 o
C , 81.5
o
C and 84.0
o
C respectively. 
SDHA 
CAV1.2 
ATP5B 
Amplification 
Cycles 
Cycles 
Amplification 
Amplification 
Cycles 
Melt Peak 
Temperature 
o
C 
Melt Peak 
Temperature 
o
C 
Melt Peak 
Temperature 
o
C 
(A) (B) 
(C) (D) 
(E) (F) 
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Figure 5. 6: Comparison of the expression of Cav 1.2 subunit across different 
gestational states in mouse myometrium, determined by qPCR. 
The expression of Cav 1.2 in each sample group was normalised to the 
expression of the two reference genes, SDHA and ATP5B.  Taking non-
pregnant (NP) as control, the expression of Cav 1.2 drops at day 14, followed 
by steady increase towards term (day 19) and further increases postpartum 
(PP). Postpartum tissue was collected close to delivery. 
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5.5 Discussion 
The relationship between changes in intracellular calcium concentration and 
myometrial contraction is well documented (Longbottom et al., 2000, Word et al., 
1993, Fomin et al., 2009). It is the L-type calcium channel which plays a major role in 
increasing intracellular calcium during excitation-contraction coupling. Despite the 
importance of the L-type calcium channels especially the α1C subunit in uterine 
contractility, only a few studies have extensively examined the levels of expression 
throughout gestation and post labour. To the best of my knowledge, no study has 
investigated its expression throughout gestation in the mouse. 
This chapter was undertaken to determine the expression and relative abundance 
of different calcium channels throughout gestation in mouse myometrium. In 
particular, it describes the changes in expression of L-type calcium channel α 
subunits throughout pregnancy and after labour. We also determine the most 
stable reference genes for use in studies of gene expression in mouse myometrium 
at different gestational states as this was previously unreported. 
My results show the absence of Cav 1.1 and Cav 1.3 subunits in mouse uterine 
tissues at any gestational time point. Although it may be difficult to conclude for the 
Cav 1.3 subunit, especially since it was also not detected in the positive control 
(heart). As expected, Cav 1.2 was detected in uterine tissues in all pregnant samples 
as well as non-pregnant and postpartum tissues.  
Published stable reference genes versus geNorm analysis 
Real-time qPCR was carried out to quantify the expression of the Cav 1.2 in the 
different uterine samples. This method has become very popular in detection and 
measurement of gene expression. Due to the sensitivity of gene expression, the use 
of reference genes is used as the gold standard for efficient normalization (Almeida 
et al., 2014). It is known that the choice of stable and suitable reference gene is 
essential for accurate and reproducible gene expression analysis in real-time PCR 
experiments (Xu et al., 2016), hence it was important that I determine the most 
stable genes for use in this study.  
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In this study, 12 housekeeping genes were investigated; 18S, ACTB, ATP5B, B2M, 
CANX, CYC1, EIF4A2, GAPDH, RPL13A, SDHA, UBC, and YWHAZ. These genes 
consisted of genes known to be stably expressed in a number of tissues and 
experimental conditions and included some previously reported as suitable 
reference genes in studies of myometrial gene expression.  Our literature search 
revealed the most commonly used genes in mouse myometrium studies to be 
GAPDH, 18S and ACTB.  Only 4 used geNorm software to determine the most 
suitable reference genes. Interestingly, in this study, these genes commonly used as 
reference genes in mouse myometrium were ranked amongst the most variable 
genes by geNorm across gestational states in the mouse uterus. This highlights the 
need to determine the most appropriate reference genes for every protocol and 
tissue under investigation.  
It is recommended that gene expression data may be more reliable if it is 
normalised by geometric means of more than one reference gene (Bionaz and Loor, 
2007). In our samples, pairwise variation analysis showed that the optimal number 
of reference targets for qPCR data normalisation is two, indicating the most suitable 
reference genes with little variation across mouse gestational sample subsets to be 
ATP5B and SDHA. This also indicates that their geometric means would be sufficient 
and provide accurate data normalization factor for expression across gestational 
states of mouse uterine tissues, which I have applied in this study.  
Quantification of Cav 1.2 expression in mouse uterine tissues 
Using ATP5B and SDHA as reference genes and non-pregnant samples as a control, 
our results indicate a marked decrease in expression at day 14 (compared to Non-
pregnant). This was followed by an increase at days 18 and 19, although levels did 
not reach that of non-pregnant samples. A further increase in expression was also 
noted in postpartum samples. Our results are somewhat similar to the findings of 
Mershon et al who reported mRNA expression of Cav 1.2 (α1C subunit) in rat 
myometrium (Mershon et al., 1994). Using dot blot analysis, they showed that 
compared to non-pregnant samples, expression at day 7 remained unchanged. This 
was followed by a significant decrease at day 14. The expression then increased 
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steadily in the last three days of gestation, returning to control levels on day 21. 
They also showed marked reduction of expression during labour followed by a 
sharp increase in postpartum samples (Mershon et al., 1994). Similar results by 
Tezuka et al using RT-PCR, showed a gradual increase in Cav 1.2 mRNA expression 
before labour, however this was followed by a decrease during labour and 
postpartum (Tezuka et al., 1995). Despite the variations in results, our findings 
support the generalized trend of increased mRNA expression of Cav 1.2 as gestation 
progresses toward term.  
As described by Mershon et al, the state of quiescence at mid-gestation (day 14) 
may explain the reduced expression noticed at day 14. The onward increase in the 
expression of Cav 1.2 towards term may indicate the role of L-type calcium channels 
in the myometrium in preparation for parturition (Mershon et al., 1994).  
In summary, this chapter indicates the absence of Cav 1.1 and Cav 1.3 subunits 
across mouse gestational uterine samples, but shows the presence of Cav 1.2 in all 
gestational states studied. Overall, the end-point PCR data showed some primer 
dimer formation, which could be explained by lack of proper optimization of the 
conditions used. Nevertheless, this didn’t affect my findings as my main focus was 
detecting the presence or absence of the α1 subunits in these samples.   
This chapter also enforces the need to determine the most suitable reference genes 
especially when involving different experimental procedures and on different tissue 
types. My data provides fresh insight into the expression of L-type calcium channel 
(Cav 1.2) at different gestational states in mice. Overall, increased expression was 
noticed in pregnancy towards term supporting the role of L-type calcium channel in 
parturition process. I have also identified the most suitable reference genes for 
studies of gene expression in mouse uterus using pan-gestational tissues which will 
be a useful addition to the literature and valuable tool for others to use in future 
studies. 
5.5.1 Limitations of this study 
I was unable to investigate the expression of the L-type calcium channel subunit, 
Cav 1.2 in labouring mouse uterine samples. It would be interesting to see the level 
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of expression between term-pregnant and postpartum in the mouse uterus as this 
may have provided further insight to the events and influence of L-type calcium 
channels during labour. 
Further optimisation of the end-point PCR technique is required e.g. to limit primer 
dimer formation and hence increase efficiency of the PCR reaction. 
I was unable to investigate the presence of Cav 1.4 subunit in my samples.  
There was lack of control for Cav 1.2 as well as positive controls not detected in Cav 
1.3, Cav 3.1 and Cav 3.2. Further studies would explore suitable positive controls in 
mouse and optimise the conditions in which PCR was undertaken. 
The samples from similar gestation were pooled, making it impossible to calculate 
the standard error mean and determine significance levels of the effect seen 
between gestations. 
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5.6 Conclusion 
This study is the first to quantify the expression of L-type calcium channel subunit 
(Cav 1.2) across mouse gestational states. 
In this chapter, I have shown that Cav 1.1 and Cav 1.3 are not present in mouse 
myometrial tissues, but Cav 1.2 was detected across all gestational stages including 
non-pregnant and postpartum tissues. 
I also carried out literature search of the most commonly used reference genes.  
The result showed GAPDH, ACTB and 18S to be the most commonly used reference 
genes and the choice of these genes was not predetermined by the use of gene 
analysis software.   
Using geNorm software I investigated further the most stable genes throughout 
mouse gestational states. My results showed ATP5B and SDHA to be the most 
stable expressed genes while GAPDH and ACTB were among the least stable genes. 
Finally, using ATP5B and SDHA as reference genes, the expression of Cav 1.2 subunit 
was determined.  Results showed an expression in pregnancy which increased 
towards term, although the levels did not reach that of non-pregnant. The highest 
expression was seen immediately after delivery. 
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Chapter 6 
Final Discussion 
Clinically, the use of magnesium as a tocolytic has been questioned. Nevertheless, 
in the UK, it has been recommended for use in very preterm cases- not as a 
tocolytic but for neuroprotection. The main aim of this study therefore was to 
investigate how combining magnesium with other commonly used tocolytics might 
improve tocolytic efficacy and how physiological and hormonal factors may affect 
its efficacy. In doing so, the effect of magnesium at different gestational states was 
studied. Since magnesium is known to act on the L-type calcium channels, the 
mRNA expression of α1C subunit in mouse was also determined.  I believe this work 
gives a better insight into why some tocolytics may not be effective clinically. 
6.1 Magnesium and Gestation 
There has only been one study that has investigated the effect of magnesium in 
mid-pregnant mouse myometrium; this study was carried out in a liposaccharide 
mouse model (Sugawara et al., 2007).This is the first study however that has 
studied magnesium’s effect across mouse gestational states of spontaneous and 
oxytocin-induced contractions. In both spontaneous and oxytocin-induced 
contractions, magnesium reduced contractions, in a concentration-dependent 
manner.  
My results highlight magnesium’s relaxing effect on uterine smooth muscle.  This 
effect is due to magnesium’s cationic competition with calcium (Phillippe, 1998), 
producing a fall in [Ca2+]i and calcium levels within the SR. At all gestational states, 
the addition of MgSO4 triggered a decrease in frequency before a fall in the force of 
contractions. This finding suggests that magnesium may have a role in intracellular 
coupling, decreasing gap junctions (Rimkute et al., 2018), thereby reducing the 
possibility of frequent and synchronised contractions. These results also showed 
that magnesium’s effect on spontaneous contractions was more potent at term and 
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least potent in non-pregnant tissues. Magnesium is thought to act by decreasing 
calcium entry and excitability. This mechanism may not explain the effect seen in 
our samples except the increased α-1 expression gives rise to increased response to 
magnesium blockade. My data suggests that at term, magnesium’s effect is 
sufficient to reduce excitable, and make action potential firing less likely. 
To investigate the effect of magnesium in the presence of an agonist, its effect on 
oxytocin-induced contractions was determined. My data showed that a greater 
concentration of magnesium was needed to inhibit oxytocin-induced contractions 
compared to spontaneous in all pregnant gestations studied. There was however no 
significant change between non-pregnant groups. In general, there was no 
significant difference in magnesium’s effect on oxytocin-induced contractions 
across gestations. Oxytocin’s mechanism of increasing membrane potential and 
releasing calcium from the SR, will counteract magnesium effect, and may partly 
explain why its effect is minimal. 
My data shows that the preterm uterus is less sensitive to the tocolytic effect of 
magnesium than term uterus, which could explain the lack of efficacy seen in the 
clinics. In the presence of oxytocin, its efficacy was further reduced at all gestations 
studied, with oxytocin decreasing the potency of magnesium. Therefore, 
magnesium’s actions in mouse are influenced by both gestational state and 
hormones, with magnesium been less effective in early gestation with oxytocin 
present and most effective at term in the absence of oxytocin.  
A limitation of this study is the use of MgSO4 at supra-pharmacological doses in 
the in vitro model. The appropriate total dosage for magnesium as a foetal 
neuroprotectant is not known, nevertheless, it is suggested that 6g is used over a 30 
minute period followed by 2g continuous infusion per hour (Rouse et al., 2009) or 
4g for 30 minutes followed by 1g per hour until birth (Magee et al., 2011).  In 
preeclampsia, the upper limit of the therapeutic plasma level for seizure 
management is 3 mM, with toxicity occurring at concentrations > 3.5 mM. There is 
respiratory paralysis at 5-6 mM, cardiac conduction defects at > 7.5 mM, and 
cardiac arrest at > 12.5 mM (Lu and Nightingale, 2000, Tang et al., 2015). In my 
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experiments, the rationale for using high concentration of MgSO4 was to provoke a 
response that could potentially occur at the upper end of its use. In normal clinical 
practice, where infusion rates are generally set at 1 or 2 g/hr after a bolus of 6g or 
4g, it is rare to observe levels > 4 mM, nevertheless, with the organ bath method, 
higher concentrations are needed to produce similar effects to what is seen in vivo. 
It cannot also be assumed that the contractile changes shown in vitro would also be 
seen in vivo as the multitude of oxytocic effects in vivo could imply the need for 
further studies.  
 
6.2 Effect of Individual Tocolytics. 
The effect of indomethacin, atosiban and nifedipine has individually been 
investigated in vitro and in vivo and well-documented in term pregnant human 
myometrium. It was however important to establish their effect on pregnant mouse 
myometrium. The result will provide a basis on interpreting the data for the dual 
tocolytics work in this thesis. 
In my tissues, indomethacin concentration-dependently inhibited spontaneous 
contractions, however, its effect were less in oxytocin-induced contractions. At 
higher concentrations, indomethacin abolished contractions rapidly indicating that 
it may be acting via a mechanism other than inhibiting COX and prostaglandin 
production.  Prostaglandins are produced by COX activity throughout pregnancy 
with their levels increasing steadily through gestation and peaking before delivery, 
stimulating myometrial activity. Although it is well known that indomethacin 
inhibits prostaglandin synthesis, indomethacin is also believed to function via 
prostaglandin-independent mechanisms, such as inhibition of nitric oxide synthase 
and phosphodiesterase 4 (Garza et al., 2004).  Perhaps in-depth study of the other 
mechanisms may be needed to have a better understanding of indomethacin’s 
activity on myometrial contractions.  Atosiban also had a concentration-dependent 
inhibitory effect on force and frequency of oxytocin-induced contractions. This 
effect is as a result of atosiban’s effect on oxytocin and vasopressin receptors. While 
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investigating the effect of nifedipine on uterine contractions, I found that nifedipine 
produced a time-dependent effect on contractions. Nifedipine inhibited 
contractions in both spontaneous and oxytocin-induced contractions. Nifedipine is 
classed as a dihydropyridine and also acts by binding to the VGCCs, inhibiting action 
potential and uterine contractions. Nifedipine causes a reduction in [Ca2+]i levels by 
blocking the extracellular flow of calcium into the myometrial cells thereby 
decreasing contractions  (Moynihan et al., 2008a). 
All the tocolytics examined operate via different intracellular pathways and have 
different side effects 
 
6.3 Effect of Combining Magnesium and Other Tocolytics 
Since the effect of magnesium on myometrium has been controversial, I first 
established the effect of magnesium in my tissues (Chapter 3). I then determined 
the inhibitory effect and IC50 values of the other tocolytics (indomethacin, atosiban 
and nifedipine), before proceeding to investigate its effect in vitro in combination 
with other tocolytics. It was hypothesised that combining two tocolytics that act on 
different contractility pathway may produce a synergistic inhibition. The results of 
the hypothesis are presented in Chapter 4 of this thesis. 
The results showed that combining magnesium and indomethacin produced a 
concentration-dependent reduction of spontaneous contractions, which was 
additive. In oxytocin-induced contractions however, the effect of the combination 
was antagonistic. This antagonistic effect may be as a result of indomethacin not 
been able to antagonise oxytocin’s action. Similar conclusion was drawn from 
another study that investigated the effect of indomethacin on rat uteri (Vane and 
Williams, 1973). The combination of magnesium and atosiban produced a 
synergistic concentration-dependent inhibitory effect on oxytocin-induced 
contractions. The combination abolished contractions at even low concentration. 
This finding is similar to that obtained in human myometrium (Arrowsmith et al., 
2016). Although a singular concentration of magnesium and nifedipine caused a 
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significant inhibitory effect compared to control, this did not reach statistical 
significance when compared to either drug alone. This might be as a result of 
magnesium reducing calcium entry via the L-type calcium channel and nifedipine 
blocking L-type calcium channels: similar mechanisms. 
Most tocolytics are associated with adverse effects on the mother and on the foetus 
e.g β-mimetics, indomethacin and nifedipine (Goldenberg, 2002, Nelson et al., 
2014, van Veen et al., 2005, Khan et al., 2010) Nelson et al., 2014, Khan K et al 2010, 
van Veen et al 2005), while others like atosiban have been shown to have no 
evident effect on prolongation of pregnancy (Romero et al., 2000). Studies show 
that although these drugs may be capable of providing some clinical benefit of 
delay, the high doses required to achieve relaxation of the myometrium increases 
the risk of adverse systemic effects (van Veen et al., 2005, Khan et al., 2010). 
Indomethacin for example is associated with an increased risk for severe 
intraventricular haemorrhage, and necrotising enterocolitis (Sawdy et al., 2003) .  
One limitation of this study is that samples were obtained from term pregnant and 
not labouring mice, whereas tocolytics are used in preterm labouring women. These 
results therefore may not translate to clinical scenarios. The strength of this study 
however, is the combination of magnesium, a neuroprotectant, with the most 
commonly used tocolytics in the UK clinical practice. The clinical relevance of my 
findings suggests that combining two tocolytics acting via different pathways may 
be more effective and may also result in low doses being used, reducing side effects 
and improving perinatal outcome. To confirm the clinical effectiveness of the dual 
combination of tocolytics with MgSO4, and demonstrate the synergistic effect of 
MgSO4 + atosiban, clinical studies are required.  
Comparing all combinations in the presence of oxytocin, my data indicate that 
magnesium and atosiban are more potent than magnesium and nifedipine which in 
turn are more potent by magnesium and indomethacin. We therefore postulate 
that drugs acting via different mechanistic pathways may produce a synergistic 
effect. The clinical implications are that using magnesium as a foetal 
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neuroprotectant may enable existing tocolytics especially those that function at 
different intracellular sites to be administered with improved efficacy and improved 
safety.  This may reduce the quantity of drug required to achieve therapeutic 
efficacy, reduce the likelihood of maternal and foetal side effects, and may 
therefore represent a significant advancement for maternal-foetal medicine. 
6.4 Effect of Acidification on Magnesium and Atosiban 
 The effect of acidification on pregnant human myometrium has previously been 
documented with changes in extracellular and intracellular pH altering uterine 
contractions (Parratt et al., 1995, Taggart and Wray, 1993).  Since my data suggests 
that the effect of magnesium is improved when combined with atosiban, it was 
important to investigate how acidification may affect its tocolytic efficacy in vitro.  
My data showed that acidic external pH reduces the tocolytic efficacy of magnesium 
combined with atosiban by increasing the force and frequency of uterine 
contractions.  This may partly be as a result of H+ and Ca2+ competing for 
intracellular binding sites (Wray, 1988) leading to increase in levels of intracellular 
free Ca2+.  
It is known that uterine perfusion reduces during labour contraction as the blood 
vessels are temporarily occluded. This  occlusion results in hypoxia/ ischaemia and 
acidification (Harrison et al., 1994). The work reported here suggests that 
acidification occurring during forceful contractions of labour may result in a more 
forceful and frequent uterine contractions. If similar changes occur in preterm 
labour, the potency of tocolytics may be affected. To explore this further, the effect 
of intracellular acidification in the presence of tocolysis should be investigated. 
6.5 L-type Calcium Channel Expression in Mouse Uterus 
In Chapter 3, I showed that there were variations in the efficacy of magnesium at 
different gestational states. Since magnesium is thought to act at the L-type calcium 
channel, it was therefore important to determine the expression of L-type calcium 
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channels across different gestational states of mice. Understanding this would give 
better insight to the use of tocolytics (especially those acting on L-type calcium 
channels) in preterm labour. I therefore examined the mRNA expression and 
relative abundance of different calcium subunits throughout gestation. Using 
conventional PCR technique, I found no expression of Cav 1.1 in myometrial 
samples studied.  As expected, Cav 1.2 was expressed in all gestations including 
non-pregnant and post-partum.  
In order to quantify the level of Cav 1.2 gene expression, I first determined the most 
stable reference genes at different gestational states in mouse myometrium. 
Results from literature search suggest GAPDH, 18S and ACTB as the most frequently 
used housekeeping genes in mouse myometrium. It was also noted that most of the 
studies did not employ the use of any gene expression software. Therefore to 
confirm the stability of these housekeeping genes, we used geNorm to investigate 
12 genes. Results showed these genes to be among the least stable across different 
gestations. This finding enforces the need to determine the most suitable reference 
genes especially when there is variation in experimental procedures. Pairwise 
variation analysis showed the optimal number of reference targets to be two and 
indicated ATP5B and SDHA as the most stable housekeeping genes. The geometric 
means were then used as data normalisation factor in Cav 1.2 expression across 
gestations in mouse uterus.  
Compared to non-pregnant (control) the qPCR data indicate a marked decrease in 
expression at day 14, which was followed by an increase at days 18 and 19 although 
levels did not reach that of non-pregnant.  It is suggested that the state of 
quiescence at mid-gestation (day 14) may explain the reduced expression noticed at 
day 14 while the onward increase in expression towards term may indicate the role 
of  L-type calcium channels in preparation for parturition. Interestingly, a sharp 
increase was also seen in postpartum samples, with expression greater than all 
gestations studied.  
In summary, this study has demonstrated significant changes in the expression of 
the L-type VGCC in pregnancy. An increase in the expression of calcium channels, 
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also indicating an increase in dihydropyridine binding sites, was seen from day 14 
through the last day of gestation. This supports a role for the L-type calcium 
channels in uterine smooth muscle contraction. With no drastic increase in 
expression at term, it implies that the L-type channels may not be important in 
triggering the onset of labour. My data suggest that at term, magnesium is able to 
reduce excitability and reduce the firing of action potential. However, it may be 
difficult to explain gestational differences by the effect of calcium entry, except the 
increased expression of the α1C subunit results in increased reception to 
magnesium blockade.  Further studies are necessary to correlate the results of 
mRNA quantification to functional data. 
 
6.6 Summary of Clinical Implications 
Management of preterm labour is very complex as different aspects have to be 
considered including the impact on the unborn baby, and complications on both 
mother and baby. The goal of managing preterm labour is to prolong pregnancy as 
safely as possible and enable foetal development and maturation. The current 
tocolytics in clinical practice delay labour long enough until corticosteroids are 
administered and until maternal transfer to a hospital with appropriate neonatal 
facilities. 
In summary, my results showed an additive effect with magnesium and nifedipine, 
which may be due to a combined effect on calcium ion influx. Most women with 
severe preeclampsia and may be given MgSO4 (Magee et al., 2003).  A trial involving 
1469 women, given both MgSO4 and nifedipine (Magee et al., 2005), showed that 
there was no documented case of neuromuscular blockade, and there was no 
excess of maternal hypotension. They also calculated the risk of neuromuscular 
blockade among the women to be <2%. They therefore suggested that such a risk 
would not justify recommendations to avoid concomitant therapy with both drug, 
especially given nifedipine's ease of administration and effectiveness for the 
treatment of severe preeclampsia (Magee et al., 2005).  On the other hand, several 
studies have shown that the combination of magnesium and nifedipine may 
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potentiate the side effects of the drugs such as myocardial depression and 
hypotension (Thorp et al., 1990, Neustein et al., 1998). Although it may be difficult 
to extrapolate clinical significance from animal studies, however, if the effect of 
both drugs in vivo results in significant induction of hypotension, this may 
jeopardize uterine perfusion pressure and subsequently lead to foetal distress in 
pregnant patients (Neustein et al., 1998). We also have to consider that the side 
effects common to both drugs (such as cardiovascular side effects) may also be 
enhanced by this combination.   
My results also show that there is a synergistic tocolytic effect when magnesium is 
combined with atosiban. This synergistic effect exhibited by the combination with 
magnesium would result in the use of lower effective concentrations of atosiban, 
hence leading to a reduction in maternal and foetal side effects. Despite the 
tocolytic efficacy of both drugs individually, the clinical use of atosiban remains 
limited by its high cost (Doret et al., 2003). This suggests that the combination of 
magnesium with atosiban may also have an added advantage of decreasing the cost 
of tocolysis. These drugs used individually are not without their side effects, and my 
work may lead to less drugs being used therefore less side effects. A Cochrane 
review showed that about 38% of women treated with antenatal magnesium report 
any adverse effect (Bain et al., 2013). 50% of these patients have an increased risk 
of respiratory depression, and other side effects include neuromuscular blockade, 
postpartum haemorrhage, urinary stone formation and hypotension. Atosiban has 
also been shown to be associated with tachycardia, nausea, vomiting, headaches, 
dizziness and hyperglycaemia. Therefore, the synergistic tocolytic effect of 
magnesium used in combination with atosiban may provide the opportunity to 
improve the maternal and foetal side effect profile. 
My results also showed that the synergistic tocolytic effect was reversed by 
extracellular acidification. If the increase in force and frequency of contractions 
seen with acidification is characteristic of preterm labour, full knowledge of the 
mechanism is of value to clinicians as more caution would be taken when 
administering this combination. 
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6.7 Future work 
From the findings in this thesis, there are potential opportunities for further 
research that could be pursued.  
Magnesium 
The finding that magnesium reduced contractions in pregnant and non-pregnant 
mouse in vitro could be further explored by investigating magnesium’s effect on a 
preterm labour mouse model in vivo. Also, it will be interesting to investigate the 
effect of magnesium on intracellular calcium signalling by using calcium sensitive 
indicator Indo-1 AM.  
Potassium channels reduce membrane excitability and its expression is reported to 
decrease significantly in late pregnancy compared to non-pregnant and early 
pregnant stages (Khan et al., 2001, Mazzone et al., 2002). Further studies could 
explore the possible effect of magnesium on potassium channels at different 
gestations. 
Combined tocolytics 
This in vitro study was carried out to determine the tocolytic efficacy of 
combination therapy involving magnesium, however, only biochemical interaction 
between the drugs was achieved with this in vitro mouse model. In vivo studies will 
be beneficial and would give better insight into pharmacodynamics and 
pharmacokinetic interaction dependent on drug absorption and metabolism. It is 
also important to evaluate the foetal side effect of combined tocolytics on animal 
models before carrying out any human studies. Similar to the effect of magnesium 
on contractions, the effect of combining tocolytics could be explored further by 
measuring force and calcium signalling simultaneously. In addition, the combined 
tocolytic effect could be investigated on preterm labouring instead of term non-
labouring tissues.  Once the combined tocolytic effect is proven in human labouring 
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tissues, and foetal side effects of combination are evaluated, further clinical studies 
would be needed. 
The finding that extracellular acidification reversed the tocolytic efficacy of 
magnesium + atosiban could be investigated further by examining how intracellular 
pH is affected, using the pH-sensitive indicator carboxyl-SNARF. In addition, the 
effects of other factors like lactate, stretch and hypoxia could also be investigated. 
Calcium channel expression 
This thesis has shown the mRNA expression in non-pregnant, days 14, 18, 19 and 
postpartum tissues. It will be interesting to investigate the mRNA expression 
between non-pregnant and day 14 as well as labouring tissues. Although 
quantifying mRNA expression is a good indicator of gene regulation, is often an 
excellent indication of the presence of protein. Nevertheless, relative mRNA levels 
may or may not be directly correlated to the relative abundance of proteins (Vogel 
and Marcotte, 2012); hence, protein expression of the α1C subunit should also be 
investigated. This could be done using western blot technique. 
In this thesis, whole uterine tissue has been used. Further studies should compare 
the expression between myometrium and whole or full thickness tissues. Studies 
have also shown variation between longitudinal and circular muscles of rat uterus 
(Lee et al., 2009, Ohkubo et al., 2005); therefore investigating the difference in 
mouse myometrium might prove useful.  
 
6.8 Conclusion 
The main findings of this thesis are: 
- Magnesium concentration-dependently inhibits spontaneous and oxytocin-induced 
uterine contractions of both pregnant and non-pregnant mouse, with its greatest 
effect occurring in term-pregnant  
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- The combination magnesium plus atosiban produced a synergistic effect and was 
more potent than magnesium plus nifedipine and magnesium + indomethacin. 
- Extracellular acidification reversed the tocolytic efficacy of magnesium plus 
atosiban, causing increase in force and frequency of contractions. 
- There is increased expression of the α1C subunit during pregnancy and progresses 
towards term supporting the role of L-type calcium channel in parturition process. 
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pathways during a window of implantation in mice. 
2018 
IRF5 is increased in labouring myometrium and regulates 
pro-labour mediators. 
2018 
Generation of Mouse for Conditional Expression of 
Forkhead Box A2. 
2018 
Uterine Foxl2 regulates the adherence of the 
Trophectoderm cells to the endometrial epithelium. 
2018 
Seipin deficiency leads to defective parturition in mice. 2017 
Expression of Matrix Metalloproteinases in the Mouse 
Uterus and Human Myometrium During Pregnancy, 
Labor, and Preterm Labor. 
2018 
Selenoprotein N Was Required for the Regulation of 
Selenium on the Uterine Smooth Muscle Contraction in 
Mice. 
2017 
The transcriptional repressor GATAD2B mediates 
progesterone receptor suppression of myometrial 
contractile gene expression. 
2017 
Bitter taste receptors as targets for tocolytics in preterm 
labor therapy. 
2017 
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Distinct effects of short- and long-term type 1 diabetes 
to the placental extracellular matrix and fetal 
development in mice. 
2017 
The Local and Systemic Immune Response to 
Intrauterine LPS in the Prepartum Mouse. 
2016 
Lactate produced during labor modulates uterine 
inflammation via GPR81 (HCA<sub>1</sub>). 
2017 
Modeling hormonal and inflammatory contributions to 
preterm and term labor using uterine temporal 
transcriptomics. 
2016 
Age-related changes in murine myometrial transcript 
profile are mediated by exposure to the female sex 
hormones. 
2016 
The transient receptor potential vanilloid 4 channel 
modulates uterine tone during pregnancy. 
2015 
Constitutive activation of transforming growth factor 
Beta receptor 1 in the mouse uterus impairs uterine 
morphology and function. 
2015 
Prolonged pregnancy in women is associated with 
attenuated myometrial expression of progesterone 
receptor co-regulator Krüppel-like Factor 9. 
2015 
FSH receptor (FSHR) expression in human extragonadal 
reproductive tissues and the developing placenta, and 
2014 
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the impact of its deletion on pregnancy in mice. 
The inwardly rectifying K+ channel KIR7.1 controls 
uterine excitability throughout pregnancy. 
2014 
Inhibition of infection-mediated preterm birth by 
administration of broad spectrum chemokine inhibitor in 
mice. 
2014 
Lactoferrin-iCre: a new mouse line to study uterine 
epithelial gene function. 
2014 
Follistatin is essential for normal postnatal development 
and function of mouse oviduct and uterus. 
2015 
Statins prevent cervical remodeling, myometrial 
contractions and preterm labor through a mechanism 
that involves hemoxygenase-1 and complement 
inhibition. 
2014 
TGFBR1 is required for mouse myometrial development. 2013 
Expression of the small conductance Ca²⁺-activated 
potassium channel subtype 3 (SK3) in rat uterus after 
stimulation with 17β-estradiol. 
2014 
Increased tissue levels of omega-3 polyunsaturated fatty 
acids prevents pathological preterm birth. 
2013 
Uterine endoplasmic reticulum stress and its unfolded 
protein response may regulate caspase 3 activation in 
the pregnant mouse uterus. 
2013 
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Distinct spatiotemporal expression of serine proteases 
Prss23 and Prss35 in periimplantation mouse uterus and 
dispensable function of Prss35 in fertility. 
2013 
Myometrial immune cells contribute to term parturition, 
preterm labour and post-partum involution in mice. 
2012 
Mice deficient in surfactant protein A (SP-A) and SP-D or 
in TLR2 manifest delayed parturition and decreased 
expression of inflammatory and contractile genes. 
2013 
The microRNA (miR)-199a/214 cluster mediates 
opposing effects of progesterone and estrogen on 
uterine contractility during pregnancy and labor. 
2012 
Stromal-to-epithelial transition during postpartum 
endometrial regeneration. 
2012 
Generation of myometrium-specific Bmal1 knockout 
mice for parturition analysis. 
2012 
Chemokine gene silencing in decidual stromal cells limits 
T cell access to the maternal-fetal interface. 
2012 
N-acetylcysteine prevents preterm birth by attenuating 
the LPS-induced expression of contractile associated 
proteins in an animal model. 
2012 
MicroRNA-200a serves a key role in the decline of 
progesterone receptor function leading to term and 
preterm labor. 
2012 
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Smoothelin-like 1 protein is a bifunctional regulator of 
the progesterone receptor during pregnancy. 
2011 
Mast cells reside in myometrium and cervix, but are 
dispensable in mice for successful pregnancy and labor. 
2012 
How does progesterone relax the uterus in pregnancy? 2011 
miR-200 family and targets, ZEB1 and ZEB2, modulate 
uterine quiescence and contractility during pregnancy 
and labor. 
2010 
Decidual PTEN expression is required for trophoblast 
invasion in the mouse. 
2010 
Neuromedin B and its receptor induce labor onset and 
are associated with the RELA (NFKB P65)/IL6 pathway in 
pregnant mice. 
2011 
Decreased expression of the rat myometrial relaxin 
receptor (RXFP1) in late pregnancy is partially mediated 
by the presence of the conceptus. 
2010 
SK3 channel expression during pregnancy is regulated 
through estrogen and Sp factor-mediated transcriptional 
control of the KCNN3 gene. 
2010 
Broad tissue expression of membrane progesterone 
receptor Alpha in normal mice. 
2010 
The contribution of Kv7 channels to pregnant mouse and 
human myometrial contractility. 
2011 
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Loss of functional K+ channels encoded by ether-à-go-
go-related genes in mouse myometrium prior to labour 
onset. 
2009 
Dicer is required for female reproductive tract 
development and fertility in the mouse. 
2009 
A dominant loss-of-function GJA1 (Cx43) mutant impairs 
parturition in the mouse. 
2009 
The estrous cycle modulates small leucine-rich 
proteoglycans expression in mouse uterine tissues. 
2009 
Expression and function of K(v)7 channels in murine 
myometrium throughout oestrous cycle. 
2009 
Long form of leptin receptor gene and protein 
expression in the porcine trophoblast and uterine tissues 
during early pregnancy and the oestrous cycle. 
2009 
Expression of progesterone receptor membrane 
component 1 and its partner serpine 1 mRNA binding 
protein in uterine and placental tissues of the mouse 
and human. 
2008 
Estrogen and progesterone metabolism in the cervix 
during pregnancy and parturition. 
2008 
Delayed parturition and altered myometrial 
progesterone receptor isoform A expression in mice null 
for Krüppel-like factor 9. 
2008 
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Overexpression of SK3 channels dampens uterine 
contractility to prevent preterm labor in mice. 
2008 
Activin-A in myometrium: characterization of the actions 
on myometrial cells. 
2008 
Infusion of oxytocin induces successful delivery in 
prostanoid FP-receptor-deficient mice. 
2008 
Side population in human uterine myometrium displays 
phenotypic and functional characteristics of myometrial 
stem cells. 
2007 
Are natural killer cells distributed in relationship to nerve 
fibers in the pregnant mouse uterus? 
2007 
Role of RYR3 splice variants in calcium signaling in 
mouse nonpregnant and pregnant myometrium. 
2007 
Expression of uterine sensitization-associated gene-1 
(USAG-1) in the mouse uterus during the peri-
implantation period. 
2007 
TRPC6. 2007 
Overlapping and distinct expression of progesterone 
receptors A and B in mouse uterus and mammary gland 
during the estrous cycle. 
2006 
Signaling via the type I IL-1 and TNF receptors is 
necessary for bacterially induced preterm labor in a 
murine model. 
2006 
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Ablation of connexin43 in uterine smooth muscle cells of 
the mouse causes delayed parturition. 
2006 
The estrogen-responsive adrenomedullin and receptor-
modifying protein 3 gene identified by DNA microarray 
analysis are directly regulated by estrogen receptor. 
2006 
Change in prostaglandin E synthases (PGESs) in 
microsomal PGES-1 knockout mice in a preterm delivery 
model. 
2005 
Conditional deletion of beta-catenin in the mesenchyme 
of the developing mouse uterus results in a switch to 
adipogenesis in the myometrium. 
2005 
Interleukin-18 (IL-18) mRNA expression and localization 
of IL-18 mRNA-expressing cells in the mouse uterus. 
2005 
Dynamic cell type specificity of SRC-1 coactivator in 
modulating uterine progesterone receptor function in 
mice. 
2005 
Gestational-dependent changes in the expression of 
signal transduction and contractile filament-associated 
proteins in mouse myometrium. 
2005 
Oxytocin and estrogen receptor expression in the 
myometrium of pregnant relaxin-deficient (Rlx-/-) mice. 
2005 
Neonatal tamoxifen treatment of mice leads to 
adenomyosis but not uterine cancer. 
2005 
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Carbonic anhydrase regulate endometrial gland 
development in the neonatal uterus. 
2005 
Identifying genetic networks underlying myometrial 
transition to labor. 
2005 
Uterine extracellular matrix components are altered 
during defective decidualization in interleukin-11 
receptor alpha deficient mice. 
2004 
Differential activation of the connexin 43 promoter by 
dimers of activator protein-1 transcription factors in 
myometrial cells. 
2005 
Mammalian tachykinins and uterine smooth muscle: the 
challenge escalates. 
2004 
Gene expression profiling of neonatal mouse uterine 
development. 
2004 
Up-regulation of thymosin beta 4 gene expression in 
experimentally-induced uterine adenomyosis in mice. 
2003 
Expression, localization and function of prostaglandin 
receptors in myometrium. 
2004 
Differential expression of genes in the endometrium at 
implantation: upregulation of a novel member of the E2 
class of ubiquitin-conjugating enzymes. 
2003 
Highly efficient and minimally invasive in-vivo gene 
transfer to the mouse uterus using haemagglutinating 
2003 
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virus of Japan (HVJ) envelope vector. 
Inhibition of oxytocin receptor and estrogen receptor-
alpha expression, but not relaxin receptors (LGR7), in the 
myometrium of late pregnant relaxin gene knockout 
mice. 
2003 
Diminished surface clustering and increased perinuclear 
accumulation of large conductance Ca2+-activated K+ 
channel in mouse myometrium with pregnancy. 
2003 
Bacterially-induced preterm labor and regulation of 
prostaglandin-metabolizing enzyme expression in mice: 
the role of toll-like receptor 4. 
2003 
Increase in the number of integrinbeta1-
immunoreactive monocyte-lineage cells in 
experimentally-induced adenomyosis in mice. 
2003 
Microarray analysis of uterine gene expression in mouse 
and human pregnancy. 
2003 
Mouse Spam1 (PH-20) is a multifunctional protein: 
evidence for its expression in the female reproductive 
tract. 
2003 
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Mean Data ± SEM for Chapter 3 
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(A
) 
(B) 
(C) (D) 
Changes in contractile properties of spontaneous contracting non-pregnant 
myometrium in response MgSO4 
Mean data showing concentration-dependent decrease in (A) amplitude force, (B), 
frequency, (C) duration and (D) AUC of spontaneously contracting non-pregnant 
myometrium. Values are expressed as Mean ± standard error mean (SEM). A 
significant difference in activity was found using ANOVA with Bonferroni post hoc 
analysis. * denotes a significant difference compared to control period (100%) 
p<0.05, **p<0.01, ***p<0.0001, ns is not significant  
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(B) 
(C) (D) 
(A) 
Changes in contractile properties of spontaneous contracting day 14 pregnant 
myometrium in response MgSO4 
Mean data showing concentration-dependent decrease in (A) amplitude force, (B), 
frequency, (C) duration and (D) AUC of spontaneously contracting day 14 pregnant 
myometrium. Values are expressed as Mean ± SEM. A significant difference in activity 
was found using ANOVA with Bonferroni post hoc analysis. * denotes a significant 
difference compared to control period (100%) p<0.05, **p<0.01, ***p<0.0001, ns is 
not significant. 
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(A) (B) 
(C) (D) 
Changes in contractile properties of spontaneous contracting day 16 pregnant 
myometrium in response to MgSO
4
 
Mean data showing concentration-dependent decrease in (A) amplitude force, (B), 
frequency, (C) duration and (D) AUC of spontaneously contracting day 16 pregnant 
myometrium. Values are expressed as Mean ± SEM. A significant difference in activity was 
found using ANOVA with Bonferroni post hoc analysis. * denotes a significant difference 
compared to control period (100%) p<0.05, **p<0.01, ***p<0.0001, ns is not significant. 
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(A) (B) 
(C) (D) 
Changes in contractile properties of spontaneous contracting term pregnant 
myometrium in response to MgSO
4
 
Mean data showing concentration-dependent decrease in (A) amplitude force, 
(B), frequency, (C) duration and (D) AUC of spontaneously contracting day 18 
pregnant myometrium. Values are expressed as Mean ± standard error mean 
(SEM). A significant difference in activity was found using ANOVA with 
Bonferroni post hoc analysis. * denotes a significant difference compared to 
control period (100%) p<0.05, **p<0.01, ***p<0.0001, ns is not significant  
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(A) (B) 
(C) (D) 
Changes in contractile properties of oxytocin-induced contracting non-pregnant 
myometrium in response to MgSO
4
 
Mean data showing concentration-dependent decrease in (A) amplitude force, (B), 
frequency, (C) duration and (D) AUC of oxytocin-induced contracting non-pregnant 
myometrium. Values are expressed as Mean ± standard error mean (SEM). A significant 
difference in activity was found using ANOVA with Bonferroni post hoc analysis. * 
denotes a significant difference compared to control period (100%) p<0.05, **p<0.01, 
***p<0.0001, ns is not significant  
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(A) (B) 
(C) (D) 
Changes in contractile properties of oxytocin-induced contracting day 14 
pregnant myometrium in response to MgSO
4
 
Mean data showing concentration-dependent decrease in (A) amplitude force, 
(B), frequency, (C) duration and (D) AUC of oxytocin-induced of day 14 pregnant 
myometrium. Values are expressed as mean ± standard error mean (SEM). A 
significant difference in activity was found using ANOVA with Bonferroni post hoc 
analysis. * denotes a significant difference compared to control period (100%) 
p<0.05, **p<0.01, ***p<0.0001, ns is not significant. 
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(A) (B) 
(C) (D) 
Changes in contractile properties of oxytocin-induced contracting term pregnant 
myometrium in response to MgSO
4
 
Mean data showing concentration-dependent decrease in (A) amplitude force, (B), 
frequency, (C) duration and (D) AUC of oxytocin-induced contracting day 18 
pregnant myometrium. Values are expressed as Mean ± standard error mean (SEM). 
A significant difference in activity was found using ANOVA with Bonferroni post hoc 
analysis. * denotes a significant difference compared to control period (100%) 
p<0.05, **p<0.01, ***p<0.0001, ns is not significant  
